id	sid	tid	token	lemma	pos
bioethics02-25741	1	1	bangladesh	bangladesh	PROPN
bioethics02-25741	1	2	journal	journal	NOUN
bioethics02-25741	1	3	of	of	ADP
bioethics02-25741	1	4	bioethics	bioethic	NOUN
bioethics02-25741	1	5	2015	2015	NUM
bioethics02-25741	1	6	;	;	PUNCT
bioethics02-25741	1	7	6(2):15	6(2):15	X
bioethics02-25741	1	8	-	-	SYM
bioethics02-25741	1	9	22	22	NUM
bioethics02-25741	1	10	15	15	NUM
bioethics02-25741	1	11	undue	undue	ADJ
bioethics02-25741	1	12	influences	influence	NOUN
bioethics02-25741	1	13	on	on	ADP
bioethics02-25741	1	14	drugs	drug	NOUN
bioethics02-25741	1	15	and	and	CCONJ
bioethics02-25741	1	16	device	device	NOUN
bioethics02-25741	1	17	industries	industry	NOUN
bioethics02-25741	1	18	distort	distort	VERB
bioethics02-25741	1	19	healthcare	healthcare	PROPN
bioethics02-25741	1	20	research	research	NOUN
bioethics02-25741	1	21	,	,	PUNCT
bioethics02-25741	1	22	and	and	CCONJ
bioethics02-25741	1	23	practice	practice	NOUN
bioethics02-25741	1	24	mohammad	mohammad	NOUN
bioethics02-25741	1	25	arifur	arifur	NOUN
bioethics02-25741	1	26	rahman	rahman	PROPN
bioethics02-25741	1	27	1	1	NUM
bioethics02-25741	1	28	,	,	PUNCT
bioethics02-25741	1	29	laila	laila	PROPN
bioethics02-25741	1	30	farzana	farzana	PROPN
bioethics02-25741	1	31	2	2	NUM
bioethics02-25741	1	32	1	1	NUM
bioethics02-25741	1	33	.	.	PUNCT
bioethics02-25741	2	1	national	national	PROPN
bioethics02-25741	2	2	institute	institute	PROPN
bioethics02-25741	2	3	of	of	ADP
bioethics02-25741	2	4	cardiovascular	cardiovascular	ADJ
bioethics02-25741	2	5	diseases	disease	NOUN
bioethics02-25741	2	6	,	,	PUNCT
bioethics02-25741	2	7	sher	sher	PROPN
bioethics02-25741	2	8	e	e	PROPN
bioethics02-25741	2	9	bangla	bangla	PROPN
bioethics02-25741	2	10	nagar	nagar	PROPN
bioethics02-25741	2	11	,	,	PUNCT
bioethics02-25741	2	12	dhaka	dhaka	PROPN
bioethics02-25741	2	13	1207	1207	NUM
bioethics02-25741	2	14	,	,	PUNCT
bioethics02-25741	2	15	bangladesh	bangladesh	NOUN
bioethics02-25741	2	16	.	.	PUNCT
bioethics02-25741	3	1	email	email	NOUN
bioethics02-25741	3	2	:	:	PUNCT
bioethics02-25741	3	3	drarif79@yahoo.com	drarif79@yahoo.com	X
bioethics02-25741	3	4	2	2	NUM
bioethics02-25741	3	5	.	.	PUNCT
bioethics02-25741	3	6	holy	holy	PROPN
bioethics02-25741	3	7	family	family	PROPN
bioethics02-25741	3	8	red	red	PROPN
bioethics02-25741	3	9	crescent	crescent	PROPN
bioethics02-25741	3	10	medical	medical	PROPN
bioethics02-25741	3	11	college	college	PROPN
bioethics02-25741	3	12	and	and	CCONJ
bioethics02-25741	3	13	hospital	hospital	NOUN
bioethics02-25741	3	14	,	,	PUNCT
bioethics02-25741	3	15	dhaka	dhaka	PROPN
bioethics02-25741	3	16	,	,	PUNCT
bioethics02-25741	3	17	bangladesh	bangladesh	PROPN
bioethics02-25741	3	18	.	.	PUNCT
bioethics02-25741	4	1	abstract	abstract	ADJ
bioethics02-25741	4	2	:	:	PUNCT
bioethics02-25741	4	3	background	background	NOUN
bioethics02-25741	4	4	:	:	PUNCT
bioethics02-25741	4	5	expenditure	expenditure	NOUN
bioethics02-25741	4	6	on	on	ADP
bioethics02-25741	4	7	industry	industry	NOUN
bioethics02-25741	4	8	products	product	NOUN
bioethics02-25741	4	9	(	(	PUNCT
bioethics02-25741	4	10	mostly	mostly	ADV
bioethics02-25741	4	11	drugs	drug	NOUN
bioethics02-25741	4	12	and	and	CCONJ
bioethics02-25741	4	13	devices	device	NOUN
bioethics02-25741	4	14	)	)	PUNCT
bioethics02-25741	4	15	has	have	AUX
bioethics02-25741	4	16	spiraled	spiral	VERB
bioethics02-25741	4	17	over	over	ADP
bioethics02-25741	4	18	the	the	DET
bioethics02-25741	4	19	last	last	ADJ
bioethics02-25741	4	20	15	15	NUM
bioethics02-25741	4	21	years	year	NOUN
bioethics02-25741	4	22	and	and	CCONJ
bioethics02-25741	4	23	accounts	account	NOUN
bioethics02-25741	4	24	for	for	ADP
bioethics02-25741	4	25	substantial	substantial	ADJ
bioethics02-25741	4	26	part	part	NOUN
bioethics02-25741	4	27	of	of	ADP
bioethics02-25741	4	28	healthcare	healthcare	NOUN
bioethics02-25741	4	29	expenditure	expenditure	NOUN
bioethics02-25741	4	30	.	.	PUNCT
bioethics02-25741	5	1	the	the	DET
bioethics02-25741	5	2	enormous	enormous	ADJ
bioethics02-25741	5	3	financial	financial	ADJ
bioethics02-25741	5	4	interests	interest	NOUN
bioethics02-25741	5	5	involved	involve	VERB
bioethics02-25741	5	6	in	in	ADP
bioethics02-25741	5	7	the	the	DET
bioethics02-25741	5	8	development	development	NOUN
bioethics02-25741	5	9	and	and	CCONJ
bioethics02-25741	5	10	marketing	marketing	NOUN
bioethics02-25741	5	11	of	of	ADP
bioethics02-25741	5	12	drugs	drug	NOUN
bioethics02-25741	5	13	and	and	CCONJ
bioethics02-25741	5	14	devices	device	NOUN
bioethics02-25741	5	15	may	may	AUX
bioethics02-25741	5	16	have	have	AUX
bioethics02-25741	5	17	given	give	VERB
bioethics02-25741	5	18	excessive	excessive	ADJ
bioethics02-25741	5	19	power	power	NOUN
bioethics02-25741	5	20	to	to	ADP
bioethics02-25741	5	21	these	these	DET
bioethics02-25741	5	22	industries	industry	NOUN
bioethics02-25741	5	23	to	to	PART
bioethics02-25741	5	24	influence	influence	VERB
bioethics02-25741	5	25	medical	medical	ADJ
bioethics02-25741	5	26	research	research	NOUN
bioethics02-25741	5	27	,	,	PUNCT
bioethics02-25741	5	28	policy	policy	NOUN
bioethics02-25741	5	29	,	,	PUNCT
bioethics02-25741	5	30	and	and	CCONJ
bioethics02-25741	5	31	practice	practice	NOUN
bioethics02-25741	5	32	.	.	PUNCT
bioethics02-25741	6	1	material	material	NOUN
bioethics02-25741	6	2	and	and	CCONJ
bioethics02-25741	6	3	methods	method	NOUN
bioethics02-25741	6	4	:	:	PUNCT
bioethics02-25741	6	5	review	review	NOUN
bioethics02-25741	6	6	of	of	ADP
bioethics02-25741	6	7	the	the	DET
bioethics02-25741	6	8	literature	literature	NOUN
bioethics02-25741	6	9	and	and	CCONJ
bioethics02-25741	6	10	analysis	analysis	NOUN
bioethics02-25741	6	11	of	of	ADP
bioethics02-25741	6	12	the	the	DET
bioethics02-25741	6	13	multiple	multiple	ADJ
bioethics02-25741	6	14	pathways	pathway	NOUN
bioethics02-25741	6	15	through	through	ADP
bioethics02-25741	6	16	which	which	PRON
bioethics02-25741	6	17	the	the	DET
bioethics02-25741	6	18	industry	industry	NOUN
bioethics02-25741	6	19	has	have	AUX
bioethics02-25741	6	20	directly	directly	ADV
bioethics02-25741	6	21	or	or	CCONJ
bioethics02-25741	6	22	indirectly	indirectly	ADV
bioethics02-25741	6	23	infiltrated	infiltrate	VERB
bioethics02-25741	6	24	the	the	DET
bioethics02-25741	6	25	broader	broad	ADJ
bioethics02-25741	6	26	healthcare	healthcare	NOUN
bioethics02-25741	6	27	systems	system	NOUN
bioethics02-25741	6	28	.	.	PUNCT
bioethics02-25741	7	1	we	we	PRON
bioethics02-25741	7	2	present	present	VERB
bioethics02-25741	7	3	the	the	DET
bioethics02-25741	7	4	analysis	analysis	NOUN
bioethics02-25741	7	5	of	of	ADP
bioethics02-25741	7	6	the	the	DET
bioethics02-25741	7	7	industry	industry	NOUN
bioethics02-25741	7	8	influences	influence	VERB
bioethics02-25741	7	9	at	at	ADP
bioethics02-25741	7	10	the	the	DET
bioethics02-25741	7	11	following	following	ADJ
bioethics02-25741	7	12	levels	level	NOUN
bioethics02-25741	7	13	:	:	PUNCT
bioethics02-25741	7	14	(	(	PUNCT
bioethics02-25741	7	15	i	i	NOUN
bioethics02-25741	7	16	)	)	PUNCT
bioethics02-25741	7	17	evidence	evidence	NOUN
bioethics02-25741	7	18	base	base	NOUN
bioethics02-25741	7	19	production	production	NOUN
bioethics02-25741	7	20	,	,	PUNCT
bioethics02-25741	7	21	(	(	PUNCT
bioethics02-25741	7	22	ii	ii	NOUN
bioethics02-25741	7	23	)	)	PUNCT
bioethics02-25741	7	24	evidence	evidence	NOUN
bioethics02-25741	7	25	synthesis	synthesis	NOUN
bioethics02-25741	7	26	,	,	PUNCT
bioethics02-25741	7	27	(	(	PUNCT
bioethics02-25741	7	28	iii	iii	X
bioethics02-25741	7	29	)	)	PUNCT
bioethics02-25741	7	30	understanding	understanding	NOUN
bioethics02-25741	7	31	of	of	ADP
bioethics02-25741	7	32	safety	safety	NOUN
bioethics02-25741	7	33	and	and	CCONJ
bioethics02-25741	7	34	harms	harm	VERB
bioethics02-25741	7	35	issues	issue	NOUN
bioethics02-25741	7	36	,	,	PUNCT
bioethics02-25741	7	37	(	(	PUNCT
bioethics02-25741	7	38	iv	iv	X
bioethics02-25741	7	39	)	)	PUNCT
bioethics02-25741	7	40	cost	cost	NOUN
bioethics02-25741	7	41	-	-	PUNCT
bioethics02-25741	7	42	effectiveness	effectiveness	NOUN
bioethics02-25741	7	43	evaluation	evaluation	NOUN
bioethics02-25741	7	44	,	,	PUNCT
bioethics02-25741	7	45	(	(	PUNCT
bioethics02-25741	7	46	v	v	NOUN
bioethics02-25741	7	47	)	)	PUNCT
bioethics02-25741	7	48	clinical	clinical	ADJ
bioethics02-25741	7	49	practice	practice	NOUN
bioethics02-25741	7	50	guidelines	guideline	NOUN
bioethics02-25741	7	51	formation	formation	NOUN
bioethics02-25741	7	52	,	,	PUNCT
bioethics02-25741	7	53	(	(	PUNCT
bioethics02-25741	7	54	vi	vi	NOUN
bioethics02-25741	7	55	)	)	PUNCT
bioethics02-25741	7	56	healthcare	healthcare	PROPN
bioethics02-25741	7	57	professional	professional	ADJ
bioethics02-25741	7	58	education	education	NOUN
bioethics02-25741	7	59	,	,	PUNCT
bioethics02-25741	7	60	(	(	PUNCT
bioethics02-25741	7	61	vii	vii	PROPN
bioethics02-25741	7	62	)	)	PUNCT
bioethics02-25741	7	63	healthcare	healthcare	NOUN
bioethics02-25741	7	64	practice	practice	NOUN
bioethics02-25741	7	65	,	,	PUNCT
bioethics02-25741	7	66	(	(	PUNCT
bioethics02-25741	7	67	viii	viii	NOUN
bioethics02-25741	7	68	)	)	PUNCT
bioethics02-25741	7	69	healthcare	healthcare	NOUN
bioethics02-25741	7	70	consumer‘s	consumer‘s	NUM
bioethics02-25741	7	71	decisions	decision	NOUN
bioethics02-25741	7	72	.	.	PUNCT
bioethics02-25741	8	1	results	result	NOUN
bioethics02-25741	8	2	:	:	PUNCT
bioethics02-25741	8	3	we	we	PRON
bioethics02-25741	8	4	located	locate	VERB
bioethics02-25741	8	5	abundance	abundance	NOUN
bioethics02-25741	8	6	of	of	ADP
bioethics02-25741	8	7	consistent	consistent	ADJ
bioethics02-25741	8	8	evidence	evidence	NOUN
bioethics02-25741	8	9	demonstrating	demonstrate	VERB
bioethics02-25741	8	10	that	that	SCONJ
bioethics02-25741	8	11	the	the	DET
bioethics02-25741	8	12	industry	industry	NOUN
bioethics02-25741	8	13	has	have	AUX
bioethics02-25741	8	14	created	create	VERB
bioethics02-25741	8	15	means	mean	NOUN
bioethics02-25741	8	16	to	to	PART
bioethics02-25741	8	17	intervene	intervene	VERB
bioethics02-25741	8	18	in	in	ADP
bioethics02-25741	8	19	all	all	DET
bioethics02-25741	8	20	steps	step	NOUN
bioethics02-25741	8	21	of	of	ADP
bioethics02-25741	8	22	the	the	DET
bioethics02-25741	8	23	processes	process	NOUN
bioethics02-25741	8	24	that	that	PRON
bioethics02-25741	8	25	determine	determine	VERB
bioethics02-25741	8	26	healthcare	healthcare	PROPN
bioethics02-25741	8	27	research	research	NOUN
bioethics02-25741	8	28	,	,	PUNCT
bioethics02-25741	8	29	strategy	strategy	NOUN
bioethics02-25741	8	30	,	,	PUNCT
bioethics02-25741	8	31	expenditure	expenditure	NOUN
bioethics02-25741	8	32	,	,	PUNCT
bioethics02-25741	8	33	practice	practice	NOUN
bioethics02-25741	8	34	and	and	CCONJ
bioethics02-25741	8	35	education	education	NOUN
bioethics02-25741	8	36	.	.	PUNCT
bioethics02-25741	9	1	as	as	ADP
bioethics02-25741	9	2	a	a	DET
bioethics02-25741	9	3	result	result	NOUN
bioethics02-25741	9	4	of	of	ADP
bioethics02-25741	9	5	these	these	DET
bioethics02-25741	9	6	interferences	interference	NOUN
bioethics02-25741	9	7	,	,	PUNCT
bioethics02-25741	9	8	the	the	DET
bioethics02-25741	9	9	benefits	benefit	NOUN
bioethics02-25741	9	10	of	of	ADP
bioethics02-25741	9	11	drugs	drug	NOUN
bioethics02-25741	9	12	and	and	CCONJ
bioethics02-25741	9	13	other	other	ADJ
bioethics02-25741	9	14	products	product	NOUN
bioethics02-25741	9	15	are	be	AUX
bioethics02-25741	9	16	often	often	ADV
bioethics02-25741	9	17	exaggerated	exaggerated	ADJ
bioethics02-25741	9	18	and	and	CCONJ
bioethics02-25741	9	19	their	their	PRON
bioethics02-25741	9	20	potential	potential	ADJ
bioethics02-25741	9	21	harms	harm	NOUN
bioethics02-25741	9	22	are	be	AUX
bioethics02-25741	9	23	downplayed	downplay	VERB
bioethics02-25741	9	24	,	,	PUNCT
bioethics02-25741	9	25	and	and	CCONJ
bioethics02-25741	9	26	clinical	clinical	ADJ
bioethics02-25741	9	27	guidelines	guideline	NOUN
bioethics02-25741	9	28	,	,	PUNCT
bioethics02-25741	9	29	medical	medical	ADJ
bioethics02-25741	9	30	practice	practice	NOUN
bioethics02-25741	9	31	,	,	PUNCT
bioethics02-25741	9	32	and	and	CCONJ
bioethics02-25741	9	33	healthcare	healthcare	NOUN
bioethics02-25741	9	34	expenditure	expenditure	NOUN
bioethics02-25741	9	35	decisions	decision	NOUN
bioethics02-25741	9	36	are	be	AUX
bioethics02-25741	9	37	biased	biased	ADJ
bioethics02-25741	9	38	.	.	PUNCT
bioethics02-25741	10	1	conclusion	conclusion	NOUN
bioethics02-25741	10	2	:	:	PUNCT
bioethics02-25741	10	3	to	to	PART
bioethics02-25741	10	4	serve	serve	VERB
bioethics02-25741	10	5	its	its	PRON
bioethics02-25741	10	6	interests	interest	NOUN
bioethics02-25741	10	7	,	,	PUNCT
bioethics02-25741	10	8	the	the	DET
bioethics02-25741	10	9	industry	industry	NOUN
bioethics02-25741	10	10	masterfully	masterfully	ADV
bioethics02-25741	10	11	influences	influence	VERB
bioethics02-25741	10	12	evidence	evidence	NOUN
bioethics02-25741	10	13	base	base	NOUN
bioethics02-25741	10	14	production	production	NOUN
bioethics02-25741	10	15	,	,	PUNCT
bioethics02-25741	10	16	evidence	evidence	NOUN
bioethics02-25741	10	17	synthesis	synthesis	NOUN
bioethics02-25741	10	18	,	,	PUNCT
bioethics02-25741	10	19	understanding	understanding	NOUN
bioethics02-25741	10	20	of	of	ADP
bioethics02-25741	10	21	harms	harm	NOUN
bioethics02-25741	10	22	issues	issue	NOUN
bioethics02-25741	10	23	,	,	PUNCT
bioethics02-25741	10	24	cost	cost	NOUN
bioethics02-25741	10	25	-	-	PUNCT
bioethics02-25741	10	26	effectiveness	effectiveness	NOUN
bioethics02-25741	10	27	evaluations	evaluation	NOUN
bioethics02-25741	10	28	,	,	PUNCT
bioethics02-25741	10	29	clinical	clinical	ADJ
bioethics02-25741	10	30	practice	practice	NOUN
bioethics02-25741	10	31	guidelines	guideline	NOUN
bioethics02-25741	10	32	and	and	CCONJ
bioethics02-25741	10	33	healthcare	healthcare	PROPN
bioethics02-25741	10	34	professional	professional	ADJ
bioethics02-25741	10	35	education	education	NOUN
bioethics02-25741	10	36	and	and	CCONJ
bioethics02-25741	10	37	also	also	ADV
bioethics02-25741	10	38	exerts	exert	VERB
bioethics02-25741	10	39	direct	direct	ADJ
bioethics02-25741	10	40	influences	influence	NOUN
bioethics02-25741	10	41	on	on	ADP
bioethics02-25741	10	42	professional	professional	ADJ
bioethics02-25741	10	43	decisions	decision	NOUN
bioethics02-25741	10	44	and	and	CCONJ
bioethics02-25741	10	45	health	health	NOUN
bioethics02-25741	10	46	consumers	consumer	NOUN
bioethics02-25741	10	47	.	.	PUNCT
bioethics02-25741	11	1	there	there	PRON
bioethics02-25741	11	2	is	be	VERB
bioethics02-25741	11	3	an	an	DET
bioethics02-25741	11	4	urgent	urgent	ADJ
bioethics02-25741	11	5	need	need	NOUN
bioethics02-25741	11	6	for	for	ADP
bioethics02-25741	11	7	regulation	regulation	NOUN
bioethics02-25741	11	8	and	and	CCONJ
bioethics02-25741	11	9	other	other	ADJ
bioethics02-25741	11	10	action	action	NOUN
bioethics02-25741	11	11	towards	towards	ADP
bioethics02-25741	11	12	redefining	redefine	VERB
bioethics02-25741	11	13	the	the	DET
bioethics02-25741	11	14	mission	mission	NOUN
bioethics02-25741	11	15	of	of	ADP
bioethics02-25741	11	16	medicine	medicine	NOUN
bioethics02-25741	11	17	towards	towards	ADP
bioethics02-25741	11	18	a	a	DET
bioethics02-25741	11	19	more	more	ADV
bioethics02-25741	11	20	objective	objective	ADJ
bioethics02-25741	11	21	and	and	CCONJ
bioethics02-25741	11	22	patient-	patient-	NOUN
bioethics02-25741	11	23	,	,	PUNCT
bioethics02-25741	11	24	populationand	populationand	VERB
bioethics02-25741	11	25	society	society	NOUN
bioethics02-25741	11	26	-	-	PUNCT
bioethics02-25741	11	27	benefit	benefit	NOUN
bioethics02-25741	11	28	direction	direction	NOUN
bioethics02-25741	11	29	that	that	PRON
bioethics02-25741	11	30	is	be	AUX
bioethics02-25741	11	31	free	free	ADJ
bioethics02-25741	11	32	from	from	ADP
bioethics02-25741	11	33	conflict	conflict	NOUN
bioethics02-25741	11	34	of	of	ADP
bioethics02-25741	11	35	interests	interest	NOUN
bioethics02-25741	11	36	.	.	PUNCT
bioethics02-25741	12	1	keywords	keyword	NOUN
bioethics02-25741	12	2	:	:	PUNCT
bioethics02-25741	12	3	undue	undue	ADJ
bioethics02-25741	12	4	influence	influence	NOUN
bioethics02-25741	12	5	,	,	PUNCT
bioethics02-25741	12	6	conflict	conflict	NOUN
bioethics02-25741	12	7	of	of	ADP
bioethics02-25741	12	8	interests	interest	NOUN
bioethics02-25741	12	9	,	,	PUNCT
bioethics02-25741	12	10	evidence	evidence	NOUN
bioethics02-25741	12	11	-	-	PUNCT
bioethics02-25741	12	12	based	base	VERB
bioethics02-25741	12	13	medicine	medicine	NOUN
bioethics02-25741	12	14	,	,	PUNCT
bioethics02-25741	12	15	healthcare	healthcare	NOUN
bioethics02-25741	12	16	industry	industry	NOUN
bioethics02-25741	12	17	,	,	PUNCT
bioethics02-25741	12	18	medication	medication	NOUN
bioethics02-25741	12	19	,	,	PUNCT
bioethics02-25741	12	20	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	12	21	industry	industry	NOUN
bioethics02-25741	12	22	.	.	PUNCT
bioethics02-25741	13	1	introduction	introduction	NOUN
bioethics02-25741	13	2	:	:	PUNCT
bioethics02-25741	13	3	a	a	DET
bioethics02-25741	13	4	universal	universal	ADJ
bioethics02-25741	13	5	characteristic	characteristic	NOUN
bioethics02-25741	13	6	of	of	ADP
bioethics02-25741	13	7	most	most	ADJ
bioethics02-25741	13	8	healthcare	healthcare	NOUN
bioethics02-25741	13	9	systems	system	NOUN
bioethics02-25741	13	10	in	in	ADP
bioethics02-25741	13	11	developed	develop	VERB
bioethics02-25741	13	12	countries	country	NOUN
bioethics02-25741	13	13	is	be	AUX
bioethics02-25741	13	14	the	the	DET
bioethics02-25741	13	15	heavy	heavy	ADJ
bioethics02-25741	13	16	focus	focus	NOUN
bioethics02-25741	13	17	on	on	ADP
bioethics02-25741	13	18	pharmacological	pharmacological	ADJ
bioethics02-25741	13	19	approaches	approach	NOUN
bioethics02-25741	13	20	for	for	ADP
bioethics02-25741	13	21	treating	treat	VERB
bioethics02-25741	13	22	and	and	CCONJ
bioethics02-25741	13	23	preventing	prevent	VERB
bioethics02-25741	13	24	chronic	chronic	ADJ
bioethics02-25741	13	25	disease	disease	NOUN
bioethics02-25741	13	26	and	and	CCONJ
bioethics02-25741	13	27	the	the	DET
bioethics02-25741	13	28	considerable	considerable	ADJ
bioethics02-25741	13	29	expenditure	expenditure	NOUN
bioethics02-25741	13	30	on	on	ADP
bioethics02-25741	13	31	hightech	hightech	ADJ
bioethics02-25741	13	32	medical	medical	ADJ
bioethics02-25741	13	33	equipment	equipment	NOUN
bioethics02-25741	13	34	,	,	PUNCT
bioethics02-25741	13	35	devices	device	NOUN
bioethics02-25741	13	36	and	and	CCONJ
bioethics02-25741	13	37	technologies	technology	NOUN
bioethics02-25741	13	38	.	.	PUNCT
bioethics02-25741	14	1	this	this	DET
bioethics02-25741	14	2	focus	focus	NOUN
bioethics02-25741	14	3	is	be	AUX
bioethics02-25741	14	4	often	often	ADV
bioethics02-25741	14	5	linked	link	VERB
bioethics02-25741	14	6	to	to	ADP
bioethics02-25741	14	7	astonishing	astonishing	ADJ
bioethics02-25741	14	8	financial	financial	ADJ
bioethics02-25741	14	9	interests	interest	NOUN
bioethics02-25741	14	10	,	,	PUNCT
bioethics02-25741	14	11	such	such	ADJ
bioethics02-25741	14	12	as	as	ADP
bioethics02-25741	14	13	the	the	DET
bioethics02-25741	14	14	$	$	SYM
bioethics02-25741	14	15	130	130	NUM
bioethics02-25741	14	16	billion	billion	NUM
bioethics02-25741	14	17	a	a	DET
bioethics02-25741	14	18	single	single	ADJ
bioethics02-25741	14	19	drug	drug	NOUN
bioethics02-25741	14	20	(	(	PUNCT
bioethics02-25741	14	21	lipitor	lipitor	NOUN
bioethics02-25741	14	22	)	)	PUNCT
bioethics02-25741	14	23	generated	generate	VERB
bioethics02-25741	14	24	over	over	ADP
bioethics02-25741	14	25	14	14	NUM
bioethics02-25741	14	26	years	year	NOUN
bioethics02-25741	14	27	1	1	NUM
bioethics02-25741	14	28	an	an	DET
bioethics02-25741	14	29	amount	amount	NOUN
bioethics02-25741	14	30	that	that	PRON
bioethics02-25741	14	31	is	be	AUX
bioethics02-25741	14	32	higher	high	ADJ
bioethics02-25741	14	33	than	than	ADP
bioethics02-25741	14	34	the	the	DET
bioethics02-25741	14	35	2010	2010	NUM
bioethics02-25741	14	36	gross	gross	ADJ
bioethics02-25741	14	37	domestic	domestic	ADJ
bioethics02-25741	14	38	product	product	NOUN
bioethics02-25741	14	39	of	of	ADP
bioethics02-25741	14	40	129	129	NUM
bioethics02-25741	14	41	of	of	ADP
bioethics02-25741	14	42	the	the	DET
bioethics02-25741	14	43	184	184	NUM
bioethics02-25741	14	44	countries	country	NOUN
bioethics02-25741	14	45	in	in	ADP
bioethics02-25741	14	46	the	the	DET
bioethics02-25741	14	47	world	world	NOUN
bioethics02-25741	14	48	2	2	NUM
bioethics02-25741	14	49	.	.	PUNCT
bioethics02-25741	15	1	besides	besides	SCONJ
bioethics02-25741	15	2	traditional	traditional	ADJ
bioethics02-25741	15	3	drugs	drug	NOUN
bioethics02-25741	15	4	,	,	PUNCT
bioethics02-25741	15	5	biologics	biologic	NOUN
bioethics02-25741	15	6	and	and	CCONJ
bioethics02-25741	15	7	devices	device	NOUN
bioethics02-25741	15	8	can	can	AUX
bioethics02-25741	15	9	also	also	ADV
bioethics02-25741	15	10	produce	produce	VERB
bioethics02-25741	15	11	huge	huge	ADJ
bioethics02-25741	15	12	revenue	revenue	NOUN
bioethics02-25741	15	13	.	.	PUNCT
bioethics02-25741	16	1	for	for	ADP
bioethics02-25741	16	2	example	example	NOUN
bioethics02-25741	16	3	,	,	PUNCT
bioethics02-25741	16	4	the	the	DET
bioethics02-25741	16	5	manufacturers	manufacturer	NOUN
bioethics02-25741	16	6	of	of	ADP
bioethics02-25741	16	7	anti	anti	ADJ
bioethics02-25741	16	8	-	-	ADJ
bioethics02-25741	16	9	tnf	tnf	ADJ
bioethics02-25741	16	10	biological	biological	ADJ
bioethics02-25741	16	11	drugs	drug	NOUN
bioethics02-25741	16	12	and	and	CCONJ
bioethics02-25741	16	13	therapies	therapy	NOUN
bioethics02-25741	16	14	have	have	AUX
bioethics02-25741	16	15	created	create	VERB
bioethics02-25741	16	16	a	a	DET
bioethics02-25741	16	17	$	$	SYM
bioethics02-25741	16	18	10	10	NUM
bioethics02-25741	16	19	billion	billion	NUM
bioethics02-25741	16	20	annual	annual	ADJ
bioethics02-25741	16	21	market	market	NOUN
bioethics02-25741	16	22	3,4	3,4	NUM
bioethics02-25741	16	23	even	even	ADV
bioethics02-25741	16	24	though	though	SCONJ
bioethics02-25741	16	25	these	these	DET
bioethics02-25741	16	26	agents	agent	NOUN
bioethics02-25741	16	27	are	be	AUX
bioethics02-25741	16	28	used	use	VERB
bioethics02-25741	16	29	for	for	ADP
bioethics02-25741	16	30	indications	indication	NOUN
bioethics02-25741	16	31	with	with	ADP
bioethics02-25741	16	32	rather	rather	ADV
bioethics02-25741	16	33	modest	modest	ADJ
bioethics02-25741	16	34	,	,	PUNCT
bioethics02-25741	16	35	incremental	incremental	ADJ
bioethics02-25741	16	36	benefits	benefit	NOUN
bioethics02-25741	16	37	.	.	PUNCT
bioethics02-25741	17	1	the	the	DET
bioethics02-25741	17	2	market	market	NOUN
bioethics02-25741	17	3	for	for	ADP
bioethics02-25741	17	4	drug	drug	NOUN
bioethics02-25741	17	5	-	-	PUNCT
bioethics02-25741	17	6	eluting	elute	VERB
bioethics02-25741	17	7	stents	stent	NOUN
bioethics02-25741	17	8	for	for	ADP
bioethics02-25741	17	9	coronary	coronary	ADJ
bioethics02-25741	17	10	artery	artery	NOUN
bioethics02-25741	17	11	disease	disease	NOUN
bioethics02-25741	17	12	is	be	AUX
bioethics02-25741	17	13	$	$	SYM
bioethics02-25741	17	14	4_6	4_6	NUM
bioethics02-25741	17	15	billion	billion	NUM
bioethics02-25741	17	16	per	per	ADP
bioethics02-25741	17	17	year	year	NOUN
bioethics02-25741	17	18	in	in	ADP
bioethics02-25741	17	19	the	the	DET
bioethics02-25741	17	20	united	united	PROPN
bioethics02-25741	17	21	states	states	PROPN
bioethics02-25741	17	22	alone	alone	ADJ
bioethics02-25741	17	23	5	5	NUM
bioethics02-25741	17	24	,	,	PUNCT
bioethics02-25741	17	25	even	even	ADV
bioethics02-25741	17	26	though	though	SCONJ
bioethics02-25741	17	27	a	a	DET
bioethics02-25741	17	28	large	large	ADJ
bioethics02-25741	17	29	share	share	NOUN
bioethics02-25741	17	30	of	of	ADP
bioethics02-25741	17	31	the	the	DET
bioethics02-25741	17	32	indications	indication	NOUN
bioethics02-25741	17	33	for	for	ADP
bioethics02-25741	17	34	which	which	PRON
bioethics02-25741	17	35	these	these	DET
bioethics02-25741	17	36	stents	stent	NOUN
bioethics02-25741	17	37	are	be	AUX
bioethics02-25741	17	38	used	use	VERB
bioethics02-25741	17	39	(	(	PUNCT
bioethics02-25741	17	40	e.g.	e.g.	ADV
bioethics02-25741	17	41	stable	stable	ADJ
bioethics02-25741	17	42	coronary	coronary	ADJ
bioethics02-25741	17	43	disease	disease	NOUN
bioethics02-25741	17	44	)	)	PUNCT
bioethics02-25741	17	45	has	have	VERB
bioethics02-25741	17	46	no	no	DET
bioethics02-25741	17	47	supporting	support	VERB
bioethics02-25741	17	48	evidence	evidence	NOUN
bioethics02-25741	17	49	6–9	6–9	PROPN
bioethics02-25741	17	50	.	.	PUNCT
bioethics02-25741	18	1	this	this	DET
bioethics02-25741	18	2	excessive	excessive	ADJ
bioethics02-25741	18	3	financial	financial	ADJ
bioethics02-25741	18	4	capacity	capacity	NOUN
bioethics02-25741	18	5	and	and	CCONJ
bioethics02-25741	18	6	the	the	DET
bioethics02-25741	18	7	associated	associated	ADJ
bioethics02-25741	18	8	political	political	ADJ
bioethics02-25741	18	9	and	and	CCONJ
bioethics02-25741	18	10	lobbying	lobbying	NOUN
bioethics02-25741	18	11	power	power	NOUN
bioethics02-25741	18	12	allow	allow	VERB
bioethics02-25741	18	13	the	the	DET
bioethics02-25741	18	14	industry	industry	NOUN
bioethics02-25741	18	15	to	to	PART
bioethics02-25741	18	16	dictate	dictate	VERB
bioethics02-25741	18	17	the	the	DET
bioethics02-25741	18	18	rules	rule	NOUN
bioethics02-25741	18	19	of	of	ADP
bioethics02-25741	18	20	the	the	DET
bioethics02-25741	18	21	healthcare	healthcare	NOUN
bioethics02-25741	18	22	game	game	NOUN
bioethics02-25741	18	23	to	to	PART
bioethics02-25741	18	24	serve	serve	VERB
bioethics02-25741	18	25	its	its	PRON
bioethics02-25741	18	26	interests	interest	NOUN
bioethics02-25741	18	27	at	at	ADP
bioethics02-25741	18	28	several	several	ADJ
bioethics02-25741	18	29	levels	level	NOUN
bioethics02-25741	18	30	.	.	PUNCT
bioethics02-25741	19	1	the	the	DET
bioethics02-25741	19	2	industry‘s	industry‘s	PROPN
bioethics02-25741	19	3	interests	interest	NOUN
bioethics02-25741	19	4	are	be	AUX
bioethics02-25741	19	5	often	often	ADV
bioethics02-25741	19	6	at	at	ADP
bioethics02-25741	19	7	stark	stark	ADJ
bioethics02-25741	19	8	contrast	contrast	NOUN
bioethics02-25741	19	9	to	to	ADP
bioethics02-25741	19	10	those	those	PRON
bioethics02-25741	19	11	of	of	ADP
bioethics02-25741	19	12	the	the	DET
bioethics02-25741	19	13	patients	patient	NOUN
bioethics02-25741	19	14	and	and	CCONJ
bioethics02-25741	19	15	the	the	DET
bioethics02-25741	19	16	society	society	NOUN
bioethics02-25741	19	17	.	.	PUNCT
bioethics02-25741	20	1	in	in	ADP
bioethics02-25741	20	2	this	this	DET
bioethics02-25741	20	3	article	article	NOUN
bioethics02-25741	20	4	,	,	PUNCT
bioethics02-25741	20	5	we	we	PRON
bioethics02-25741	20	6	try	try	VERB
bioethics02-25741	20	7	to	to	PART
bioethics02-25741	20	8	analyse	analyse	VERB
bioethics02-25741	20	9	the	the	DET
bioethics02-25741	20	10	multiple	multiple	ADJ
bioethics02-25741	20	11	complex	complex	ADJ
bioethics02-25741	20	12	pathways	pathway	NOUN
bioethics02-25741	20	13	through	through	ADP
bioethics02-25741	20	14	which	which	PRON
bioethics02-25741	20	15	the	the	DET
bioethics02-25741	20	16	industry	industry	NOUN
bioethics02-25741	20	17	has	have	AUX
bioethics02-25741	20	18	directly	directly	ADV
bioethics02-25741	20	19	or	or	CCONJ
bioethics02-25741	20	20	indirectly	indirectly	ADV
bioethics02-25741	20	21	infiltrated	infiltrate	VERB
bioethics02-25741	20	22	healthcare	healthcare	NOUN
bioethics02-25741	20	23	systems	system	NOUN
bioethics02-25741	20	24	including	include	VERB
bioethics02-25741	20	25	strategic	strategic	ADJ
bioethics02-25741	20	26	direction	direction	NOUN
bioethics02-25741	20	27	,	,	PUNCT
bioethics02-25741	20	28	expenditure	expenditure	NOUN
bioethics02-25741	20	29	,	,	PUNCT
bioethics02-25741	20	30	research	research	NOUN
bioethics02-25741	20	31	,	,	PUNCT
bioethics02-25741	20	32	medical	medical	ADJ
bioethics02-25741	20	33	education	education	NOUN
bioethics02-25741	20	34	and	and	CCONJ
bioethics02-25741	20	35	daily	daily	ADJ
bioethics02-25741	20	36	clinical	clinical	ADJ
bioethics02-25741	20	37	practice	practice	NOUN
bioethics02-25741	20	38	.	.	PUNCT
bioethics02-25741	21	1	how	how	SCONJ
bioethics02-25741	21	2	the	the	DET
bioethics02-25741	21	3	industry	industry	NOUN
bioethics02-25741	21	4	influences	influence	VERB
bioethics02-25741	21	5	healthcare	healthcare	PROPN
bioethics02-25741	21	6	research	research	NOUN
bioethics02-25741	21	7	,	,	PUNCT
bioethics02-25741	21	8	strategy	strategy	NOUN
bioethics02-25741	21	9	,	,	PUNCT
bioethics02-25741	21	10	expenditure	expenditure	NOUN
bioethics02-25741	21	11	and	and	CCONJ
bioethics02-25741	21	12	practice	practice	NOUN
bioethics02-25741	21	13	:	:	PUNCT
bioethics02-25741	21	14	the	the	DET
bioethics02-25741	21	15	industry	industry	NOUN
bioethics02-25741	21	16	has	have	AUX
bioethics02-25741	21	17	created	create	VERB
bioethics02-25741	21	18	means	mean	NOUN
bioethics02-25741	21	19	to	to	PART
bioethics02-25741	21	20	intervene	intervene	VERB
bioethics02-25741	21	21	in	in	ADP
bioethics02-25741	21	22	all	all	DET
bioethics02-25741	21	23	steps	step	NOUN
bioethics02-25741	21	24	of	of	ADP
bioethics02-25741	21	25	the	the	DET
bioethics02-25741	21	26	processes	process	NOUN
bioethics02-25741	21	27	that	that	PRON
bioethics02-25741	21	28	influence	influence	VERB
bioethics02-25741	21	29	healthcare	healthcare	PROPN
bioethics02-25741	21	30	research	research	NOUN
bioethics02-25741	21	31	,	,	PUNCT
bioethics02-25741	21	32	strategy	strategy	NOUN
bioethics02-25741	21	33	,	,	PUNCT
bioethics02-25741	21	34	expenditure	expenditure	NOUN
bioethics02-25741	21	35	and	and	CCONJ
bioethics02-25741	21	36	practice	practice	NOUN
bioethics02-25741	21	37	.	.	PUNCT
bioethics02-25741	22	1	these	these	PRON
bioethics02-25741	22	2	include	include	VERB
bioethics02-25741	22	3	evidence	evidence	NOUN
bioethics02-25741	22	4	base	base	NOUN
bioethics02-25741	22	5	production	production	NOUN
bioethics02-25741	22	6	,	,	PUNCT
bioethics02-25741	22	7	evidence	evidence	NOUN
bioethics02-25741	22	8	synthesis	synthesis	NOUN
bioethics02-25741	22	9	,	,	PUNCT
bioethics02-25741	22	10	understanding	understanding	NOUN
bioethics02-25741	22	11	of	of	ADP
bioethics02-25741	22	12	harms	harm	NOUN
bioethics02-25741	22	13	issues	issue	NOUN
bioethics02-25741	22	14	,	,	PUNCT
bioethics02-25741	22	15	cost	cost	NOUN
bioethics02-25741	22	16	-	-	PUNCT
bioethics02-25741	22	17	effectiveness	effectiveness	NOUN
bioethics02-25741	22	18	evaluation	evaluation	NOUN
bioethics02-25741	22	19	,	,	PUNCT
bioethics02-25741	22	20	clinical	clinical	ADJ
bioethics02-25741	22	21	guidelines	guideline	NOUN
bioethics02-25741	22	22	formation	formation	NOUN
bioethics02-25741	22	23	,	,	PUNCT
bioethics02-25741	22	24	healthcare	healthcare	PROPN
bioethics02-25741	22	25	professional	professional	ADJ
bioethics02-25741	22	26	education	education	NOUN
bioethics02-25741	22	27	and	and	CCONJ
bioethics02-25741	22	28	direct	direct	ADJ
bioethics02-25741	22	29	influences	influence	NOUN
bioethics02-25741	22	30	on	on	ADP
bioethics02-25741	22	31	healthcare	healthcare	PROPN
bioethics02-25741	22	32	professional	professional	ADJ
bioethics02-25741	22	33	decisions	decision	NOUN
bioethics02-25741	22	34	.	.	PUNCT
bioethics02-25741	23	1	mailto:drarif79@yahoo.com	mailto:drarif79@yahoo.com	PROPN
bioethics02-25741	23	2	bangladesh	bangladesh	PROPN
bioethics02-25741	23	3	journal	journal	PROPN
bioethics02-25741	23	4	of	of	ADP
bioethics02-25741	23	5	bioethics	bioethic	NOUN
bioethics02-25741	23	6	2015	2015	NUM
bioethics02-25741	23	7	;	;	PUNCT
bioethics02-25741	23	8	6(2):15	6(2):15	X
bioethics02-25741	23	9	-	-	SYM
bioethics02-25741	23	10	22	22	NUM
bioethics02-25741	23	11	16	16	NUM
bioethics02-25741	23	12	evidence	evidence	NOUN
bioethics02-25741	23	13	base	base	NOUN
bioethics02-25741	23	14	production	production	NOUN
bioethics02-25741	23	15	:	:	PUNCT
bioethics02-25741	23	16	industry	industry	NOUN
bioethics02-25741	23	17	funds	fund	NOUN
bioethics02-25741	23	18	and	and	CCONJ
bioethics02-25741	23	19	often	often	ADV
bioethics02-25741	23	20	designs	design	VERB
bioethics02-25741	23	21	and	and	CCONJ
bioethics02-25741	23	22	controls	control	VERB
bioethics02-25741	23	23	a	a	DET
bioethics02-25741	23	24	large	large	ADJ
bioethics02-25741	23	25	portion	portion	NOUN
bioethics02-25741	23	26	of	of	ADP
bioethics02-25741	23	27	the	the	DET
bioethics02-25741	23	28	most	most	ADV
bioethics02-25741	23	29	influential	influential	ADJ
bioethics02-25741	23	30	medical	medical	ADJ
bioethics02-25741	23	31	studies	study	NOUN
bioethics02-25741	23	32	.	.	PUNCT
bioethics02-25741	24	1	trials	trial	NOUN
bioethics02-25741	24	2	funded	fund	VERB
bioethics02-25741	24	3	by	by	ADP
bioethics02-25741	24	4	for	for	ADP
bioethics02-25741	24	5	profit	profit	NOUN
bioethics02-25741	24	6	organizations	organization	NOUN
bioethics02-25741	24	7	are	be	AUX
bioethics02-25741	24	8	on	on	ADP
bioethics02-25741	24	9	average	average	ADJ
bioethics02-25741	24	10	4	4	NUM
bioethics02-25741	24	11	times	time	NOUN
bioethics02-25741	24	12	more	more	ADV
bioethics02-25741	24	13	likely	likely	ADJ
bioethics02-25741	24	14	than	than	ADP
bioethics02-25741	24	15	trials	trial	NOUN
bioethics02-25741	24	16	sponsored	sponsor	VERB
bioethics02-25741	24	17	by	by	ADP
bioethics02-25741	24	18	non	non	ADJ
bioethics02-25741	24	19	-	-	ADJ
bioethics02-25741	24	20	for	for	ADP
bioethics02-25741	24	21	-	-	PUNCT
bioethics02-25741	24	22	profit	profit	NOUN
bioethics02-25741	24	23	organizations	organization	NOUN
bioethics02-25741	24	24	to	to	PART
bioethics02-25741	24	25	favour	favour	VERB
bioethics02-25741	24	26	the	the	DET
bioethics02-25741	24	27	sponsored	sponsor	VERB
bioethics02-25741	24	28	drug	drug	NOUN
bioethics02-25741	24	29	10,11	10,11	NOUN
bioethics02-25741	24	30	.	.	PUNCT
bioethics02-25741	25	1	empirical	empirical	ADJ
bioethics02-25741	25	2	evidence	evidence	NOUN
bioethics02-25741	25	3	suggests	suggest	VERB
bioethics02-25741	25	4	that	that	SCONJ
bioethics02-25741	25	5	while	while	SCONJ
bioethics02-25741	25	6	methodological	methodological	ADJ
bioethics02-25741	25	7	quality	quality	NOUN
bioethics02-25741	25	8	is	be	AUX
bioethics02-25741	25	9	the	the	DET
bioethics02-25741	25	10	same	same	ADJ
bioethics02-25741	25	11	in	in	ADP
bioethics02-25741	25	12	industry	industry	NOUN
bioethics02-25741	25	13	-	-	PUNCT
bioethics02-25741	25	14	sponsored	sponsor	VERB
bioethics02-25741	25	15	and	and	CCONJ
bioethics02-25741	25	16	other	other	ADJ
bioethics02-25741	25	17	trials	trial	NOUN
bioethics02-25741	25	18	10	10	NUM
bioethics02-25741	25	19	,	,	PUNCT
bioethics02-25741	25	20	industry	industry	NOUN
bioethics02-25741	25	21	-	-	PUNCT
bioethics02-25741	25	22	sponsored	sponsor	VERB
bioethics02-25741	25	23	trials	trial	NOUN
bioethics02-25741	25	24	are	be	AUX
bioethics02-25741	25	25	more	more	ADV
bioethics02-25741	25	26	likely	likely	ADJ
bioethics02-25741	25	27	to	to	PART
bioethics02-25741	25	28	compare	compare	VERB
bioethics02-25741	25	29	the	the	DET
bioethics02-25741	25	30	sponsored	sponsor	VERB
bioethics02-25741	25	31	intervention	intervention	NOUN
bioethics02-25741	25	32	against	against	ADP
bioethics02-25741	25	33	an	an	DET
bioethics02-25741	25	34	inactive	inactive	ADJ
bioethics02-25741	25	35	or	or	CCONJ
bioethics02-25741	25	36	straw	straw	NOUN
bioethics02-25741	25	37	man	man	NOUN
bioethics02-25741	25	38	comparator	comparator	NOUN
bioethics02-25741	25	39	3,10	3,10	NUM
bioethics02-25741	25	40	.	.	PUNCT
bioethics02-25741	26	1	an	an	DET
bioethics02-25741	26	2	evaluation	evaluation	NOUN
bioethics02-25741	26	3	of	of	ADP
bioethics02-25741	26	4	over	over	ADP
bioethics02-25741	26	5	600	600	NUM
bioethics02-25741	26	6	trials	trial	NOUN
bioethics02-25741	26	7	registered	register	VERB
bioethics02-25741	26	8	in	in	ADP
bioethics02-25741	26	9	clinicaltrials.gov	clinicaltrials.gov	PROPN
bioethics02-25741	26	10	shows	show	VERB
bioethics02-25741	26	11	that	that	SCONJ
bioethics02-25741	26	12	with	with	ADP
bioethics02-25741	26	13	few	few	ADJ
bioethics02-25741	26	14	exceptions	exception	NOUN
bioethics02-25741	26	15	,	,	PUNCT
bioethics02-25741	26	16	single	single	ADJ
bioethics02-25741	26	17	trials	trial	NOUN
bioethics02-25741	26	18	address	address	VERB
bioethics02-25741	26	19	only	only	ADV
bioethics02-25741	26	20	products	product	NOUN
bioethics02-25741	26	21	of	of	ADP
bioethics02-25741	26	22	a	a	DET
bioethics02-25741	26	23	single	single	ADJ
bioethics02-25741	26	24	company	company	NOUN
bioethics02-25741	26	25	12	12	NUM
bioethics02-25741	26	26	.	.	PUNCT
bioethics02-25741	27	1	however	however	ADV
bioethics02-25741	27	2	,	,	PUNCT
bioethics02-25741	27	3	for	for	ADP
bioethics02-25741	27	4	most	most	ADJ
bioethics02-25741	27	5	conditions	condition	NOUN
bioethics02-25741	27	6	,	,	PUNCT
bioethics02-25741	27	7	there	there	PRON
bioethics02-25741	27	8	exist	exist	VERB
bioethics02-25741	27	9	many	many	ADJ
bioethics02-25741	27	10	possible	possible	ADJ
bioethics02-25741	27	11	interventions	intervention	NOUN
bioethics02-25741	27	12	,	,	PUNCT
bioethics02-25741	27	13	including	include	VERB
bioethics02-25741	27	14	lifestyle	lifestyle	NOUN
bioethics02-25741	27	15	changes	change	NOUN
bioethics02-25741	27	16	and	and	CCONJ
bioethics02-25741	27	17	products	product	NOUN
bioethics02-25741	27	18	manufactured	manufacture	VERB
bioethics02-25741	27	19	by	by	ADP
bioethics02-25741	27	20	diverse	diverse	ADJ
bioethics02-25741	27	21	companies	company	NOUN
bioethics02-25741	27	22	.	.	PUNCT
bioethics02-25741	28	1	finally	finally	ADV
bioethics02-25741	28	2	,	,	PUNCT
bioethics02-25741	28	3	for	for	ADP
bioethics02-25741	28	4	many	many	ADJ
bioethics02-25741	28	5	years	year	NOUN
bioethics02-25741	28	6	now	now	ADV
bioethics02-25741	28	7	,	,	PUNCT
bioethics02-25741	28	8	the	the	DET
bioethics02-25741	28	9	public	public	ADJ
bioethics02-25741	28	10	sector	sector	NOUN
bioethics02-25741	28	11	has	have	AUX
bioethics02-25741	28	12	largely	largely	ADV
bioethics02-25741	28	13	abandoned	abandon	VERB
bioethics02-25741	28	14	the	the	DET
bioethics02-25741	28	15	conduct	conduct	NOUN
bioethics02-25741	28	16	of	of	ADP
bioethics02-25741	28	17	randomized	randomized	ADJ
bioethics02-25741	28	18	trials	trial	NOUN
bioethics02-25741	28	19	to	to	ADP
bioethics02-25741	28	20	the	the	DET
bioethics02-25741	28	21	industry	industry	NOUN
bioethics02-25741	28	22	and	and	CCONJ
bioethics02-25741	28	23	thus	thus	ADV
bioethics02-25741	28	24	,	,	PUNCT
bioethics02-25741	28	25	not	not	PART
bioethics02-25741	28	26	surprisingly	surprisingly	ADV
bioethics02-25741	28	27	,	,	PUNCT
bioethics02-25741	28	28	the	the	DET
bioethics02-25741	28	29	most	most	ADV
bioethics02-25741	28	30	cited	cite	VERB
bioethics02-25741	28	31	trials	trial	NOUN
bioethics02-25741	28	32	are	be	AUX
bioethics02-25741	28	33	almost	almost	ADV
bioethics02-25741	28	34	always	always	ADV
bioethics02-25741	28	35	industry	industry	NOUN
bioethics02-25741	28	36	sponsored	sponsor	VERB
bioethics02-25741	28	37	,	,	PUNCT
bioethics02-25741	28	38	often	often	ADV
bioethics02-25741	28	39	exclusively	exclusively	ADV
bioethics02-25741	28	40	so	so	ADV
bioethics02-25741	28	41	12	12	NUM
bioethics02-25741	28	42	.	.	PUNCT
bioethics02-25741	29	1	these	these	DET
bioethics02-25741	29	2	trials	trial	NOUN
bioethics02-25741	29	3	then	then	ADV
bioethics02-25741	29	4	also	also	ADV
bioethics02-25741	29	5	guide	guide	VERB
bioethics02-25741	29	6	the	the	DET
bioethics02-25741	29	7	conduct	conduct	NOUN
bioethics02-25741	29	8	of	of	ADP
bioethics02-25741	29	9	other	other	ADJ
bioethics02-25741	29	10	clinical	clinical	ADJ
bioethics02-25741	29	11	research	research	NOUN
bioethics02-25741	29	12	.	.	PUNCT
bioethics02-25741	30	1	medical	medical	ADJ
bioethics02-25741	30	2	research	research	NOUN
bioethics02-25741	30	3	is	be	AUX
bioethics02-25741	30	4	doomed	doom	VERB
bioethics02-25741	30	5	to	to	PART
bioethics02-25741	30	6	navigate	navigate	VERB
bioethics02-25741	30	7	only	only	ADJ
bioethics02-25741	30	8	questions	question	NOUN
bioethics02-25741	30	9	posed	pose	VERB
bioethics02-25741	30	10	by	by	ADP
bioethics02-25741	30	11	the	the	DET
bioethics02-25741	30	12	industry	industry	NOUN
bioethics02-25741	30	13	and	and	CCONJ
bioethics02-25741	30	14	their	their	PRON
bioethics02-25741	30	15	extensions	extension	NOUN
bioethics02-25741	30	16	.	.	PUNCT
bioethics02-25741	31	1	there	there	PRON
bioethics02-25741	31	2	is	be	VERB
bioethics02-25741	31	3	increasing	increase	VERB
bioethics02-25741	31	4	direct	direct	ADJ
bioethics02-25741	31	5	evidence	evidence	NOUN
bioethics02-25741	31	6	about	about	ADP
bioethics02-25741	31	7	the	the	DET
bioethics02-25741	31	8	manipulation	manipulation	NOUN
bioethics02-25741	31	9	of	of	ADP
bioethics02-25741	31	10	reported	report	VERB
bioethics02-25741	31	11	results	result	NOUN
bioethics02-25741	31	12	in	in	ADP
bioethics02-25741	31	13	industry	industry	NOUN
bioethics02-25741	31	14	-	-	PUNCT
bioethics02-25741	31	15	sponsored	sponsor	VERB
bioethics02-25741	31	16	trials	trial	NOUN
bioethics02-25741	31	17	,	,	PUNCT
bioethics02-25741	31	18	which	which	PRON
bioethics02-25741	31	19	demonstrate	demonstrate	VERB
bioethics02-25741	31	20	favourable	favourable	ADJ
bioethics02-25741	31	21	results	result	NOUN
bioethics02-25741	31	22	and	and	CCONJ
bioethics02-25741	31	23	the	the	DET
bioethics02-25741	31	24	avoidance	avoidance	NOUN
bioethics02-25741	31	25	of	of	ADP
bioethics02-25741	31	26	inconvenient	inconvenient	ADJ
bioethics02-25741	31	27	findings	finding	NOUN
bioethics02-25741	31	28	,	,	PUNCT
bioethics02-25741	31	29	as	as	ADP
bioethics02-25741	31	30	in	in	ADP
bioethics02-25741	31	31	the	the	DET
bioethics02-25741	31	32	case	case	NOUN
bioethics02-25741	31	33	of	of	ADP
bioethics02-25741	31	34	gabapentin	gabapentin	NOUN
bioethics02-25741	31	35	for	for	ADP
bioethics02-25741	31	36	off	off	ADP
bioethics02-25741	31	37	-	-	PUNCT
bioethics02-25741	31	38	label	label	NOUN
bioethics02-25741	31	39	use	use	NOUN
bioethics02-25741	31	40	13	13	NUM
bioethics02-25741	31	41	.	.	PUNCT
bioethics02-25741	32	1	in	in	ADP
bioethics02-25741	32	2	addition	addition	NOUN
bioethics02-25741	32	3	to	to	ADP
bioethics02-25741	32	4	these	these	DET
bioethics02-25741	32	5	direct	direct	ADJ
bioethics02-25741	32	6	biases	bias	NOUN
bioethics02-25741	32	7	,	,	PUNCT
bioethics02-25741	32	8	the	the	DET
bioethics02-25741	32	9	industry	industry	NOUN
bioethics02-25741	32	10	has	have	VERB
bioethics02-25741	32	11	a	a	DET
bioethics02-25741	32	12	major	major	ADJ
bioethics02-25741	32	13	impact	impact	NOUN
bioethics02-25741	32	14	on	on	ADP
bioethics02-25741	32	15	which	which	PRON
bioethics02-25741	32	16	research	research	NOUN
bioethics02-25741	32	17	is	be	AUX
bioethics02-25741	32	18	published	publish	VERB
bioethics02-25741	32	19	in	in	ADP
bioethics02-25741	32	20	the	the	DET
bioethics02-25741	32	21	most	most	ADV
bioethics02-25741	32	22	influential	influential	ADJ
bioethics02-25741	32	23	medical	medical	ADJ
bioethics02-25741	32	24	journals	journal	NOUN
bioethics02-25741	32	25	through	through	ADP
bioethics02-25741	32	26	ghost	ghost	NOUN
bioethics02-25741	32	27	authorship	authorship	NOUN
bioethics02-25741	32	28	14,15	14,15	NUM
bioethics02-25741	32	29	,	,	PUNCT
bioethics02-25741	32	30	(	(	PUNCT
bioethics02-25741	32	31	i.e.	i.e.	X
bioethics02-25741	32	32	raising	raise	VERB
bioethics02-25741	32	33	the	the	DET
bioethics02-25741	32	34	status	status	NOUN
bioethics02-25741	32	35	of	of	ADP
bioethics02-25741	32	36	trial	trial	NOUN
bioethics02-25741	32	37	results	result	NOUN
bioethics02-25741	32	38	by	by	ADP
bioethics02-25741	32	39	listing	list	VERB
bioethics02-25741	32	40	academically	academically	ADV
bioethics02-25741	32	41	affiliated	affiliate	VERB
bioethics02-25741	32	42	investigators	investigator	NOUN
bioethics02-25741	32	43	as	as	ADP
bioethics02-25741	32	44	first	first	ADJ
bioethics02-25741	32	45	or	or	CCONJ
bioethics02-25741	32	46	second	second	ADJ
bioethics02-25741	32	47	authors	author	NOUN
bioethics02-25741	32	48	in	in	ADP
bioethics02-25741	32	49	manuscripts	manuscript	NOUN
bioethics02-25741	32	50	)	)	PUNCT
bioethics02-25741	32	51	written	write	VERB
bioethics02-25741	32	52	by	by	ADP
bioethics02-25741	32	53	company	company	NOUN
bioethics02-25741	32	54	staff	staff	NOUN
bioethics02-25741	32	55	or	or	CCONJ
bioethics02-25741	32	56	professional	professional	ADJ
bioethics02-25741	32	57	medical	medical	ADJ
bioethics02-25741	32	58	writers	writer	NOUN
bioethics02-25741	32	59	paid	pay	VERB
bioethics02-25741	32	60	by	by	ADP
bioethics02-25741	32	61	the	the	DET
bioethics02-25741	32	62	companies	company	NOUN
bioethics02-25741	32	63	.	.	PUNCT
bioethics02-25741	33	1	it	it	PRON
bioethics02-25741	33	2	is	be	AUX
bioethics02-25741	33	3	possible	possible	ADJ
bioethics02-25741	33	4	that	that	SCONJ
bioethics02-25741	33	5	major	major	ADJ
bioethics02-25741	33	6	journals	journal	NOUN
bioethics02-25741	33	7	have	have	AUX
bioethics02-25741	33	8	often	often	ADV
bioethics02-25741	33	9	undisclosed	undisclose	VERB
bioethics02-25741	33	10	conflict	conflict	NOUN
bioethics02-25741	33	11	of	of	ADP
bioethics02-25741	33	12	interests	interest	NOUN
bioethics02-25741	33	13	from	from	ADP
bioethics02-25741	33	14	publishing	publish	VERB
bioethics02-25741	33	15	industry	industry	NOUN
bioethics02-25741	33	16	trials	trial	NOUN
bioethics02-25741	33	17	.	.	PUNCT
bioethics02-25741	34	1	journals	journal	NOUN
bioethics02-25741	34	2	also	also	ADV
bioethics02-25741	34	3	have	have	VERB
bioethics02-25741	34	4	conflicts	conflict	NOUN
bioethics02-25741	34	5	themselves	themselves	PRON
bioethics02-25741	34	6	,	,	PUNCT
bioethics02-25741	34	7	because	because	SCONJ
bioethics02-25741	34	8	such	such	ADJ
bioethics02-25741	34	9	industry	industry	NOUN
bioethics02-25741	34	10	trials	trial	NOUN
bioethics02-25741	34	11	generate	generate	VERB
bioethics02-25741	34	12	considerable	considerable	ADJ
bioethics02-25741	34	13	revenue	revenue	NOUN
bioethics02-25741	34	14	from	from	ADP
bioethics02-25741	34	15	offprints	offprint	NOUN
bioethics02-25741	34	16	and	and	CCONJ
bioethics02-25741	34	17	can	can	AUX
bioethics02-25741	34	18	boost	boost	VERB
bioethics02-25741	34	19	the	the	DET
bioethics02-25741	34	20	journal‘s	journal‘s	PROPN
bioethics02-25741	34	21	impact	impact	NOUN
bioethics02-25741	34	22	factor	factor	NOUN
bioethics02-25741	34	23	by	by	ADP
bioethics02-25741	34	24	as	as	ADV
bioethics02-25741	34	25	much	much	ADJ
bioethics02-25741	34	26	as	as	ADP
bioethics02-25741	34	27	15	15	NUM
bioethics02-25741	34	28	%	%	NOUN
bioethics02-25741	34	29	6	6	NUM
bioethics02-25741	34	30	.	.	PUNCT
bioethics02-25741	35	1	evidence	evidence	NOUN
bioethics02-25741	35	2	synthesis	synthesis	NOUN
bioethics02-25741	35	3	:	:	PUNCT
bioethics02-25741	35	4	systematic	systematic	ADJ
bioethics02-25741	35	5	reviews	review	NOUN
bioethics02-25741	35	6	that	that	PRON
bioethics02-25741	35	7	summarize	summarize	VERB
bioethics02-25741	35	8	trials	trial	NOUN
bioethics02-25741	35	9	addressing	address	VERB
bioethics02-25741	35	10	the	the	DET
bioethics02-25741	35	11	wrong	wrong	ADJ
bioethics02-25741	35	12	questions	question	NOUN
bioethics02-25741	35	13	(	(	PUNCT
bioethics02-25741	35	14	as	as	ADP
bioethics02-25741	35	15	above	above	ADJ
bioethics02-25741	35	16	)	)	PUNCT
bioethics02-25741	35	17	will	will	AUX
bioethics02-25741	35	18	simply	simply	ADV
bioethics02-25741	35	19	reinforce	reinforce	VERB
bioethics02-25741	35	20	the	the	DET
bioethics02-25741	35	21	wrong	wrong	ADJ
bioethics02-25741	35	22	messages	message	NOUN
bioethics02-25741	35	23	17	17	NUM
bioethics02-25741	35	24	,	,	PUNCT
bioethics02-25741	35	25	unless	unless	SCONJ
bioethics02-25741	35	26	meta	meta	NOUN
bioethics02-25741	35	27	-	-	PUNCT
bioethics02-25741	35	28	analysts	analyst	NOUN
bioethics02-25741	35	29	are	be	AUX
bioethics02-25741	35	30	astute	astute	ADJ
bioethics02-25741	35	31	to	to	PART
bioethics02-25741	35	32	diagnose	diagnose	VERB
bioethics02-25741	35	33	the	the	DET
bioethics02-25741	35	34	problems	problem	NOUN
bioethics02-25741	35	35	in	in	ADP
bioethics02-25741	35	36	the	the	DET
bioethics02-25741	35	37	generation	generation	NOUN
bioethics02-25741	35	38	of	of	ADP
bioethics02-25741	35	39	the	the	DET
bioethics02-25741	35	40	evidence	evidence	NOUN
bioethics02-25741	35	41	,	,	PUNCT
bioethics02-25741	35	42	let	let	VERB
bioethics02-25741	35	43	alone	alone	ADJ
bioethics02-25741	35	44	publication	publication	NOUN
bioethics02-25741	35	45	and	and	CCONJ
bioethics02-25741	35	46	other	other	ADJ
bioethics02-25741	35	47	selection	selection	NOUN
bioethics02-25741	35	48	biases	bias	NOUN
bioethics02-25741	35	49	.	.	PUNCT
bioethics02-25741	36	1	access	access	NOUN
bioethics02-25741	36	2	to	to	ADP
bioethics02-25741	36	3	raw	raw	ADJ
bioethics02-25741	36	4	data	datum	NOUN
bioethics02-25741	36	5	of	of	ADP
bioethics02-25741	36	6	clinical	clinical	ADJ
bioethics02-25741	36	7	trials	trial	NOUN
bioethics02-25741	36	8	to	to	ADP
bioethics02-25741	36	9	date	date	NOUN
bioethics02-25741	36	10	has	have	AUX
bioethics02-25741	36	11	been	be	AUX
bioethics02-25741	36	12	limited	limit	VERB
bioethics02-25741	36	13	,	,	PUNCT
bioethics02-25741	36	14	and	and	CCONJ
bioethics02-25741	36	15	integration	integration	NOUN
bioethics02-25741	36	16	in	in	ADP
bioethics02-25741	36	17	systematic	systematic	ADJ
bioethics02-25741	36	18	reviews	review	NOUN
bioethics02-25741	36	19	of	of	ADP
bioethics02-25741	36	20	the	the	DET
bioethics02-25741	36	21	data	datum	NOUN
bioethics02-25741	36	22	that	that	PRON
bioethics02-25741	36	23	are	be	AUX
bioethics02-25741	36	24	readily	readily	ADV
bioethics02-25741	36	25	available	available	ADJ
bioethics02-25741	36	26	may	may	AUX
bioethics02-25741	36	27	perpetuate	perpetuate	VERB
bioethics02-25741	36	28	and	and	CCONJ
bioethics02-25741	36	29	solidify	solidify	VERB
bioethics02-25741	36	30	the	the	DET
bioethics02-25741	36	31	biases	bias	NOUN
bioethics02-25741	36	32	of	of	ADP
bioethics02-25741	36	33	the	the	DET
bioethics02-25741	36	34	primary	primary	ADJ
bioethics02-25741	36	35	literature	literature	NOUN
bioethics02-25741	36	36	18	18	NUM
bioethics02-25741	36	37	.	.	PUNCT
bioethics02-25741	37	1	moreover	moreover	ADV
bioethics02-25741	37	2	,	,	PUNCT
bioethics02-25741	37	3	as	as	SCONJ
bioethics02-25741	37	4	systematic	systematic	ADJ
bioethics02-25741	37	5	reviews	review	NOUN
bioethics02-25741	37	6	and	and	CCONJ
bioethics02-25741	37	7	meta	meta	NOUN
bioethics02-25741	37	8	-	-	PUNCT
bioethics02-25741	37	9	analyses	analysis	NOUN
bioethics02-25741	37	10	have	have	AUX
bioethics02-25741	37	11	grown	grow	VERB
bioethics02-25741	37	12	in	in	ADP
bioethics02-25741	37	13	prestige	prestige	NOUN
bioethics02-25741	37	14	and	and	CCONJ
bioethics02-25741	37	15	influence	influence	NOUN
bioethics02-25741	37	16	,	,	PUNCT
bioethics02-25741	37	17	the	the	DET
bioethics02-25741	37	18	industry	industry	NOUN
bioethics02-25741	37	19	has	have	AUX
bioethics02-25741	37	20	also	also	ADV
bioethics02-25741	37	21	infiltrated	infiltrate	VERB
bioethics02-25741	37	22	this	this	DET
bioethics02-25741	37	23	type	type	NOUN
bioethics02-25741	37	24	of	of	ADP
bioethics02-25741	37	25	research	research	NOUN
bioethics02-25741	37	26	.	.	PUNCT
bioethics02-25741	38	1	a	a	DET
bioethics02-25741	38	2	systematic	systematic	ADJ
bioethics02-25741	38	3	review	review	NOUN
bioethics02-25741	38	4	comparing	compare	VERB
bioethics02-25741	38	5	the	the	DET
bioethics02-25741	38	6	methodological	methodological	ADJ
bioethics02-25741	38	7	quality	quality	NOUN
bioethics02-25741	38	8	of	of	ADP
bioethics02-25741	38	9	meta	meta	NOUN
bioethics02-25741	38	10	-	-	PUNCT
bioethics02-25741	38	11	analyses	analysis	NOUN
bioethics02-25741	38	12	of	of	ADP
bioethics02-25741	38	13	the	the	DET
bioethics02-25741	38	14	same	same	ADJ
bioethics02-25741	38	15	drugs	drug	NOUN
bioethics02-25741	38	16	by	by	ADP
bioethics02-25741	38	17	source	source	NOUN
bioethics02-25741	38	18	of	of	ADP
bioethics02-25741	38	19	funding	funding	NOUN
bioethics02-25741	38	20	(	(	PUNCT
bioethics02-25741	38	21	industry	industry	NOUN
bioethics02-25741	38	22	-	-	PUNCT
bioethics02-25741	38	23	funded	fund	VERB
bioethics02-25741	38	24	verses	verses	ADP
bioethics02-25741	38	25	nonindustry	nonindustry	PROPN
bioethics02-25741	38	26	funded	fund	VERB
bioethics02-25741	38	27	)	)	PUNCT
bioethics02-25741	38	28	19	19	NUM
bioethics02-25741	38	29	concluded	conclude	VERB
bioethics02-25741	38	30	that	that	SCONJ
bioethics02-25741	38	31	the	the	DET
bioethics02-25741	38	32	former	former	ADJ
bioethics02-25741	38	33	type	type	NOUN
bioethics02-25741	38	34	of	of	ADP
bioethics02-25741	38	35	study	study	NOUN
bioethics02-25741	38	36	is	be	AUX
bioethics02-25741	38	37	of	of	ADP
bioethics02-25741	38	38	lower	low	ADJ
bioethics02-25741	38	39	methodological	methodological	ADJ
bioethics02-25741	38	40	quality	quality	NOUN
bioethics02-25741	38	41	and	and	CCONJ
bioethics02-25741	38	42	considerably	considerably	ADV
bioethics02-25741	38	43	more	more	ADV
bioethics02-25741	38	44	likely	likely	ADJ
bioethics02-25741	38	45	to	to	PART
bioethics02-25741	38	46	omit	omit	VERB
bioethics02-25741	38	47	reporting	report	VERB
bioethics02-25741	38	48	bias	bias	NOUN
bioethics02-25741	38	49	-	-	PUNCT
bioethics02-25741	38	50	relevant	relevant	ADJ
bioethics02-25741	38	51	details	detail	NOUN
bioethics02-25741	38	52	(	(	PUNCT
bioethics02-25741	38	53	e.g.	e.g.	ADV
bioethics02-25741	38	54	descriptions	description	NOUN
bioethics02-25741	38	55	of	of	ADP
bioethics02-25741	38	56	the	the	DET
bioethics02-25741	38	57	excluded	exclude	VERB
bioethics02-25741	38	58	patients	patient	NOUN
bioethics02-25741	38	59	/	/	SYM
bioethics02-25741	38	60	studies	study	NOUN
bioethics02-25741	38	61	)	)	PUNCT
bioethics02-25741	38	62	.	.	PUNCT
bioethics02-25741	39	1	although	although	SCONJ
bioethics02-25741	39	2	the	the	DET
bioethics02-25741	39	3	estimated	estimate	VERB
bioethics02-25741	39	4	treatment	treatment	NOUN
bioethics02-25741	39	5	effects	effect	NOUN
bioethics02-25741	39	6	were	be	AUX
bioethics02-25741	39	7	similar	similar	ADJ
bioethics02-25741	39	8	on	on	ADP
bioethics02-25741	39	9	average	average	ADJ
bioethics02-25741	39	10	,	,	PUNCT
bioethics02-25741	39	11	100	100	NUM
bioethics02-25741	39	12	%	%	NOUN
bioethics02-25741	39	13	of	of	ADP
bioethics02-25741	39	14	industry	industry	NOUN
bioethics02-25741	39	15	-	-	PUNCT
bioethics02-25741	39	16	funded	fund	VERB
bioethics02-25741	39	17	meta	meta	NOUN
bioethics02-25741	39	18	-	-	PUNCT
bioethics02-25741	39	19	analyses	analysis	NOUN
bioethics02-25741	39	20	had	have	VERB
bioethics02-25741	39	21	conclusions	conclusion	NOUN
bioethics02-25741	39	22	recommending	recommend	VERB
bioethics02-25741	39	23	the	the	DET
bioethics02-25741	39	24	experimental	experimental	ADJ
bioethics02-25741	39	25	drug	drug	NOUN
bioethics02-25741	39	26	without	without	ADP
bioethics02-25741	39	27	reservations	reservation	NOUN
bioethics02-25741	39	28	compared	compare	VERB
bioethics02-25741	39	29	with	with	ADP
bioethics02-25741	39	30	0	0	NUM
bioethics02-25741	39	31	%	%	NOUN
bioethics02-25741	39	32	of	of	ADP
bioethics02-25741	39	33	the	the	DET
bioethics02-25741	39	34	(	(	PUNCT
bioethics02-25741	39	35	independent	independent	ADJ
bioethics02-25741	39	36	)	)	PUNCT
bioethics02-25741	39	37	cochrane	cochrane	NOUN
bioethics02-25741	39	38	reviews	review	NOUN
bioethics02-25741	39	39	19	19	NUM
bioethics02-25741	39	40	.	.	PUNCT
bioethics02-25741	40	1	in	in	ADP
bioethics02-25741	40	2	metaanalyses	metaanalyse	NOUN
bioethics02-25741	40	3	of	of	ADP
bioethics02-25741	40	4	antihypertensive	antihypertensive	ADJ
bioethics02-25741	40	5	drugs	drug	NOUN
bioethics02-25741	40	6	,	,	PUNCT
bioethics02-25741	40	7	financial	financial	ADJ
bioethics02-25741	40	8	ties	tie	NOUN
bioethics02-25741	40	9	to	to	ADP
bioethics02-25741	40	10	a	a	DET
bioethics02-25741	40	11	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	40	12	company	company	NOUN
bioethics02-25741	40	13	were	be	AUX
bioethics02-25741	40	14	not	not	PART
bioethics02-25741	40	15	associated	associate	VERB
bioethics02-25741	40	16	with	with	ADP
bioethics02-25741	40	17	favourable	favourable	ADJ
bioethics02-25741	40	18	results	result	NOUN
bioethics02-25741	40	19	,	,	PUNCT
bioethics02-25741	40	20	but	but	CCONJ
bioethics02-25741	40	21	were	be	AUX
bioethics02-25741	40	22	linked	link	VERB
bioethics02-25741	40	23	to	to	ADP
bioethics02-25741	40	24	four	four	NUM
bioethics02-25741	40	25	times	time	NOUN
bioethics02-25741	40	26	higher	high	ADJ
bioethics02-25741	40	27	odds	odd	NOUN
bioethics02-25741	40	28	to	to	PART
bioethics02-25741	40	29	report	report	VERB
bioethics02-25741	40	30	favourable	favourable	ADJ
bioethics02-25741	40	31	conclusions	conclusion	NOUN
bioethics02-25741	40	32	20	20	NUM
bioethics02-25741	40	33	.	.	PUNCT
bioethics02-25741	41	1	furthermore	furthermore	ADV
bioethics02-25741	41	2	,	,	PUNCT
bioethics02-25741	41	3	conflict	conflict	NOUN
bioethics02-25741	41	4	of	of	ADP
bioethics02-25741	41	5	interests	interest	NOUN
bioethics02-25741	41	6	in	in	ADP
bioethics02-25741	41	7	the	the	DET
bioethics02-25741	41	8	original	original	ADJ
bioethics02-25741	41	9	studies	study	NOUN
bioethics02-25741	41	10	included	include	VERB
bioethics02-25741	41	11	in	in	ADP
bioethics02-25741	41	12	meta	meta	NOUN
bioethics02-25741	41	13	-	-	PUNCT
bioethics02-25741	41	14	analyses	analysis	NOUN
bioethics02-25741	41	15	are	be	AUX
bioethics02-25741	41	16	usually	usually	ADV
bioethics02-25741	41	17	silenced	silence	VERB
bioethics02-25741	41	18	and	and	CCONJ
bioethics02-25741	41	19	unreported	unreported	ADJ
bioethics02-25741	41	20	21	21	NUM
bioethics02-25741	41	21	.	.	PUNCT
bioethics02-25741	42	1	for	for	ADP
bioethics02-25741	42	2	example	example	NOUN
bioethics02-25741	42	3	,	,	PUNCT
bioethics02-25741	42	4	a	a	DET
bioethics02-25741	42	5	recent	recent	ADJ
bioethics02-25741	42	6	study	study	NOUN
bioethics02-25741	42	7	revealed	reveal	VERB
bioethics02-25741	42	8	that	that	SCONJ
bioethics02-25741	42	9	only	only	ADV
bioethics02-25741	42	10	2	2	NUM
bioethics02-25741	42	11	of	of	ADP
bioethics02-25741	42	12	29	29	NUM
bioethics02-25741	42	13	pharmacological	pharmacological	ADJ
bioethics02-25741	42	14	metaanalyses	metaanalyse	NOUN
bioethics02-25741	42	15	reported	report	VERB
bioethics02-25741	42	16	the	the	DET
bioethics02-25741	42	17	funding	funding	NOUN
bioethics02-25741	42	18	sources	source	NOUN
bioethics02-25741	42	19	of	of	ADP
bioethics02-25741	42	20	the	the	DET
bioethics02-25741	42	21	trials	trial	NOUN
bioethics02-25741	42	22	and	and	CCONJ
bioethics02-25741	42	23	none	none	NOUN
bioethics02-25741	42	24	of	of	ADP
bioethics02-25741	42	25	them	they	PRON
bioethics02-25741	42	26	reported	report	VERB
bioethics02-25741	42	27	author	author	NOUN
bioethics02-25741	42	28	–	–	PUNCT
bioethics02-25741	42	29	industry	industry	NOUN
bioethics02-25741	42	30	ties	tie	NOUN
bioethics02-25741	42	31	in	in	ADP
bioethics02-25741	42	32	the	the	DET
bioethics02-25741	42	33	primary	primary	ADJ
bioethics02-25741	42	34	trials	trial	NOUN
bioethics02-25741	42	35	21	21	NUM
bioethics02-25741	42	36	.	.	PUNCT
bioethics02-25741	43	1	finally	finally	ADV
bioethics02-25741	43	2	,	,	PUNCT
bioethics02-25741	43	3	content	content	NOUN
bioethics02-25741	43	4	experts	expert	NOUN
bioethics02-25741	43	5	who	who	PRON
bioethics02-25741	43	6	co	co	VERB
bioethics02-25741	43	7	-	-	NOUN
bioethics02-25741	43	8	author	author	NOUN
bioethics02-25741	43	9	systematic	systematic	ADJ
bioethics02-25741	43	10	reviews	review	NOUN
bioethics02-25741	43	11	and	and	CCONJ
bioethics02-25741	43	12	meta	meta	NOUN
bioethics02-25741	43	13	-	-	PUNCT
bioethics02-25741	43	14	analyses	analysis	NOUN
bioethics02-25741	43	15	may	may	AUX
bioethics02-25741	43	16	often	often	ADV
bioethics02-25741	43	17	distort	distort	VERB
bioethics02-25741	43	18	the	the	DET
bioethics02-25741	43	19	phrasing	phrasing	NOUN
bioethics02-25741	43	20	of	of	ADP
bioethics02-25741	43	21	the	the	DET
bioethics02-25741	43	22	research	research	NOUN
bioethics02-25741	43	23	questions	question	NOUN
bioethics02-25741	43	24	,	,	PUNCT
bioethics02-25741	43	25	the	the	DET
bioethics02-25741	43	26	results	result	NOUN
bioethics02-25741	43	27	and	and	CCONJ
bioethics02-25741	43	28	the	the	DET
bioethics02-25741	43	29	interpretation	interpretation	NOUN
bioethics02-25741	43	30	of	of	ADP
bioethics02-25741	43	31	these	these	DET
bioethics02-25741	43	32	reviews	review	NOUN
bioethics02-25741	43	33	in	in	ADP
bioethics02-25741	43	34	favour	favour	NOUN
bioethics02-25741	43	35	of	of	ADP
bioethics02-25741	43	36	industry	industry	NOUN
bioethics02-25741	43	37	products	product	NOUN
bioethics02-25741	43	38	22	22	NUM
bioethics02-25741	43	39	.	.	PUNCT
bioethics02-25741	44	1	understanding	understanding	NOUN
bioethics02-25741	44	2	of	of	ADP
bioethics02-25741	44	3	harms	harm	NOUN
bioethics02-25741	44	4	issues	issue	NOUN
bioethics02-25741	44	5	:	:	PUNCT
bioethics02-25741	44	6	licensing	license	VERB
bioethics02-25741	44	7	for	for	ADP
bioethics02-25741	44	8	new	new	ADJ
bioethics02-25741	44	9	products	product	NOUN
bioethics02-25741	44	10	or	or	CCONJ
bioethics02-25741	44	11	indications	indication	NOUN
bioethics02-25741	44	12	requires	require	VERB
bioethics02-25741	44	13	demonstration	demonstration	NOUN
bioethics02-25741	44	14	of	of	ADP
bioethics02-25741	44	15	effectiveness	effectiveness	NOUN
bioethics02-25741	44	16	and	and	CCONJ
bioethics02-25741	44	17	absence	absence	NOUN
bioethics02-25741	44	18	of	of	ADP
bioethics02-25741	44	19	major	major	ADJ
bioethics02-25741	44	20	harms	harm	NOUN
bioethics02-25741	44	21	.	.	PUNCT
bioethics02-25741	45	1	however	however	ADV
bioethics02-25741	45	2	,	,	PUNCT
bioethics02-25741	45	3	the	the	DET
bioethics02-25741	45	4	whole	whole	ADJ
bioethics02-25741	45	5	process	process	NOUN
bioethics02-25741	45	6	allows	allow	VERB
bioethics02-25741	45	7	plenty	plenty	NOUN
bioethics02-25741	45	8	of	of	ADP
bioethics02-25741	45	9	room	room	NOUN
bioethics02-25741	45	10	for	for	ADP
bioethics02-25741	45	11	serious	serious	ADJ
bioethics02-25741	45	12	harms	harm	NOUN
bioethics02-25741	45	13	to	to	PART
bioethics02-25741	45	14	be	be	AUX
bioethics02-25741	45	15	unrecognized	unrecognize	VERB
bioethics02-25741	45	16	by	by	ADP
bioethics02-25741	45	17	the	the	DET
bioethics02-25741	45	18	time	time	NOUN
bioethics02-25741	45	19	licensing	licensing	NOUN
bioethics02-25741	45	20	is	be	AUX
bioethics02-25741	45	21	granted	grant	VERB
bioethics02-25741	45	22	.	.	PUNCT
bioethics02-25741	46	1	many	many	ADJ
bioethics02-25741	46	2	interventions	intervention	NOUN
bioethics02-25741	46	3	are	be	AUX
bioethics02-25741	46	4	withdrawn	withdraw	VERB
bioethics02-25741	46	5	or	or	CCONJ
bioethics02-25741	46	6	acquire	acquire	VERB
bioethics02-25741	46	7	black	black	ADJ
bioethics02-25741	46	8	boxes	box	NOUN
bioethics02-25741	46	9	years	year	NOUN
bioethics02-25741	46	10	after	after	SCONJ
bioethics02-25741	46	11	they	they	PRON
bioethics02-25741	46	12	are	be	AUX
bioethics02-25741	46	13	licensed	license	VERB
bioethics02-25741	46	14	and	and	CCONJ
bioethics02-25741	46	15	after	after	SCONJ
bioethics02-25741	46	16	they	they	PRON
bioethics02-25741	46	17	have	have	AUX
bioethics02-25741	46	18	already	already	ADV
bioethics02-25741	46	19	cost	cost	VERB
bioethics02-25741	46	20	a	a	DET
bioethics02-25741	46	21	fortune	fortune	NOUN
bioethics02-25741	46	22	to	to	ADP
bioethics02-25741	46	23	the	the	DET
bioethics02-25741	46	24	healthcare	healthcare	NOUN
bioethics02-25741	46	25	system	system	NOUN
bioethics02-25741	46	26	23	23	NUM
bioethics02-25741	46	27	.	.	PUNCT
bioethics02-25741	47	1	recent	recent	ADJ
bioethics02-25741	47	2	drug	drug	NOUN
bioethics02-25741	47	3	withdrawals	withdrawal	NOUN
bioethics02-25741	47	4	suggest	suggest	VERB
bioethics02-25741	47	5	that	that	SCONJ
bioethics02-25741	47	6	financial	financial	ADJ
bioethics02-25741	47	7	ties	tie	NOUN
bioethics02-25741	47	8	with	with	ADP
bioethics02-25741	47	9	the	the	DET
bioethics02-25741	47	10	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	47	11	industry	industry	NOUN
bioethics02-25741	47	12	can	can	AUX
bioethics02-25741	47	13	determine	determine	VERB
bioethics02-25741	47	14	the	the	DET
bioethics02-25741	47	15	orientation	orientation	NOUN
bioethics02-25741	47	16	of	of	ADP
bioethics02-25741	47	17	the	the	DET
bioethics02-25741	47	18	authors	author	NOUN
bioethics02-25741	47	19	of	of	ADP
bioethics02-25741	47	20	trials	trial	NOUN
bioethics02-25741	47	21	and	and	CCONJ
bioethics02-25741	47	22	meta	meta	NOUN
bioethics02-25741	47	23	-	-	PUNCT
bioethics02-25741	47	24	analyses	analysis	NOUN
bioethics02-25741	47	25	in	in	ADP
bioethics02-25741	47	26	drug	drug	NOUN
bioethics02-25741	47	27	safety	safety	NOUN
bioethics02-25741	47	28	issues	issue	NOUN
bioethics02-25741	47	29	.	.	PUNCT
bioethics02-25741	48	1	rosiglitazone	rosiglitazone	NOUN
bioethics02-25741	48	2	,	,	PUNCT
bioethics02-25741	48	3	a	a	DET
bioethics02-25741	48	4	multibillion	multibillion	NOUN
bioethics02-25741	48	5	selling	sell	VERB
bioethics02-25741	48	6	drug	drug	NOUN
bioethics02-25741	48	7	for	for	ADP
bioethics02-25741	48	8	type	type	NOUN
bioethics02-25741	48	9	2	2	NUM
bioethics02-25741	48	10	diabetes	diabetes	NOUN
bioethics02-25741	48	11	,	,	PUNCT
bioethics02-25741	48	12	was	be	AUX
bioethics02-25741	48	13	approved	approve	VERB
bioethics02-25741	48	14	and	and	CCONJ
bioethics02-25741	48	15	prescribed	prescribe	VERB
bioethics02-25741	48	16	to	to	ADP
bioethics02-25741	48	17	millions	million	NOUN
bioethics02-25741	48	18	of	of	ADP
bioethics02-25741	48	19	patients	patient	NOUN
bioethics02-25741	48	20	worldwide	worldwide	ADV
bioethics02-25741	48	21	for	for	ADP
bioethics02-25741	48	22	10	10	NUM
bioethics02-25741	48	23	years	year	NOUN
bioethics02-25741	48	24	despite	despite	SCONJ
bioethics02-25741	48	25	limited	limited	ADJ
bioethics02-25741	48	26	evidence	evidence	NOUN
bioethics02-25741	48	27	on	on	ADP
bioethics02-25741	48	28	its	its	PRON
bioethics02-25741	48	29	benefits	benefit	NOUN
bioethics02-25741	48	30	and	and	CCONJ
bioethics02-25741	48	31	,	,	PUNCT
bioethics02-25741	48	32	especially	especially	ADV
bioethics02-25741	48	33	,	,	PUNCT
bioethics02-25741	48	34	safety	safety	NOUN
bioethics02-25741	48	35	24	24	NUM
bioethics02-25741	48	36	.	.	PUNCT
bioethics02-25741	49	1	rosiglitazone	rosiglitazone	NOUN
bioethics02-25741	49	2	potentially	potentially	ADV
bioethics02-25741	49	3	increases	increase	VERB
bioethics02-25741	49	4	the	the	DET
bioethics02-25741	49	5	risk	risk	NOUN
bioethics02-25741	49	6	of	of	ADP
bioethics02-25741	49	7	cardiovascular	cardiovascular	ADJ
bioethics02-25741	49	8	disease	disease	NOUN
bioethics02-25741	49	9	and	and	CCONJ
bioethics02-25741	49	10	comorbidities	comorbiditie	NOUN
bioethics02-25741	49	11	such	such	ADJ
bioethics02-25741	49	12	as	as	ADP
bioethics02-25741	49	13	weight	weight	NOUN
bioethics02-25741	49	14	gain	gain	NOUN
bioethics02-25741	49	15	and	and	CCONJ
bioethics02-25741	49	16	increases	increase	VERB
bioethics02-25741	49	17	blood	blood	NOUN
bioethics02-25741	49	18	lipids	lipid	NOUN
bioethics02-25741	49	19	.	.	PUNCT
bioethics02-25741	50	1	it	it	PRON
bioethics02-25741	50	2	has	have	AUX
bioethics02-25741	50	3	recently	recently	ADV
bioethics02-25741	50	4	been	be	AUX
bioethics02-25741	50	5	withdrawn	withdraw	VERB
bioethics02-25741	50	6	from	from	ADP
bioethics02-25741	50	7	both	both	CCONJ
bioethics02-25741	50	8	the	the	DET
bioethics02-25741	50	9	eu	eu	PROPN
bioethics02-25741	50	10	and	and	CCONJ
bioethics02-25741	50	11	new	new	PROPN
bioethics02-25741	50	12	zealand	zealand	PROPN
bioethics02-25741	50	13	markets	market	NOUN
bioethics02-25741	50	14	,	,	PUNCT
bioethics02-25741	50	15	and	and	CCONJ
bioethics02-25741	50	16	its	its	PRON
bioethics02-25741	50	17	indications	indication	NOUN
bioethics02-25741	50	18	have	have	AUX
bioethics02-25741	50	19	been	be	AUX
bioethics02-25741	50	20	severely	severely	ADV
bioethics02-25741	50	21	restricted	restrict	VERB
bioethics02-25741	50	22	in	in	ADP
bioethics02-25741	50	23	the	the	DET
bioethics02-25741	50	24	united	united	PROPN
bioethics02-25741	50	25	states	states	PROPN
bioethics02-25741	50	26	25	25	NUM
bioethics02-25741	50	27	.	.	PUNCT
bioethics02-25741	51	1	among	among	ADP
bioethics02-25741	51	2	the	the	DET
bioethics02-25741	51	3	many	many	ADJ
bioethics02-25741	51	4	similar	similar	ADJ
bioethics02-25741	51	5	revelations	revelation	NOUN
bioethics02-25741	51	6	,	,	PUNCT
bioethics02-25741	51	7	perhaps	perhaps	ADV
bioethics02-25741	51	8	the	the	DET
bioethics02-25741	51	9	best	well	ADV
bioethics02-25741	51	10	known	know	VERB
bioethics02-25741	51	11	case	case	NOUN
bioethics02-25741	51	12	is	be	AUX
bioethics02-25741	51	13	rofecoxib	rofecoxib	ADJ
bioethics02-25741	51	14	(	(	PUNCT
bioethics02-25741	51	15	vioxx	vioxx	NOUN
bioethics02-25741	51	16	)	)	PUNCT
bioethics02-25741	51	17	,	,	PUNCT
bioethics02-25741	51	18	a	a	DET
bioethics02-25741	51	19	blockbuster	blockbuster	ADJ
bioethics02-25741	51	20	non	non	ADJ
bioethics02-25741	51	21	steroidal	steroidal	NOUN
bioethics02-25741	51	22	anti	anti	ADJ
bioethics02-25741	51	23	-	-	ADJ
bioethics02-25741	51	24	inflammatory	inflammatory	ADJ
bioethics02-25741	51	25	drug	drug	NOUN
bioethics02-25741	51	26	that	that	PRON
bioethics02-25741	51	27	nearly	nearly	ADV
bioethics02-25741	51	28	doubled	double	VERB
bioethics02-25741	51	29	the	the	DET
bioethics02-25741	51	30	chances	chance	NOUN
bioethics02-25741	51	31	of	of	ADP
bioethics02-25741	51	32	both	both	CCONJ
bioethics02-25741	51	33	myocardial	myocardial	ADJ
bioethics02-25741	51	34	infarction	infarction	NOUN
bioethics02-25741	51	35	and	and	CCONJ
bioethics02-25741	51	36	stroke	stroke	NOUN
bioethics02-25741	51	37	26	26	NUM
bioethics02-25741	51	38	.	.	PUNCT
bioethics02-25741	52	1	data	datum	NOUN
bioethics02-25741	52	2	revealed	reveal	VERB
bioethics02-25741	52	3	during	during	ADP
bioethics02-25741	52	4	a	a	DET
bioethics02-25741	52	5	litigation	litigation	NOUN
bioethics02-25741	52	6	case	case	NOUN
bioethics02-25741	52	7	suggested	suggest	VERB
bioethics02-25741	52	8	the	the	DET
bioethics02-25741	52	9	manufacturer	manufacturer	NOUN
bioethics02-25741	52	10	intentionally	intentionally	ADV
bioethics02-25741	52	11	distorted	distort	VERB
bioethics02-25741	52	12	the	the	DET
bioethics02-25741	52	13	presentation	presentation	NOUN
bioethics02-25741	52	14	of	of	ADP
bioethics02-25741	52	15	trial	trial	NOUN
bioethics02-25741	52	16	safety	safety	NOUN
bioethics02-25741	52	17	data	datum	NOUN
bioethics02-25741	52	18	27	27	NUM
bioethics02-25741	52	19	and	and	CCONJ
bioethics02-25741	52	20	trained	train	VERB
bioethics02-25741	52	21	its	its	PRON
bioethics02-25741	52	22	sale	sale	NOUN
bioethics02-25741	52	23	representatives	representative	NOUN
bioethics02-25741	52	24	to	to	PART
bioethics02-25741	52	25	tactfully	tactfully	ADV
bioethics02-25741	52	26	avoid	avoid	VERB
bioethics02-25741	52	27	physician	physician	NOUN
bioethics02-25741	52	28	questions	question	NOUN
bioethics02-25741	52	29	on	on	ADP
bioethics02-25741	52	30	safety	safety	NOUN
bioethics02-25741	52	31	28	28	NUM
bioethics02-25741	52	32	.	.	PUNCT
bioethics02-25741	53	1	bangladesh	bangladesh	PROPN
bioethics02-25741	53	2	journal	journal	PROPN
bioethics02-25741	53	3	of	of	ADP
bioethics02-25741	53	4	bioethics	bioethic	NOUN
bioethics02-25741	53	5	2015	2015	NUM
bioethics02-25741	53	6	;	;	PUNCT
bioethics02-25741	53	7	6(2):15	6(2):15	X
bioethics02-25741	53	8	-	-	SYM
bioethics02-25741	53	9	22	22	NUM
bioethics02-25741	53	10	17	17	NUM
bioethics02-25741	53	11	cost	cost	NOUN
bioethics02-25741	53	12	-	-	PUNCT
bioethics02-25741	53	13	effectiveness	effectiveness	NOUN
bioethics02-25741	53	14	evaluation	evaluation	NOUN
bioethics02-25741	53	15	:	:	PUNCT
bioethics02-25741	53	16	cost	cost	NOUN
bioethics02-25741	53	17	-	-	PUNCT
bioethics02-25741	53	18	effectiveness	effectiveness	NOUN
bioethics02-25741	53	19	of	of	ADP
bioethics02-25741	53	20	therapies	therapy	NOUN
bioethics02-25741	53	21	is	be	AUX
bioethics02-25741	53	22	a	a	DET
bioethics02-25741	53	23	major	major	ADJ
bioethics02-25741	53	24	criterion	criterion	NOUN
bioethics02-25741	53	25	when	when	SCONJ
bioethics02-25741	53	26	allocating	allocate	VERB
bioethics02-25741	53	27	scarce	scarce	ADJ
bioethics02-25741	53	28	public	public	ADJ
bioethics02-25741	53	29	resources	resource	NOUN
bioethics02-25741	53	30	and	and	CCONJ
bioethics02-25741	53	31	is	be	AUX
bioethics02-25741	53	32	directly	directly	ADV
bioethics02-25741	53	33	influenced	influence	VERB
bioethics02-25741	53	34	by	by	ADP
bioethics02-25741	53	35	commercial	commercial	ADJ
bioethics02-25741	53	36	pricing	pricing	NOUN
bioethics02-25741	53	37	strategies	strategy	NOUN
bioethics02-25741	53	38	.	.	PUNCT
bioethics02-25741	54	1	most	most	ADJ
bioethics02-25741	54	2	published	publish	VERB
bioethics02-25741	54	3	analyses	analysis	NOUN
bioethics02-25741	54	4	report	report	VERB
bioethics02-25741	54	5	favourable	favourable	ADJ
bioethics02-25741	54	6	incremental	incremental	ADJ
bioethics02-25741	54	7	cost	cost	NOUN
bioethics02-25741	54	8	-	-	PUNCT
bioethics02-25741	54	9	effectiveness	effectiveness	NOUN
bioethics02-25741	54	10	ratios	ratio	NOUN
bioethics02-25741	54	11	,	,	PUNCT
bioethics02-25741	54	12	and	and	CCONJ
bioethics02-25741	54	13	studies	study	NOUN
bioethics02-25741	54	14	funded	fund	VERB
bioethics02-25741	54	15	by	by	ADP
bioethics02-25741	54	16	industry	industry	NOUN
bioethics02-25741	54	17	are	be	AUX
bioethics02-25741	54	18	more	more	ADV
bioethics02-25741	54	19	likely	likely	ADJ
bioethics02-25741	54	20	to	to	PART
bioethics02-25741	54	21	report	report	VERB
bioethics02-25741	54	22	ratios	ratio	NOUN
bioethics02-25741	54	23	below	below	ADP
bioethics02-25741	54	24	required	require	VERB
bioethics02-25741	54	25	thresholds	threshold	NOUN
bioethics02-25741	54	26	on	on	ADP
bioethics02-25741	54	27	cost	cost	NOUN
bioethics02-25741	54	28	-	-	PUNCT
bioethics02-25741	54	29	effectiveness	effectiveness	NOUN
bioethics02-25741	54	30	29	29	NUM
bioethics02-25741	54	31	.	.	PUNCT
bioethics02-25741	55	1	studies	study	NOUN
bioethics02-25741	55	2	funded	fund	VERB
bioethics02-25741	55	3	by	by	ADP
bioethics02-25741	55	4	industry	industry	NOUN
bioethics02-25741	55	5	are	be	AUX
bioethics02-25741	55	6	more	more	ADJ
bioethics02-25741	55	7	than	than	ADP
bioethics02-25741	55	8	twice	twice	ADV
bioethics02-25741	55	9	as	as	ADV
bioethics02-25741	55	10	likely	likely	ADJ
bioethics02-25741	55	11	to	to	PART
bioethics02-25741	55	12	report	report	VERB
bioethics02-25741	55	13	costeffectiveness	costeffectiveness	NOUN
bioethics02-25741	55	14	ratios	ratio	NOUN
bioethics02-25741	55	15	below	below	ADP
bioethics02-25741	55	16	$	$	SYM
bioethics02-25741	55	17	20	20	NUM
bioethics02-25741	55	18	000	000	NUM
bioethics02-25741	55	19	per	per	ADP
bioethics02-25741	55	20	quality	quality	NOUN
bioethics02-25741	55	21	-	-	PUNCT
bioethics02-25741	55	22	adjusted	adjust	VERB
bioethics02-25741	55	23	life	life	NOUN
bioethics02-25741	55	24	year	year	NOUN
bioethics02-25741	55	25	compared	compare	VERB
bioethics02-25741	55	26	with	with	ADP
bioethics02-25741	55	27	studies	study	NOUN
bioethics02-25741	55	28	funded	fund	VERB
bioethics02-25741	55	29	by	by	ADP
bioethics02-25741	55	30	other	other	ADJ
bioethics02-25741	55	31	sources	source	NOUN
bioethics02-25741	55	32	[	[	X
bioethics02-25741	55	33	30	30	NUM
bioethics02-25741	55	34	]	]	PUNCT
bioethics02-25741	55	35	.	.	PUNCT
bioethics02-25741	56	1	there	there	PRON
bioethics02-25741	56	2	are	be	VERB
bioethics02-25741	56	3	many	many	ADJ
bioethics02-25741	56	4	different	different	ADJ
bioethics02-25741	56	5	methods	method	NOUN
bioethics02-25741	56	6	by	by	ADP
bioethics02-25741	56	7	which	which	PRON
bioethics02-25741	56	8	industry	industry	NOUN
bioethics02-25741	56	9	-	-	PUNCT
bioethics02-25741	56	10	sponsored	sponsor	VERB
bioethics02-25741	56	11	cost	cost	NOUN
bioethics02-25741	56	12	effectiveness	effectiveness	NOUN
bioethics02-25741	56	13	analyses	analysis	NOUN
bioethics02-25741	56	14	can	can	AUX
bioethics02-25741	56	15	achieve	achieve	VERB
bioethics02-25741	56	16	more	more	ADV
bioethics02-25741	56	17	favorable	favorable	ADJ
bioethics02-25741	56	18	results	result	NOUN
bioethics02-25741	56	19	,	,	PUNCT
bioethics02-25741	56	20	including	include	VERB
bioethics02-25741	56	21	but	but	CCONJ
bioethics02-25741	56	22	not	not	PART
bioethics02-25741	56	23	limited	limit	VERB
bioethics02-25741	56	24	to	to	ADP
bioethics02-25741	56	25	biased	biased	ADJ
bioethics02-25741	56	26	assumptions	assumption	NOUN
bioethics02-25741	56	27	about	about	ADP
bioethics02-25741	56	28	the	the	DET
bioethics02-25741	56	29	intervention	intervention	NOUN
bioethics02-25741	56	30	,	,	PUNCT
bioethics02-25741	56	31	its	its	PRON
bioethics02-25741	56	32	comparators	comparator	NOUN
bioethics02-25741	56	33	(	(	PUNCT
bioethics02-25741	56	34	e.g.	e.g.	ADV
bioethics02-25741	56	35	underestimating	underestimate	VERB
bioethics02-25741	56	36	the	the	DET
bioethics02-25741	56	37	sensitivity/	sensitivity/	NUM
bioethics02-25741	56	38	specificity	specificity	NOUN
bioethics02-25741	56	39	of	of	ADP
bioethics02-25741	56	40	the	the	DET
bioethics02-25741	56	41	standard	standard	PROPN
bioethics02-25741	56	42	pap	pap	NOUN
bioethics02-25741	56	43	test	test	NOUN
bioethics02-25741	56	44	for	for	ADP
bioethics02-25741	56	45	analyses	analysis	NOUN
bioethics02-25741	56	46	of	of	ADP
bioethics02-25741	56	47	hpv	hpv	ADJ
bioethics02-25741	56	48	vaccines	vaccine	NOUN
bioethics02-25741	56	49	or	or	CCONJ
bioethics02-25741	56	50	hpv	hpv	ADJ
bioethics02-25741	56	51	dna	dna	NOUN
bioethics02-25741	56	52	tests	test	VERB
bioethics02-25741	56	53	for	for	ADP
bioethics02-25741	56	54	cervical	cervical	ADJ
bioethics02-25741	56	55	cancer	cancer	NOUN
bioethics02-25741	56	56	prevention	prevention	NOUN
bioethics02-25741	56	57	)	)	PUNCT
bioethics02-25741	56	58	31	31	NUM
bioethics02-25741	56	59	or	or	CCONJ
bioethics02-25741	56	60	other	other	ADJ
bioethics02-25741	56	61	parameters	parameter	NOUN
bioethics02-25741	56	62	that	that	PRON
bioethics02-25741	56	63	need	need	VERB
bioethics02-25741	56	64	to	to	PART
bioethics02-25741	56	65	be	be	AUX
bioethics02-25741	56	66	modeled	model	VERB
bioethics02-25741	56	67	(	(	PUNCT
bioethics02-25741	56	68	e.g.	e.g.	ADV
bioethics02-25741	56	69	extent	extent	NOUN
bioethics02-25741	56	70	of	of	ADP
bioethics02-25741	56	71	indirect	indirect	ADJ
bioethics02-25741	56	72	effects	effect	NOUN
bioethics02-25741	56	73	for	for	ADP
bioethics02-25741	56	74	vaccines	vaccine	NOUN
bioethics02-25741	56	75	)	)	PUNCT
bioethics02-25741	56	76	32	32	NUM
bioethics02-25741	56	77	.	.	PUNCT
bioethics02-25741	57	1	clinical	clinical	ADJ
bioethics02-25741	57	2	practice	practice	NOUN
bioethics02-25741	57	3	guidelines	guideline	NOUN
bioethics02-25741	57	4	:	:	PUNCT
bioethics02-25741	57	5	clinical	clinical	ADJ
bioethics02-25741	57	6	practice	practice	NOUN
bioethics02-25741	57	7	guidelines	guideline	NOUN
bioethics02-25741	57	8	are	be	AUX
bioethics02-25741	57	9	supposed	suppose	VERB
bioethics02-25741	57	10	to	to	PART
bioethics02-25741	57	11	be	be	AUX
bioethics02-25741	57	12	based	base	VERB
bioethics02-25741	57	13	on	on	ADP
bioethics02-25741	57	14	best	good	ADJ
bioethics02-25741	57	15	evidence	evidence	NOUN
bioethics02-25741	57	16	.	.	PUNCT
bioethics02-25741	58	1	they	they	PRON
bioethics02-25741	58	2	are	be	AUX
bioethics02-25741	58	3	endorsed	endorse	VERB
bioethics02-25741	58	4	by	by	ADP
bioethics02-25741	58	5	recognized	recognize	VERB
bioethics02-25741	58	6	authorities	authority	NOUN
bioethics02-25741	58	7	,	,	PUNCT
bioethics02-25741	58	8	and	and	CCONJ
bioethics02-25741	58	9	to	to	ADP
bioethics02-25741	58	10	a	a	DET
bioethics02-25741	58	11	large	large	ADJ
bioethics02-25741	58	12	extent	extent	NOUN
bioethics02-25741	58	13	,	,	PUNCT
bioethics02-25741	58	14	they	they	PRON
bioethics02-25741	58	15	define	define	VERB
bioethics02-25741	58	16	daily	daily	ADJ
bioethics02-25741	58	17	medical	medical	ADJ
bioethics02-25741	58	18	practice	practice	NOUN
bioethics02-25741	58	19	.	.	PUNCT
bioethics02-25741	59	1	integrity	integrity	NOUN
bioethics02-25741	59	2	,	,	PUNCT
bioethics02-25741	59	3	objectivity	objectivity	NOUN
bioethics02-25741	59	4	and	and	CCONJ
bioethics02-25741	59	5	independence	independence	NOUN
bioethics02-25741	59	6	are	be	AUX
bioethics02-25741	59	7	of	of	ADP
bioethics02-25741	59	8	paramount	paramount	ADJ
bioethics02-25741	59	9	importance	importance	NOUN
bioethics02-25741	59	10	for	for	ADP
bioethics02-25741	59	11	a	a	DET
bioethics02-25741	59	12	correct	correct	ADJ
bioethics02-25741	59	13	translation	translation	NOUN
bioethics02-25741	59	14	of	of	ADP
bioethics02-25741	59	15	the	the	DET
bioethics02-25741	59	16	evidence	evidence	NOUN
bioethics02-25741	59	17	into	into	ADP
bioethics02-25741	59	18	clinical	clinical	ADJ
bioethics02-25741	59	19	guidelines	guideline	NOUN
bioethics02-25741	59	20	.	.	PUNCT
bioethics02-25741	60	1	these	these	DET
bioethics02-25741	60	2	three	three	NUM
bioethics02-25741	60	3	crucial	crucial	ADJ
bioethics02-25741	60	4	attributes	attribute	NOUN
bioethics02-25741	60	5	are	be	AUX
bioethics02-25741	60	6	difficult	difficult	ADJ
bioethics02-25741	60	7	to	to	PART
bioethics02-25741	60	8	safeguard	safeguard	VERB
bioethics02-25741	60	9	.	.	PUNCT
bioethics02-25741	61	1	most	most	ADJ
bioethics02-25741	61	2	(	(	PUNCT
bioethics02-25741	61	3	56	56	NUM
bioethics02-25741	61	4	%	%	NOUN
bioethics02-25741	61	5	)	)	PUNCT
bioethics02-25741	61	6	scientists	scientist	NOUN
bioethics02-25741	61	7	involved	involve	VERB
bioethics02-25741	61	8	in	in	ADP
bioethics02-25741	61	9	the	the	DET
bioethics02-25741	61	10	17	17	NUM
bioethics02-25741	61	11	most	most	ADV
bioethics02-25741	61	12	authoritative	authoritative	ADJ
bioethics02-25741	61	13	us	we	PRON
bioethics02-25741	61	14	cardiovascular	cardiovascular	ADJ
bioethics02-25741	61	15	clinical	clinical	ADJ
bioethics02-25741	61	16	practice	practice	NOUN
bioethics02-25741	61	17	guidelines	guideline	NOUN
bioethics02-25741	61	18	released	release	VERB
bioethics02-25741	61	19	between	between	ADP
bioethics02-25741	61	20	2004	2004	NUM
bioethics02-25741	61	21	and	and	CCONJ
bioethics02-25741	61	22	2008	2008	NUM
bioethics02-25741	61	23	received	receive	VERB
bioethics02-25741	61	24	research	research	NOUN
bioethics02-25741	61	25	grants	grant	NOUN
bioethics02-25741	61	26	,	,	PUNCT
bioethics02-25741	61	27	honoraria	honorarium	NOUN
bioethics02-25741	61	28	for	for	ADP
bioethics02-25741	61	29	speeches	speech	NOUN
bioethics02-25741	61	30	in	in	ADP
bioethics02-25741	61	31	drug	drug	NOUN
bioethics02-25741	61	32	-	-	PUNCT
bioethics02-25741	61	33	promoting	promote	VERB
bioethics02-25741	61	34	events	event	NOUN
bioethics02-25741	61	35	,	,	PUNCT
bioethics02-25741	61	36	stocks	stock	NOUN
bioethics02-25741	61	37	(	(	PUNCT
bioethics02-25741	61	38	shares	share	NOUN
bioethics02-25741	61	39	)	)	PUNCT
bioethics02-25741	61	40	or	or	CCONJ
bioethics02-25741	61	41	consultancy	consultancy	NOUN
bioethics02-25741	61	42	fees	fee	NOUN
bioethics02-25741	61	43	by	by	ADP
bioethics02-25741	61	44	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	61	45	and	and	CCONJ
bioethics02-25741	61	46	related	related	ADJ
bioethics02-25741	61	47	industries	industry	NOUN
bioethics02-25741	61	48	33	33	NUM
bioethics02-25741	61	49	over	over	ADP
bioethics02-25741	61	50	80	80	NUM
bioethics02-25741	61	51	%	%	NOUN
bioethics02-25741	61	52	of	of	ADP
bioethics02-25741	61	53	the	the	DET
bioethics02-25741	61	54	committee	committee	NOUN
bioethics02-25741	61	55	chairs	chair	NOUN
bioethics02-25741	61	56	had	have	VERB
bioethics02-25741	61	57	such	such	ADJ
bioethics02-25741	61	58	conflict	conflict	NOUN
bioethics02-25741	61	59	of	of	ADP
bioethics02-25741	61	60	interests	interest	NOUN
bioethics02-25741	61	61	.	.	PUNCT
bioethics02-25741	62	1	over	over	ADP
bioethics02-25741	62	2	50	50	NUM
bioethics02-25741	62	3	%	%	NOUN
bioethics02-25741	62	4	of	of	ADP
bioethics02-25741	62	5	guideline	guideline	NOUN
bioethics02-25741	62	6	panel	panel	NOUN
bioethics02-25741	62	7	members	member	NOUN
bioethics02-25741	62	8	in	in	ADP
bioethics02-25741	62	9	the	the	DET
bioethics02-25741	62	10	united	united	PROPN
bioethics02-25741	62	11	states	states	PROPN
bioethics02-25741	62	12	and	and	CCONJ
bioethics02-25741	62	13	canada	canada	PROPN
bioethics02-25741	62	14	have	have	VERB
bioethics02-25741	62	15	conflict	conflict	NOUN
bioethics02-25741	62	16	of	of	ADP
bioethics02-25741	62	17	interests	interest	NOUN
bioethics02-25741	62	18	while	while	SCONJ
bioethics02-25741	62	19	the	the	DET
bioethics02-25741	62	20	respective	respective	ADJ
bioethics02-25741	62	21	figure	figure	NOUN
bioethics02-25741	62	22	for	for	ADP
bioethics02-25741	62	23	guidelines	guideline	NOUN
bioethics02-25741	62	24	sponsored	sponsor	VERB
bioethics02-25741	62	25	by	by	ADP
bioethics02-25741	62	26	nongovernment	nongovernment	NOUN
bioethics02-25741	62	27	sources	source	NOUN
bioethics02-25741	62	28	approaches	approach	VERB
bioethics02-25741	62	29	70	70	NUM
bioethics02-25741	62	30	%	%	NOUN
bioethics02-25741	62	31	34	34	NUM
bioethics02-25741	62	32	.	.	PUNCT
bioethics02-25741	63	1	overall	overall	ADV
bioethics02-25741	63	2	,	,	PUNCT
bioethics02-25741	63	3	between	between	ADP
bioethics02-25741	63	4	56	56	NUM
bioethics02-25741	63	5	and	and	CCONJ
bioethics02-25741	63	6	87	87	NUM
bioethics02-25741	63	7	%	%	NOUN
bioethics02-25741	63	8	of	of	ADP
bioethics02-25741	63	9	clinical	clinical	ADJ
bioethics02-25741	63	10	practice	practice	NOUN
bioethics02-25741	63	11	guidelines	guideline	NOUN
bioethics02-25741	63	12	,	,	PUNCT
bioethics02-25741	63	13	authors	author	NOUN
bioethics02-25741	63	14	have	have	AUX
bioethics02-25741	63	15	been	be	AUX
bioethics02-25741	63	16	found	find	VERB
bioethics02-25741	63	17	to	to	PART
bioethics02-25741	63	18	have	have	VERB
bioethics02-25741	63	19	at	at	ADP
bioethics02-25741	63	20	least	least	ADJ
bioethics02-25741	63	21	a	a	DET
bioethics02-25741	63	22	conflict	conflict	NOUN
bioethics02-25741	63	23	of	of	ADP
bioethics02-25741	63	24	interest	interest	NOUN
bioethics02-25741	63	25	(	(	PUNCT
bioethics02-25741	63	26	consultancies	consultancy	NOUN
bioethics02-25741	63	27	,	,	PUNCT
bioethics02-25741	63	28	research	research	NOUN
bioethics02-25741	63	29	support	support	NOUN
bioethics02-25741	63	30	,	,	PUNCT
bioethics02-25741	63	31	equity	equity	NOUN
bioethics02-25741	63	32	/	/	SYM
bioethics02-25741	63	33	stock	stock	NOUN
bioethics02-25741	63	34	ownership	ownership	NOUN
bioethics02-25741	63	35	)	)	PUNCT
bioethics02-25741	63	36	35	35	NUM
bioethics02-25741	63	37	.	.	PUNCT
bioethics02-25741	64	1	there	there	PRON
bioethics02-25741	64	2	is	be	VERB
bioethics02-25741	64	3	substantial	substantial	ADJ
bioethics02-25741	64	4	margin	margin	NOUN
bioethics02-25741	64	5	for	for	SCONJ
bioethics02-25741	64	6	the	the	DET
bioethics02-25741	64	7	members	member	NOUN
bioethics02-25741	64	8	of	of	ADP
bioethics02-25741	64	9	these	these	DET
bioethics02-25741	64	10	committees	committee	NOUN
bioethics02-25741	64	11	to	to	PART
bioethics02-25741	64	12	input	input	VERB
bioethics02-25741	64	13	their	their	PRON
bioethics02-25741	64	14	subjective	subjective	ADJ
bioethics02-25741	64	15	views	view	NOUN
bioethics02-25741	64	16	through	through	ADP
bioethics02-25741	64	17	‗expert	‗expert	PUNCT
bioethics02-25741	64	18	opinion	opinion	NOUN
bioethics02-25741	64	19	‘	'	PUNCT
bioethics02-25741	64	20	(	(	PUNCT
bioethics02-25741	64	21	evidence	evidence	NOUN
bioethics02-25741	64	22	level	level	NOUN
bioethics02-25741	64	23	c	c	NOUN
bioethics02-25741	64	24	)	)	PUNCT
bioethics02-25741	64	25	,	,	PUNCT
bioethics02-25741	64	26	which	which	PRON
bioethics02-25741	64	27	represented	represent	VERB
bioethics02-25741	64	28	nearly	nearly	ADV
bioethics02-25741	64	29	half	half	NOUN
bioethics02-25741	64	30	of	of	ADP
bioethics02-25741	64	31	all	all	DET
bioethics02-25741	64	32	major	major	ADJ
bioethics02-25741	64	33	us	we	PRON
bioethics02-25741	64	34	cardiovascular	cardiovascular	ADJ
bioethics02-25741	64	35	clinical	clinical	ADJ
bioethics02-25741	64	36	care	care	NOUN
bioethics02-25741	64	37	guidelines	guideline	NOUN
bioethics02-25741	64	38	published	publish	VERB
bioethics02-25741	64	39	between	between	ADP
bioethics02-25741	64	40	1984	1984	NUM
bioethics02-25741	64	41	and	and	CCONJ
bioethics02-25741	64	42	2008	2008	NUM
bioethics02-25741	64	43	36	36	NUM
bioethics02-25741	64	44	.	.	PUNCT
bioethics02-25741	65	1	even	even	ADV
bioethics02-25741	65	2	higher	high	ADJ
bioethics02-25741	65	3	levels	level	NOUN
bioethics02-25741	65	4	of	of	ADP
bioethics02-25741	65	5	interaction	interaction	NOUN
bioethics02-25741	65	6	were	be	AUX
bioethics02-25741	65	7	noted	note	VERB
bioethics02-25741	65	8	between	between	ADP
bioethics02-25741	65	9	the	the	DET
bioethics02-25741	65	10	authors	author	NOUN
bioethics02-25741	65	11	of	of	ADP
bioethics02-25741	65	12	44	44	NUM
bioethics02-25741	65	13	clinical	clinical	ADJ
bioethics02-25741	65	14	guidelines	guideline	NOUN
bioethics02-25741	65	15	and	and	CCONJ
bioethics02-25741	65	16	the	the	DET
bioethics02-25741	65	17	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	65	18	industry	industry	NOUN
bioethics02-25741	65	19	in	in	ADP
bioethics02-25741	65	20	a	a	DET
bioethics02-25741	65	21	previous	previous	ADJ
bioethics02-25741	65	22	publication	publication	NOUN
bioethics02-25741	65	23	37	37	NUM
bioethics02-25741	65	24	.	.	PUNCT
bioethics02-25741	66	1	given	give	VERB
bioethics02-25741	66	2	that	that	SCONJ
bioethics02-25741	66	3	the	the	DET
bioethics02-25741	66	4	boundary	boundary	NOUN
bioethics02-25741	66	5	between	between	ADP
bioethics02-25741	66	6	industry	industry	NOUN
bioethics02-25741	66	7	and	and	CCONJ
bioethics02-25741	66	8	academia	academia	NOUN
bioethics02-25741	66	9	has	have	AUX
bioethics02-25741	66	10	become	become	VERB
bioethics02-25741	66	11	so	so	ADV
bioethics02-25741	66	12	vague	vague	ADJ
bioethics02-25741	66	13	,	,	PUNCT
bioethics02-25741	66	14	it	it	PRON
bioethics02-25741	66	15	is	be	AUX
bioethics02-25741	66	16	hardly	hardly	ADV
bioethics02-25741	66	17	surprising	surprising	ADJ
bioethics02-25741	66	18	that	that	SCONJ
bioethics02-25741	66	19	clinical	clinical	ADJ
bioethics02-25741	66	20	practice	practice	NOUN
bioethics02-25741	66	21	guidelines	guideline	NOUN
bioethics02-25741	66	22	often	often	ADV
bioethics02-25741	66	23	are	be	AUX
bioethics02-25741	66	24	heavily	heavily	ADV
bioethics02-25741	66	25	focused	focused	ADJ
bioethics02-25741	66	26	on	on	ADP
bioethics02-25741	66	27	new	new	ADJ
bioethics02-25741	66	28	costly	costly	ADJ
bioethics02-25741	66	29	interventions	intervention	NOUN
bioethics02-25741	66	30	and	and	CCONJ
bioethics02-25741	66	31	only	only	ADV
bioethics02-25741	66	32	loosely	loosely	ADV
bioethics02-25741	66	33	follow	follow	VERB
bioethics02-25741	66	34	the	the	DET
bioethics02-25741	66	35	available	available	ADJ
bioethics02-25741	66	36	evidence	evidence	NOUN
bioethics02-25741	66	37	.	.	PUNCT
bioethics02-25741	67	1	for	for	ADP
bioethics02-25741	67	2	example	example	NOUN
bioethics02-25741	67	3	,	,	PUNCT
bioethics02-25741	67	4	current	current	ADJ
bioethics02-25741	67	5	guidelines	guideline	NOUN
bioethics02-25741	67	6	still	still	ADV
bioethics02-25741	67	7	advocate	advocate	VERB
bioethics02-25741	67	8	tight	tight	ADJ
bioethics02-25741	67	9	pharmacological	pharmacological	ADJ
bioethics02-25741	67	10	glycaemic	glycaemic	NOUN
bioethics02-25741	67	11	control	control	NOUN
bioethics02-25741	67	12	for	for	ADP
bioethics02-25741	67	13	patients	patient	NOUN
bioethics02-25741	67	14	with	with	ADP
bioethics02-25741	67	15	type	type	NOUN
bioethics02-25741	67	16	2	2	NUM
bioethics02-25741	67	17	diabetes	diabete	NOUN
bioethics02-25741	67	18	,	,	PUNCT
bioethics02-25741	67	19	despite	despite	SCONJ
bioethics02-25741	67	20	the	the	DET
bioethics02-25741	67	21	best	good	ADJ
bioethics02-25741	67	22	available	available	ADJ
bioethics02-25741	67	23	evidence	evidence	NOUN
bioethics02-25741	67	24	suggesting	suggest	VERB
bioethics02-25741	67	25	that	that	SCONJ
bioethics02-25741	67	26	there	there	PRON
bioethics02-25741	67	27	is	be	VERB
bioethics02-25741	67	28	no	no	DET
bioethics02-25741	67	29	major	major	ADJ
bioethics02-25741	67	30	benefit	benefit	NOUN
bioethics02-25741	67	31	for	for	ADP
bioethics02-25741	67	32	patients	patient	NOUN
bioethics02-25741	67	33	38	38	NUM
bioethics02-25741	67	34	and	and	CCONJ
bioethics02-25741	67	35	possibly	possibly	ADV
bioethics02-25741	67	36	even	even	ADV
bioethics02-25741	67	37	deterioration	deterioration	NOUN
bioethics02-25741	67	38	of	of	ADP
bioethics02-25741	67	39	quality	quality	NOUN
bioethics02-25741	67	40	of	of	ADP
bioethics02-25741	67	41	life	life	NOUN
bioethics02-25741	67	42	39	39	NUM
bioethics02-25741	67	43	.	.	PUNCT
bioethics02-25741	68	1	declarations	declaration	NOUN
bioethics02-25741	68	2	of	of	ADP
bioethics02-25741	68	3	the	the	DET
bioethics02-25741	68	4	conflict	conflict	NOUN
bioethics02-25741	68	5	of	of	ADP
bioethics02-25741	68	6	interests	interest	NOUN
bioethics02-25741	68	7	of	of	ADP
bioethics02-25741	68	8	expert	expert	NOUN
bioethics02-25741	68	9	panels	panel	NOUN
bioethics02-25741	68	10	and	and	CCONJ
bioethics02-25741	68	11	researchers	researcher	NOUN
bioethics02-25741	68	12	are	be	AUX
bioethics02-25741	68	13	thought	think	VERB
bioethics02-25741	68	14	to	to	PART
bioethics02-25741	68	15	guarantee	guarantee	VERB
bioethics02-25741	68	16	transparency	transparency	NOUN
bioethics02-25741	68	17	and	and	CCONJ
bioethics02-25741	68	18	integrity	integrity	NOUN
bioethics02-25741	68	19	in	in	ADP
bioethics02-25741	68	20	the	the	DET
bioethics02-25741	68	21	evidence	evidence	NOUN
bioethics02-25741	68	22	base	base	NOUN
bioethics02-25741	68	23	and	and	CCONJ
bioethics02-25741	68	24	clinical	clinical	ADJ
bioethics02-25741	68	25	recommendation	recommendation	NOUN
bioethics02-25741	68	26	generation	generation	NOUN
bioethics02-25741	68	27	process	process	NOUN
bioethics02-25741	68	28	.	.	PUNCT
bioethics02-25741	69	1	nevertheless	nevertheless	ADV
bioethics02-25741	69	2	,	,	PUNCT
bioethics02-25741	69	3	there	there	PRON
bioethics02-25741	69	4	appears	appear	VERB
bioethics02-25741	69	5	to	to	PART
bioethics02-25741	69	6	be	be	AUX
bioethics02-25741	69	7	a	a	DET
bioethics02-25741	69	8	gap	gap	NOUN
bioethics02-25741	69	9	between	between	ADP
bioethics02-25741	69	10	the	the	DET
bioethics02-25741	69	11	intended	intended	ADJ
bioethics02-25741	69	12	purpose	purpose	NOUN
bioethics02-25741	69	13	and	and	CCONJ
bioethics02-25741	69	14	practice	practice	NOUN
bioethics02-25741	69	15	as	as	ADP
bioethics02-25741	69	16	financial	financial	ADJ
bioethics02-25741	69	17	conflict	conflict	NOUN
bioethics02-25741	69	18	of	of	ADP
bioethics02-25741	69	19	interests	interest	NOUN
bioethics02-25741	69	20	are	be	AUX
bioethics02-25741	69	21	severely	severely	ADV
bioethics02-25741	69	22	under	under	ADV
bioethics02-25741	69	23	-	-	PUNCT
bioethics02-25741	69	24	reported	report	VERB
bioethics02-25741	69	25	in	in	ADP
bioethics02-25741	69	26	drug	drug	NOUN
bioethics02-25741	69	27	trial	trial	NOUN
bioethics02-25741	69	28	metaanalyses	metaanalyse	NOUN
bioethics02-25741	69	29	and	and	CCONJ
bioethics02-25741	69	30	panel	panel	NOUN
bioethics02-25741	69	31	guidelines	guideline	VERB
bioethics02-25741	69	32	34	34	NUM
bioethics02-25741	69	33	and	and	CCONJ
bioethics02-25741	69	34	practitioners	practitioner	NOUN
bioethics02-25741	69	35	very	very	ADV
bioethics02-25741	69	36	rarely	rarely	ADV
bioethics02-25741	69	37	discount	discount	VERB
bioethics02-25741	69	38	for	for	ADP
bioethics02-25741	69	39	such	such	ADJ
bioethics02-25741	69	40	conflicts	conflict	NOUN
bioethics02-25741	69	41	when	when	SCONJ
bioethics02-25741	69	42	evaluating	evaluate	VERB
bioethics02-25741	69	43	the	the	DET
bioethics02-25741	69	44	evidence	evidence	NOUN
bioethics02-25741	69	45	base	base	NOUN
bioethics02-25741	69	46	40	40	NUM
bioethics02-25741	69	47	.	.	PUNCT
bioethics02-25741	70	1	besides	besides	SCONJ
bioethics02-25741	70	2	clinical	clinical	ADJ
bioethics02-25741	70	3	guidelines	guideline	NOUN
bioethics02-25741	70	4	formation	formation	NOUN
bioethics02-25741	70	5	,	,	PUNCT
bioethics02-25741	70	6	narrative	narrative	NOUN
bioethics02-25741	70	7	review	review	NOUN
bioethics02-25741	70	8	and	and	CCONJ
bioethics02-25741	70	9	editorials	editorial	NOUN
bioethics02-25741	70	10	by	by	ADP
bioethics02-25741	70	11	key	key	ADJ
bioethics02-25741	70	12	opinion	opinion	NOUN
bioethics02-25741	70	13	leaders	leader	NOUN
bioethics02-25741	70	14	also	also	ADV
bioethics02-25741	70	15	have	have	VERB
bioethics02-25741	70	16	a	a	DET
bioethics02-25741	70	17	major	major	ADJ
bioethics02-25741	70	18	impact	impact	NOUN
bioethics02-25741	70	19	on	on	ADP
bioethics02-25741	70	20	clinical	clinical	ADJ
bioethics02-25741	70	21	practice	practice	NOUN
bioethics02-25741	70	22	decisions	decision	NOUN
bioethics02-25741	70	23	and	and	CCONJ
bioethics02-25741	70	24	the	the	DET
bioethics02-25741	70	25	medical	medical	ADJ
bioethics02-25741	70	26	community	community	NOUN
bioethics02-25741	70	27	in	in	ADP
bioethics02-25741	70	28	general	general	ADJ
bioethics02-25741	70	29	41,42	41,42	PROPN
bioethics02-25741	70	30	.	.	PUNCT
bioethics02-25741	71	1	an	an	DET
bioethics02-25741	71	2	example	example	NOUN
bioethics02-25741	71	3	of	of	ADP
bioethics02-25741	71	4	the	the	DET
bioethics02-25741	71	5	influence	influence	NOUN
bioethics02-25741	71	6	of	of	ADP
bioethics02-25741	71	7	the	the	DET
bioethics02-25741	71	8	conflict	conflict	NOUN
bioethics02-25741	71	9	of	of	ADP
bioethics02-25741	71	10	interests	interest	NOUN
bioethics02-25741	71	11	of	of	ADP
bioethics02-25741	71	12	key	key	ADJ
bioethics02-25741	71	13	opinion	opinion	NOUN
bioethics02-25741	71	14	leaders	leader	NOUN
bioethics02-25741	71	15	is	be	AUX
bioethics02-25741	71	16	that	that	SCONJ
bioethics02-25741	71	17	although	although	SCONJ
bioethics02-25741	71	18	evidence	evidence	NOUN
bioethics02-25741	71	19	does	do	AUX
bioethics02-25741	71	20	not	not	PART
bioethics02-25741	71	21	support	support	VERB
bioethics02-25741	71	22	that	that	DET
bioethics02-25741	71	23	brandname	brandname	NOUN
bioethics02-25741	71	24	drugs	drug	NOUN
bioethics02-25741	71	25	are	be	AUX
bioethics02-25741	71	26	superior	superior	ADJ
bioethics02-25741	71	27	to	to	ADP
bioethics02-25741	71	28	generic	generic	ADJ
bioethics02-25741	71	29	drugs	drug	NOUN
bioethics02-25741	71	30	4	4	NUM
bioethics02-25741	71	31	3	3	NUM
bioethics02-25741	71	32	,	,	PUNCT
bioethics02-25741	71	33	editorials	editorial	NOUN
bioethics02-25741	71	34	often	often	ADV
bioethics02-25741	71	35	counsel	counsel	VERB
bioethics02-25741	71	36	against	against	ADP
bioethics02-25741	71	37	the	the	DET
bioethics02-25741	71	38	interchangeability	interchangeability	NOUN
bioethics02-25741	71	39	of	of	ADP
bioethics02-25741	71	40	generic	generic	ADJ
bioethics02-25741	71	41	drugs	drug	NOUN
bioethics02-25741	71	42	43	43	NUM
bioethics02-25741	71	43	.	.	PUNCT
bioethics02-25741	72	1	healthcare	healthcare	PROPN
bioethics02-25741	72	2	professional	professional	ADJ
bioethics02-25741	72	3	education	education	NOUN
bioethics02-25741	72	4	:	:	PUNCT
bioethics02-25741	72	5	intense	intense	ADJ
bioethics02-25741	72	6	exposure	exposure	NOUN
bioethics02-25741	72	7	to	to	ADP
bioethics02-25741	72	8	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	72	9	marketing	marketing	NOUN
bioethics02-25741	72	10	commences	commence	NOUN
bioethics02-25741	72	11	during	during	ADP
bioethics02-25741	72	12	undergraduate	undergraduate	ADJ
bioethics02-25741	72	13	medical	medical	ADJ
bioethics02-25741	72	14	education	education	NOUN
bioethics02-25741	72	15	for	for	ADP
bioethics02-25741	72	16	future	future	ADJ
bioethics02-25741	72	17	prescribers	prescriber	NOUN
bioethics02-25741	72	18	.	.	PUNCT
bioethics02-25741	73	1	a	a	DET
bioethics02-25741	73	2	study	study	NOUN
bioethics02-25741	73	3	showed	show	VERB
bioethics02-25741	73	4	that	that	SCONJ
bioethics02-25741	73	5	third	third	ADJ
bioethics02-25741	73	6	-	-	PUNCT
bioethics02-25741	73	7	year	year	NOUN
bioethics02-25741	73	8	medical	medical	ADJ
bioethics02-25741	73	9	students	student	NOUN
bioethics02-25741	73	10	are	be	AUX
bioethics02-25741	73	11	exposed	expose	VERB
bioethics02-25741	73	12	to	to	ADP
bioethics02-25741	73	13	one	one	NUM
bioethics02-25741	73	14	industry	industry	NOUN
bioethics02-25741	73	15	-	-	PUNCT
bioethics02-25741	73	16	sponsored	sponsor	VERB
bioethics02-25741	73	17	gift	gift	NOUN
bioethics02-25741	73	18	or	or	CCONJ
bioethics02-25741	73	19	activity	activity	NOUN
bioethics02-25741	73	20	per	per	ADP
bioethics02-25741	73	21	week	week	NOUN
bioethics02-25741	73	22	and	and	CCONJ
bioethics02-25741	73	23	almost	almost	ADV
bioethics02-25741	73	24	(	(	PUNCT
bioethics02-25741	73	25	93	93	NUM
bioethics02-25741	73	26	%	%	NOUN
bioethics02-25741	73	27	)	)	PUNCT
bioethics02-25741	73	28	all	all	PRON
bioethics02-25741	73	29	have	have	AUX
bioethics02-25741	73	30	been	be	AUX
bioethics02-25741	73	31	asked	ask	VERB
bioethics02-25741	73	32	or	or	CCONJ
bioethics02-25741	73	33	required	require	VERB
bioethics02-25741	73	34	to	to	PART
bioethics02-25741	73	35	attend	attend	VERB
bioethics02-25741	73	36	at	at	ADV
bioethics02-25741	73	37	least	least	ADV
bioethics02-25741	73	38	one	one	NUM
bioethics02-25741	73	39	industry	industry	NOUN
bioethics02-25741	73	40	-	-	PUNCT
bioethics02-25741	73	41	sponsored	sponsor	VERB
bioethics02-25741	73	42	lunch	lunch	NOUN
bioethics02-25741	73	43	44	44	NUM
bioethics02-25741	73	44	.	.	PUNCT
bioethics02-25741	74	1	the	the	DET
bioethics02-25741	74	2	large	large	ADJ
bioethics02-25741	74	3	majority	majority	NOUN
bioethics02-25741	74	4	(	(	PUNCT
bioethics02-25741	74	5	67	67	NUM
bioethics02-25741	74	6	–	–	SYM
bioethics02-25741	74	7	92	92	NUM
bioethics02-25741	74	8	%	%	NOUN
bioethics02-25741	74	9	)	)	PUNCT
bioethics02-25741	74	10	of	of	ADP
bioethics02-25741	74	11	medical	medical	ADJ
bioethics02-25741	74	12	students	student	NOUN
bioethics02-25741	74	13	acknowledge	acknowledge	VERB
bioethics02-25741	74	14	that	that	SCONJ
bioethics02-25741	74	15	education	education	NOUN
bioethics02-25741	74	16	from	from	ADP
bioethics02-25741	74	17	industry	industry	NOUN
bioethics02-25741	74	18	sources	source	NOUN
bioethics02-25741	74	19	is	be	AUX
bioethics02-25741	74	20	biased	bias	VERB
bioethics02-25741	74	21	and	and	CCONJ
bioethics02-25741	74	22	that	that	SCONJ
bioethics02-25741	74	23	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	74	24	industry	industry	NOUN
bioethics02-25741	74	25	pressures	pressure	NOUN
bioethics02-25741	74	26	increase	increase	VERB
bioethics02-25741	74	27	over	over	ADP
bioethics02-25741	74	28	the	the	DET
bioethics02-25741	74	29	course	course	NOUN
bioethics02-25741	74	30	of	of	ADP
bioethics02-25741	74	31	medical	medical	ADJ
bioethics02-25741	74	32	school	school	NOUN
bioethics02-25741	74	33	45	45	NUM
bioethics02-25741	74	34	.	.	PUNCT
bioethics02-25741	75	1	this	this	DET
bioethics02-25741	75	2	exposure	exposure	NOUN
bioethics02-25741	75	3	brainwashes	brainwash	VERB
bioethics02-25741	75	4	medical	medical	ADJ
bioethics02-25741	75	5	students	student	NOUN
bioethics02-25741	75	6	‘	‘	PART
bioethics02-25741	75	7	attitudes	attitude	NOUN
bioethics02-25741	75	8	towards	towards	ADP
bioethics02-25741	75	9	the	the	DET
bioethics02-25741	75	10	marketed	market	VERB
bioethics02-25741	75	11	products	product	NOUN
bioethics02-25741	75	12	46	46	NUM
bioethics02-25741	75	13	.	.	PUNCT
bioethics02-25741	76	1	in	in	ADP
bioethics02-25741	76	2	the	the	DET
bioethics02-25741	76	3	usa	usa	PROPN
bioethics02-25741	76	4	,	,	PUNCT
bioethics02-25741	76	5	60	60	NUM
bioethics02-25741	76	6	%	%	NOUN
bioethics02-25741	76	7	of	of	ADP
bioethics02-25741	76	8	medical	medical	ADJ
bioethics02-25741	76	9	school	school	NOUN
bioethics02-25741	76	10	chairs	chair	NOUN
bioethics02-25741	76	11	have	have	VERB
bioethics02-25741	76	12	some	some	DET
bioethics02-25741	76	13	form	form	NOUN
bioethics02-25741	76	14	of	of	ADP
bioethics02-25741	76	15	personal	personal	ADJ
bioethics02-25741	76	16	relationship	relationship	NOUN
bioethics02-25741	76	17	with	with	ADP
bioethics02-25741	76	18	industry	industry	NOUN
bioethics02-25741	76	19	(	(	PUNCT
bioethics02-25741	76	20	e.g.	e.g.	ADV
bioethics02-25741	76	21	consultant	consultant	NOUN
bioethics02-25741	76	22	,	,	PUNCT
bioethics02-25741	76	23	a	a	DET
bioethics02-25741	76	24	member	member	NOUN
bioethics02-25741	76	25	of	of	ADP
bioethics02-25741	76	26	a	a	DET
bioethics02-25741	76	27	scientific	scientific	ADJ
bioethics02-25741	76	28	advisory	advisory	ADJ
bioethics02-25741	76	29	board	board	NOUN
bioethics02-25741	76	30	,	,	PUNCT
bioethics02-25741	76	31	a	a	DET
bioethics02-25741	76	32	paid	pay	VERB
bioethics02-25741	76	33	speaker	speaker	NOUN
bioethics02-25741	76	34	,	,	PUNCT
bioethics02-25741	76	35	an	an	DET
bioethics02-25741	76	36	officer	officer	NOUN
bioethics02-25741	76	37	,	,	PUNCT
bioethics02-25741	76	38	founder	founder	NOUN
bioethics02-25741	76	39	or	or	CCONJ
bioethics02-25741	76	40	member	member	NOUN
bioethics02-25741	76	41	of	of	ADP
bioethics02-25741	76	42	the	the	DET
bioethics02-25741	76	43	board	board	NOUN
bioethics02-25741	76	44	of	of	ADP
bioethics02-25741	76	45	directors	director	NOUN
bioethics02-25741	76	46	)	)	PUNCT
bioethics02-25741	76	47	47	47	NUM
bioethics02-25741	76	48	.	.	PUNCT
bioethics02-25741	77	1	continuing	continue	VERB
bioethics02-25741	77	2	medical	medical	ADJ
bioethics02-25741	77	3	education	education	NOUN
bioethics02-25741	77	4	(	(	PUNCT
bioethics02-25741	77	5	cme	cme	PROPN
bioethics02-25741	77	6	)	)	PUNCT
bioethics02-25741	77	7	is	be	AUX
bioethics02-25741	77	8	an	an	DET
bioethics02-25741	77	9	essential	essential	ADJ
bioethics02-25741	77	10	part	part	NOUN
bioethics02-25741	77	11	of	of	ADP
bioethics02-25741	77	12	the	the	DET
bioethics02-25741	77	13	development	development	NOUN
bioethics02-25741	77	14	for	for	ADP
bioethics02-25741	77	15	practicing	practice	VERB
bioethics02-25741	77	16	health	health	NOUN
bioethics02-25741	77	17	professionals	professional	NOUN
bioethics02-25741	77	18	.	.	PUNCT
bioethics02-25741	78	1	in	in	ADP
bioethics02-25741	78	2	the	the	DET
bioethics02-25741	78	3	united	united	PROPN
bioethics02-25741	78	4	states	states	PROPN
bioethics02-25741	78	5	,	,	PUNCT
bioethics02-25741	78	6	industry	industry	NOUN
bioethics02-25741	78	7	support	support	NOUN
bioethics02-25741	78	8	for	for	ADP
bioethics02-25741	78	9	cme	cme	PROPN
bioethics02-25741	78	10	increased	increase	VERB
bioethics02-25741	78	11	from	from	ADP
bioethics02-25741	78	12	$	$	SYM
bioethics02-25741	78	13	301	301	NUM
bioethics02-25741	78	14	million	million	NUM
bioethics02-25741	78	15	per	per	ADP
bioethics02-25741	78	16	year	year	NOUN
bioethics02-25741	78	17	in	in	ADP
bioethics02-25741	78	18	1998	1998	NUM
bioethics02-25741	78	19	to	to	ADP
bioethics02-25741	78	20	$	$	SYM
bioethics02-25741	78	21	1_2	1_2	NUM
bioethics02-25741	78	22	billion	billion	NUM
bioethics02-25741	78	23	per	per	ADP
bioethics02-25741	78	24	year	year	NOUN
bioethics02-25741	78	25	in	in	ADP
bioethics02-25741	78	26	2007	2007	NUM
bioethics02-25741	78	27	accounting	account	VERB
bioethics02-25741	78	28	for	for	ADP
bioethics02-25741	78	29	approximately	approximately	ADV
bioethics02-25741	78	30	60	60	NUM
bioethics02-25741	78	31	%	%	NOUN
bioethics02-25741	78	32	of	of	ADP
bioethics02-25741	78	33	the	the	DET
bioethics02-25741	78	34	total	total	ADJ
bioethics02-25741	78	35	accredited	accredit	VERB
bioethics02-25741	78	36	cme	cme	PROPN
bioethics02-25741	78	37	costs	cost	NOUN
bioethics02-25741	78	38	(	(	PUNCT
bioethics02-25741	78	39	including	include	VERB
bioethics02-25741	78	40	advertising	advertising	NOUN
bioethics02-25741	78	41	/	/	SYM
bioethics02-25741	78	42	exhibit	exhibit	NOUN
bioethics02-25741	78	43	payments	payment	NOUN
bioethics02-25741	78	44	)	)	PUNCT
bioethics02-25741	78	45	48	48	NUM
bioethics02-25741	78	46	.	.	PUNCT
bioethics02-25741	79	1	although	although	SCONJ
bioethics02-25741	79	2	there	there	PRON
bioethics02-25741	79	3	are	be	VERB
bioethics02-25741	79	4	signs	sign	NOUN
bioethics02-25741	79	5	of	of	ADP
bioethics02-25741	79	6	a	a	DET
bioethics02-25741	79	7	reversing	reverse	VERB
bioethics02-25741	79	8	trend	trend	NOUN
bioethics02-25741	79	9	(	(	PUNCT
bioethics02-25741	79	10	due	due	ADP
bioethics02-25741	79	11	to	to	ADP
bioethics02-25741	79	12	regulatory	regulatory	ADJ
bioethics02-25741	79	13	restrictions	restriction	NOUN
bioethics02-25741	79	14	and	and	CCONJ
bioethics02-25741	79	15	the	the	DET
bioethics02-25741	79	16	economic	economic	ADJ
bioethics02-25741	79	17	trends	trend	NOUN
bioethics02-25741	79	18	)	)	PUNCT
bioethics02-25741	79	19	,	,	PUNCT
bioethics02-25741	79	20	industry	industry	NOUN
bioethics02-25741	79	21	funded	fund	VERB
bioethics02-25741	79	22	cme	cme	NOUN
bioethics02-25741	79	23	still	still	ADV
bioethics02-25741	79	24	accounted	account	VERB
bioethics02-25741	79	25	for	for	ADP
bioethics02-25741	79	26	approximately	approximately	ADV
bioethics02-25741	79	27	half	half	NOUN
bioethics02-25741	79	28	of	of	ADP
bioethics02-25741	79	29	all	all	DET
bioethics02-25741	79	30	cme	cme	NOUN
bioethics02-25741	79	31	by	by	ADP
bioethics02-25741	79	32	2010	2010	NUM
bioethics02-25741	79	33	48	48	NUM
bioethics02-25741	79	34	.	.	PUNCT
bioethics02-25741	80	1	industry	industry	NOUN
bioethics02-25741	80	2	sponsors	sponsor	NOUN
bioethics02-25741	80	3	have	have	VERB
bioethics02-25741	80	4	substantial	substantial	ADJ
bioethics02-25741	80	5	influence	influence	NOUN
bioethics02-25741	80	6	over	over	ADP
bioethics02-25741	80	7	bangladesh	bangladesh	PROPN
bioethics02-25741	80	8	journal	journal	NOUN
bioethics02-25741	80	9	of	of	ADP
bioethics02-25741	80	10	bioethics	bioethic	NOUN
bioethics02-25741	80	11	2015	2015	NUM
bioethics02-25741	80	12	;	;	PUNCT
bioethics02-25741	80	13	6(2):15	6(2):15	X
bioethics02-25741	80	14	-	-	SYM
bioethics02-25741	80	15	22	22	NUM
bioethics02-25741	80	16	18	18	NUM
bioethics02-25741	80	17	the	the	DET
bioethics02-25741	80	18	content	content	NOUN
bioethics02-25741	80	19	of	of	ADP
bioethics02-25741	80	20	education	education	NOUN
bioethics02-25741	80	21	programmes	programme	NOUN
bioethics02-25741	80	22	,	,	PUNCT
bioethics02-25741	80	23	which	which	PRON
bioethics02-25741	80	24	often	often	ADV
bioethics02-25741	80	25	involve	involve	AUX
bioethics02-25741	80	26	heftily	heftily	ADV
bioethics02-25741	80	27	paid	pay	VERB
bioethics02-25741	80	28	prominent	prominent	ADJ
bioethics02-25741	80	29	medical	medical	ADJ
bioethics02-25741	80	30	figures	figure	NOUN
bioethics02-25741	80	31	presenting	present	VERB
bioethics02-25741	80	32	information	information	NOUN
bioethics02-25741	80	33	about	about	ADP
bioethics02-25741	80	34	the	the	DET
bioethics02-25741	80	35	company‘s	company‘s	NOUN
bioethics02-25741	80	36	latest	late	ADJ
bioethics02-25741	80	37	products	product	NOUN
bioethics02-25741	80	38	,	,	PUNCT
bioethics02-25741	80	39	often	often	ADV
bioethics02-25741	80	40	using	use	VERB
bioethics02-25741	80	41	slides	slide	NOUN
bioethics02-25741	80	42	provided	provide	VERB
bioethics02-25741	80	43	by	by	ADP
bioethics02-25741	80	44	the	the	DET
bioethics02-25741	80	45	company	company	NOUN
bioethics02-25741	80	46	49	49	NUM
bioethics02-25741	80	47	.	.	PUNCT
bioethics02-25741	81	1	sponsored	sponsor	VERB
bioethics02-25741	81	2	cme	cme	PROPN
bioethics02-25741	81	3	leads	lead	VERB
bioethics02-25741	81	4	to	to	ADP
bioethics02-25741	81	5	increases	increase	NOUN
bioethics02-25741	81	6	in	in	ADP
bioethics02-25741	81	7	prescription	prescription	NOUN
bioethics02-25741	81	8	rates	rate	NOUN
bioethics02-25741	81	9	by	by	ADP
bioethics02-25741	81	10	the	the	DET
bioethics02-25741	81	11	attendant	attendant	ADJ
bioethics02-25741	81	12	physicians	physician	NOUN
bioethics02-25741	81	13	of	of	ADP
bioethics02-25741	81	14	the	the	DET
bioethics02-25741	81	15	promoted	promote	VERB
bioethics02-25741	81	16	medication	medication	NOUN
bioethics02-25741	81	17	50	50	NUM
bioethics02-25741	81	18	.	.	PUNCT
bioethics02-25741	82	1	in	in	ADP
bioethics02-25741	82	2	the	the	DET
bioethics02-25741	82	3	uk	uk	PROPN
bioethics02-25741	82	4	,	,	PUNCT
bioethics02-25741	82	5	most	most	ADJ
bioethics02-25741	82	6	hospital	hospital	NOUN
bioethics02-25741	82	7	educational	educational	ADJ
bioethics02-25741	82	8	‗grand	‗grand	NOUN
bioethics02-25741	82	9	rounds	round	NOUN
bioethics02-25741	82	10	‘	'	PUNCT
bioethics02-25741	82	11	and	and	CCONJ
bioethics02-25741	82	12	many	many	ADJ
bioethics02-25741	82	13	other	other	ADJ
bioethics02-25741	82	14	medical	medical	ADJ
bioethics02-25741	82	15	education	education	NOUN
bioethics02-25741	82	16	meetings	meeting	NOUN
bioethics02-25741	82	17	are	be	AUX
bioethics02-25741	82	18	sponsored	sponsor	VERB
bioethics02-25741	82	19	by	by	ADP
bioethics02-25741	82	20	the	the	DET
bioethics02-25741	82	21	industry	industry	NOUN
bioethics02-25741	82	22	,	,	PUNCT
bioethics02-25741	82	23	with	with	ADP
bioethics02-25741	82	24	lunches	lunch	NOUN
bioethics02-25741	82	25	provided	provide	VERB
bioethics02-25741	82	26	in	in	ADP
bioethics02-25741	82	27	return	return	NOUN
bioethics02-25741	82	28	for	for	ADP
bioethics02-25741	82	29	sales	sale	NOUN
bioethics02-25741	82	30	and	and	CCONJ
bioethics02-25741	82	31	marketing	marketing	NOUN
bioethics02-25741	82	32	opportunities	opportunity	NOUN
bioethics02-25741	82	33	.	.	PUNCT
bioethics02-25741	83	1	in	in	ADP
bioethics02-25741	83	2	primary	primary	ADJ
bioethics02-25741	83	3	care	care	NOUN
bioethics02-25741	83	4	,	,	PUNCT
bioethics02-25741	83	5	many	many	ADJ
bioethics02-25741	83	6	staff	staff	NOUN
bioethics02-25741	83	7	events	event	NOUN
bioethics02-25741	83	8	are	be	AUX
bioethics02-25741	83	9	sponsored	sponsor	VERB
bioethics02-25741	83	10	by	by	ADP
bioethics02-25741	83	11	the	the	DET
bioethics02-25741	83	12	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	83	13	industry	industry	NOUN
bioethics02-25741	83	14	in	in	ADP
bioethics02-25741	83	15	return	return	NOUN
bioethics02-25741	83	16	for	for	ADP
bioethics02-25741	83	17	a	a	DET
bioethics02-25741	83	18	lunch	lunch	NOUN
bioethics02-25741	83	19	and	and	CCONJ
bioethics02-25741	83	20	‗educational	‗educational	NOUN
bioethics02-25741	83	21	‘	'	PUNCT
bioethics02-25741	83	22	opportunities	opportunity	NOUN
bioethics02-25741	83	23	on	on	ADP
bioethics02-25741	83	24	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	83	25	products	product	NOUN
bioethics02-25741	83	26	.	.	PUNCT
bioethics02-25741	84	1	postgraduate	postgraduate	NOUN
bioethics02-25741	84	2	education	education	NOUN
bioethics02-25741	84	3	departments	department	NOUN
bioethics02-25741	84	4	foster	foster	VERB
bioethics02-25741	84	5	strong	strong	ADJ
bioethics02-25741	84	6	relationships	relationship	NOUN
bioethics02-25741	84	7	with	with	ADP
bioethics02-25741	84	8	sales	sale	NOUN
bioethics02-25741	84	9	representatives	representative	NOUN
bioethics02-25741	84	10	,	,	PUNCT
bioethics02-25741	84	11	and	and	CCONJ
bioethics02-25741	84	12	educational	educational	ADJ
bioethics02-25741	84	13	meetings	meeting	NOUN
bioethics02-25741	84	14	and	and	CCONJ
bioethics02-25741	84	15	conferences	conference	NOUN
bioethics02-25741	84	16	are	be	AUX
bioethics02-25741	84	17	nearly	nearly	ADV
bioethics02-25741	84	18	always	always	ADV
bioethics02-25741	84	19	industry	industry	NOUN
bioethics02-25741	84	20	financed	finance	VERB
bioethics02-25741	84	21	51	51	NUM
bioethics02-25741	84	22	.	.	PUNCT
bioethics02-25741	85	1	direct	direct	ADJ
bioethics02-25741	85	2	influences	influence	NOUN
bioethics02-25741	85	3	on	on	ADP
bioethics02-25741	85	4	healthcare	healthcare	PROPN
bioethics02-25741	85	5	professional	professional	ADJ
bioethics02-25741	85	6	decisions	decision	NOUN
bioethics02-25741	85	7	:	:	PUNCT
bioethics02-25741	85	8	direct	direct	ADJ
bioethics02-25741	85	9	marketing	marketing	NOUN
bioethics02-25741	85	10	pressures	pressure	NOUN
bioethics02-25741	85	11	by	by	ADP
bioethics02-25741	85	12	sales	sale	NOUN
bioethics02-25741	85	13	representatives	representative	NOUN
bioethics02-25741	85	14	are	be	AUX
bioethics02-25741	85	15	substantial	substantial	ADJ
bioethics02-25741	85	16	,	,	PUNCT
bioethics02-25741	85	17	for	for	ADP
bioethics02-25741	85	18	example	example	NOUN
bioethics02-25741	85	19	,	,	PUNCT
bioethics02-25741	85	20	a	a	DET
bioethics02-25741	85	21	us	us	PROPN
bioethics02-25741	85	22	cardiologist	cardiologist	NOUN
bioethics02-25741	85	23	meets	meet	VERB
bioethics02-25741	85	24	with	with	ADP
bioethics02-25741	85	25	sales	sale	NOUN
bioethics02-25741	85	26	representatives	representative	NOUN
bioethics02-25741	85	27	nine	nine	NUM
bioethics02-25741	85	28	times	time	NOUN
bioethics02-25741	85	29	a	a	DET
bioethics02-25741	85	30	month	month	NOUN
bioethics02-25741	85	31	on	on	ADP
bioethics02-25741	85	32	average	average	ADJ
bioethics02-25741	85	33	52	52	NUM
bioethics02-25741	85	34	.	.	PUNCT
bioethics02-25741	86	1	in	in	ADP
bioethics02-25741	86	2	2004	2004	NUM
bioethics02-25741	86	3	,	,	PUNCT
bioethics02-25741	86	4	over	over	ADP
bioethics02-25741	86	5	a	a	DET
bioethics02-25741	86	6	third	third	NOUN
bioethics02-25741	86	7	of	of	ADP
bioethics02-25741	86	8	the	the	DET
bioethics02-25741	86	9	$	$	SYM
bioethics02-25741	86	10	57	57	NUM
bioethics02-25741	86	11	billion	billion	NUM
bioethics02-25741	86	12	that	that	SCONJ
bioethics02-25741	86	13	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	86	14	companies	company	NOUN
bioethics02-25741	86	15	spent	spend	VERB
bioethics02-25741	86	16	on	on	ADP
bioethics02-25741	86	17	promotional	promotional	ADJ
bioethics02-25741	86	18	activities	activity	NOUN
bioethics02-25741	86	19	went	go	VERB
bioethics02-25741	86	20	on	on	ADP
bioethics02-25741	86	21	visiting	visit	VERB
bioethics02-25741	86	22	doctors	doctor	NOUN
bioethics02-25741	86	23	to	to	PART
bioethics02-25741	86	24	promote	promote	VERB
bioethics02-25741	86	25	new	new	ADJ
bioethics02-25741	86	26	drugs	drug	NOUN
bioethics02-25741	86	27	and	and	CCONJ
bioethics02-25741	86	28	establish	establish	VERB
bioethics02-25741	86	29	relationships	relationship	NOUN
bioethics02-25741	86	30	with	with	ADP
bioethics02-25741	86	31	health	health	NOUN
bioethics02-25741	86	32	professionals	professional	NOUN
bioethics02-25741	86	33	in	in	ADP
bioethics02-25741	86	34	community	community	NOUN
bioethics02-25741	86	35	or	or	CCONJ
bioethics02-25741	86	36	academic	academic	ADJ
bioethics02-25741	86	37	settings	setting	NOUN
bioethics02-25741	86	38	53	53	NUM
bioethics02-25741	86	39	.	.	PUNCT
bioethics02-25741	87	1	regular	regular	ADJ
bioethics02-25741	87	2	interactions	interaction	NOUN
bioethics02-25741	87	3	with	with	ADP
bioethics02-25741	87	4	sales	sale	NOUN
bioethics02-25741	87	5	representatives	representative	NOUN
bioethics02-25741	87	6	increases	increase	VERB
bioethics02-25741	87	7	the	the	DET
bioethics02-25741	87	8	chances	chance	NOUN
bioethics02-25741	87	9	to	to	PART
bioethics02-25741	87	10	add	add	VERB
bioethics02-25741	87	11	the	the	DET
bioethics02-25741	87	12	drug	drug	NOUN
bioethics02-25741	87	13	company	company	NOUN
bioethics02-25741	87	14	to	to	ADP
bioethics02-25741	87	15	a	a	DET
bioethics02-25741	87	16	hospital‘s	hospital‘s	ADJ
bioethics02-25741	87	17	formulary	formulary	NOUN
bioethics02-25741	87	18	by	by	ADP
bioethics02-25741	87	19	over	over	ADP
bioethics02-25741	87	20	300	300	NUM
bioethics02-25741	87	21	%	%	NOUN
bioethics02-25741	87	22	,	,	PUNCT
bioethics02-25741	87	23	and	and	CCONJ
bioethics02-25741	87	24	the	the	DET
bioethics02-25741	87	25	combination	combination	NOUN
bioethics02-25741	87	26	of	of	ADP
bioethics02-25741	87	27	the	the	DET
bioethics02-25741	87	28	physician	physician	NOUN
bioethics02-25741	87	29	receiving	receive	VERB
bioethics02-25741	87	30	honoraria	honoraria	NOUN
bioethics02-25741	87	31	leads	lead	VERB
bioethics02-25741	87	32	to	to	ADP
bioethics02-25741	87	33	even	even	ADV
bioethics02-25741	87	34	greater	great	ADJ
bioethics02-25741	87	35	increases	increase	NOUN
bioethics02-25741	87	36	54	54	NUM
bioethics02-25741	88	1	.the	.the	DET
bioethics02-25741	88	2	culture	culture	NOUN
bioethics02-25741	88	3	of	of	ADP
bioethics02-25741	88	4	industry	industry	NOUN
bioethics02-25741	88	5	-	-	PUNCT
bioethics02-25741	88	6	offered	offer	VERB
bioethics02-25741	88	7	‗gifts	‗gift	NOUN
bioethics02-25741	88	8	‘	'	PUNCT
bioethics02-25741	88	9	or	or	CCONJ
bioethics02-25741	88	10	equipment	equipment	NOUN
bioethics02-25741	88	11	,	,	PUNCT
bioethics02-25741	88	12	educational	educational	ADJ
bioethics02-25741	88	13	textbooks	textbook	NOUN
bioethics02-25741	88	14	,	,	PUNCT
bioethics02-25741	88	15	sponsorship	sponsorship	NOUN
bioethics02-25741	88	16	or	or	CCONJ
bioethics02-25741	88	17	luxury	luxury	NOUN
bioethics02-25741	88	18	travel	travel	NOUN
bioethics02-25741	88	19	55	55	NUM
bioethics02-25741	88	20	and	and	CCONJ
bioethics02-25741	88	21	free	free	ADJ
bioethics02-25741	88	22	meals	meal	NOUN
bioethics02-25741	88	23	has	have	AUX
bioethics02-25741	88	24	been	be	AUX
bioethics02-25741	88	25	common	common	ADJ
bioethics02-25741	88	26	across	across	ADP
bioethics02-25741	88	27	the	the	DET
bioethics02-25741	88	28	entire	entire	ADJ
bioethics02-25741	88	29	spectrum	spectrum	NOUN
bioethics02-25741	88	30	of	of	ADP
bioethics02-25741	88	31	health	health	NOUN
bioethics02-25741	88	32	practitioners	practitioner	NOUN
bioethics02-25741	88	33	.	.	PUNCT
bioethics02-25741	89	1	in	in	ADP
bioethics02-25741	89	2	many	many	ADJ
bioethics02-25741	89	3	countries	country	NOUN
bioethics02-25741	89	4	,	,	PUNCT
bioethics02-25741	89	5	most	most	ADJ
bioethics02-25741	89	6	industries	industry	NOUN
bioethics02-25741	89	7	have	have	VERB
bioethics02-25741	89	8	a	a	DET
bioethics02-25741	89	9	trade	trade	NOUN
bioethics02-25741	89	10	association	association	NOUN
bioethics02-25741	89	11	representing	represent	VERB
bioethics02-25741	89	12	their	their	PRON
bioethics02-25741	89	13	profit	profit	NOUN
bioethics02-25741	89	14	-	-	PUNCT
bioethics02-25741	89	15	orientated	orientate	VERB
bioethics02-25741	89	16	members	member	NOUN
bioethics02-25741	89	17	,	,	PUNCT
bioethics02-25741	89	18	for	for	ADP
bioethics02-25741	89	19	example	example	NOUN
bioethics02-25741	89	20	,	,	PUNCT
bioethics02-25741	89	21	the	the	DET
bioethics02-25741	89	22	uk	uk	PROPN
bioethics02-25741	89	23	association	association	PROPN
bioethics02-25741	89	24	of	of	ADP
bioethics02-25741	89	25	the	the	DET
bioethics02-25741	89	26	british	british	ADJ
bioethics02-25741	89	27	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	89	28	industry	industry	NOUN
bioethics02-25741	89	29	(	(	PUNCT
bioethics02-25741	89	30	abpi	abpi	NOUN
bioethics02-25741	89	31	)	)	PUNCT
bioethics02-25741	89	32	with	with	ADP
bioethics02-25741	89	33	150	150	NUM
bioethics02-25741	89	34	members	member	NOUN
bioethics02-25741	89	35	,	,	PUNCT
bioethics02-25741	89	36	which	which	PRON
bioethics02-25741	89	37	has	have	AUX
bioethics02-25741	89	38	set	set	VERB
bioethics02-25741	89	39	up	up	ADP
bioethics02-25741	89	40	the	the	DET
bioethics02-25741	89	41	prescription	prescription	NOUN
bioethics02-25741	89	42	medicines	medicine	NOUN
bioethics02-25741	89	43	code	code	NOUN
bioethics02-25741	89	44	of	of	ADP
bioethics02-25741	89	45	practice	practice	NOUN
bioethics02-25741	89	46	authority	authority	NOUN
bioethics02-25741	89	47	to	to	PART
bioethics02-25741	89	48	administer	administer	VERB
bioethics02-25741	89	49	the	the	DET
bioethics02-25741	89	50	pharma	pharma	NOUN
bioethics02-25741	89	51	-	-	PUNCT
bioethics02-25741	89	52	ceutical	ceutical	ADJ
bioethics02-25741	89	53	industries	industry	NOUN
bioethics02-25741	89	54	‘	'	PUNCT
bioethics02-25741	89	55	own	own	ADJ
bioethics02-25741	89	56	code	code	NOUN
bioethics02-25741	89	57	of	of	ADP
bioethics02-25741	89	58	practice	practice	NOUN
bioethics02-25741	89	59	.	.	PUNCT
bioethics02-25741	90	1	however	however	ADV
bioethics02-25741	90	2	,	,	PUNCT
bioethics02-25741	90	3	there	there	PRON
bioethics02-25741	90	4	has	have	AUX
bioethics02-25741	90	5	been	be	AUX
bioethics02-25741	90	6	a	a	DET
bioethics02-25741	90	7	recent	recent	ADJ
bioethics02-25741	90	8	exodus	exodus	NOUN
bioethics02-25741	90	9	of	of	ADP
bioethics02-25741	90	10	abpi	abpi	NOUN
bioethics02-25741	90	11	members	member	NOUN
bioethics02-25741	90	12	,	,	PUNCT
bioethics02-25741	90	13	with	with	ADP
bioethics02-25741	90	14	even	even	ADV
bioethics02-25741	90	15	fewer	few	ADJ
bioethics02-25741	90	16	companies	company	NOUN
bioethics02-25741	90	17	choosing	choose	VERB
bioethics02-25741	90	18	to	to	PART
bioethics02-25741	90	19	follow	follow	VERB
bioethics02-25741	90	20	even	even	ADV
bioethics02-25741	90	21	this	this	DET
bioethics02-25741	90	22	largely	largely	ADV
bioethics02-25741	90	23	voluntary	voluntary	ADJ
bioethics02-25741	90	24	code	code	NOUN
bioethics02-25741	90	25	[	[	X
bioethics02-25741	90	26	56	56	NUM
bioethics02-25741	90	27	]	]	PUNCT
bioethics02-25741	90	28	.	.	PUNCT
bioethics02-25741	91	1	surveyed	survey	VERB
bioethics02-25741	91	2	patients	patient	NOUN
bioethics02-25741	91	3	consider	consider	VERB
bioethics02-25741	91	4	the	the	DET
bioethics02-25741	91	5	financial	financial	ADJ
bioethics02-25741	91	6	ties	tie	NOUN
bioethics02-25741	91	7	between	between	ADP
bioethics02-25741	91	8	practitioners	practitioner	NOUN
bioethics02-25741	91	9	and	and	CCONJ
bioethics02-25741	91	10	drug	drug	NOUN
bioethics02-25741	91	11	companies	company	NOUN
bioethics02-25741	91	12	unacceptable	unacceptable	ADJ
bioethics02-25741	91	13	and	and	CCONJ
bioethics02-25741	91	14	a	a	DET
bioethics02-25741	91	15	compromise	compromise	NOUN
bioethics02-25741	91	16	to	to	ADP
bioethics02-25741	91	17	their	their	PRON
bioethics02-25741	91	18	quality	quality	NOUN
bioethics02-25741	91	19	of	of	ADP
bioethics02-25741	91	20	care	care	NOUN
bioethics02-25741	91	21	57	57	NUM
bioethics02-25741	91	22	;	;	PUNCT
bioethics02-25741	91	23	however	however	ADV
bioethics02-25741	91	24	,	,	PUNCT
bioethics02-25741	91	25	patients	patient	NOUN
bioethics02-25741	91	26	are	be	AUX
bioethics02-25741	91	27	rarely	rarely	ADV
bioethics02-25741	91	28	aware	aware	ADJ
bioethics02-25741	91	29	of	of	ADP
bioethics02-25741	91	30	their	their	PRON
bioethics02-25741	91	31	doctor‘s	doctor‘s	ADP
bioethics02-25741	91	32	ties	tie	NOUN
bioethics02-25741	91	33	with	with	ADP
bioethics02-25741	91	34	the	the	DET
bioethics02-25741	91	35	industry	industry	NOUN
bioethics02-25741	91	36	,	,	PUNCT
bioethics02-25741	91	37	which	which	PRON
bioethics02-25741	91	38	may	may	AUX
bioethics02-25741	91	39	have	have	AUX
bioethics02-25741	91	40	biased	bias	VERB
bioethics02-25741	91	41	their	their	PRON
bioethics02-25741	91	42	care	care	NOUN
bioethics02-25741	91	43	plan	plan	NOUN
bioethics02-25741	91	44	.	.	PUNCT
bioethics02-25741	92	1	direct	direct	VERB
bioethics02-25741	92	2	-	-	PUNCT
bioethics02-25741	92	3	to	to	ADP
bioethics02-25741	92	4	-	-	PUNCT
bioethics02-25741	92	5	consumer	consumer	NOUN
bioethics02-25741	92	6	advertising	advertising	NOUN
bioethics02-25741	92	7	:	:	PUNCT
bioethics02-25741	92	8	in	in	ADP
bioethics02-25741	92	9	the	the	DET
bioethics02-25741	92	10	united	united	PROPN
bioethics02-25741	92	11	states	states	PROPN
bioethics02-25741	92	12	,	,	PUNCT
bioethics02-25741	92	13	where	where	SCONJ
bioethics02-25741	92	14	such	such	ADJ
bioethics02-25741	92	15	marketing	marketing	NOUN
bioethics02-25741	92	16	practices	practice	NOUN
bioethics02-25741	92	17	are	be	AUX
bioethics02-25741	92	18	permitted	permit	VERB
bioethics02-25741	92	19	by	by	ADP
bioethics02-25741	92	20	law	law	NOUN
bioethics02-25741	92	21	,	,	PUNCT
bioethics02-25741	92	22	directto	directto	NOUN
bioethics02-25741	92	23	-	-	PUNCT
bioethics02-25741	92	24	consumer	consumer	NOUN
bioethics02-25741	92	25	advertising	advertising	NOUN
bioethics02-25741	92	26	(	(	PUNCT
bioethics02-25741	92	27	dtca	dtca	ADJ
bioethics02-25741	92	28	)	)	PUNCT
bioethics02-25741	92	29	is	be	AUX
bioethics02-25741	92	30	a	a	DET
bioethics02-25741	92	31	major	major	ADJ
bioethics02-25741	92	32	force	force	NOUN
bioethics02-25741	92	33	of	of	ADP
bioethics02-25741	92	34	rising	rise	VERB
bioethics02-25741	92	35	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	92	36	costs	cost	NOUN
bioethics02-25741	92	37	58	58	NUM
bioethics02-25741	92	38	.	.	PUNCT
bioethics02-25741	93	1	industry	industry	NOUN
bioethics02-25741	93	2	spending	spending	NOUN
bioethics02-25741	93	3	on	on	ADP
bioethics02-25741	93	4	dtca	dtca	ADJ
bioethics02-25741	93	5	for	for	ADP
bioethics02-25741	93	6	pharmaceuticals	pharmaceutical	NOUN
bioethics02-25741	93	7	alone	alone	ADV
bioethics02-25741	93	8	increased	increase	VERB
bioethics02-25741	93	9	from	from	ADP
bioethics02-25741	93	10	$	$	SYM
bioethics02-25741	93	11	11	11	NUM
bioethics02-25741	93	12	billion	billion	NUM
bioethics02-25741	93	13	to	to	PART
bioethics02-25741	93	14	$	$	SYM
bioethics02-25741	93	15	30	30	NUM
bioethics02-25741	93	16	billion	billion	NUM
bioethics02-25741	93	17	within	within	ADP
bioethics02-25741	93	18	the	the	DET
bioethics02-25741	93	19	1996–2005	1996–2005	NUM
bioethics02-25741	93	20	decade	decade	NOUN
bioethics02-25741	93	21	59	59	NUM
bioethics02-25741	93	22	,	,	PUNCT
bioethics02-25741	93	23	about	about	ADP
bioethics02-25741	93	24	the	the	DET
bioethics02-25741	93	25	same	same	ADJ
bioethics02-25741	93	26	period	period	NOUN
bioethics02-25741	93	27	of	of	ADP
bioethics02-25741	93	28	time	time	NOUN
bioethics02-25741	93	29	when	when	SCONJ
bioethics02-25741	93	30	the	the	DET
bioethics02-25741	93	31	total	total	ADJ
bioethics02-25741	93	32	costs	cost	NOUN
bioethics02-25741	93	33	of	of	ADP
bioethics02-25741	93	34	prescription	prescription	NOUN
bioethics02-25741	93	35	drugs	drug	NOUN
bioethics02-25741	93	36	were	be	AUX
bioethics02-25741	93	37	rising	rise	VERB
bioethics02-25741	93	38	at	at	ADP
bioethics02-25741	93	39	a	a	DET
bioethics02-25741	93	40	rate	rate	NOUN
bioethics02-25741	93	41	higher	high	ADJ
bioethics02-25741	93	42	than	than	ADP
bioethics02-25741	93	43	30	30	NUM
bioethics02-25741	93	44	%	%	NOUN
bioethics02-25741	93	45	a	a	DET
bioethics02-25741	93	46	year	year	NOUN
bioethics02-25741	93	47	60	60	NUM
bioethics02-25741	93	48	.	.	PUNCT
bioethics02-25741	94	1	besides	besides	SCONJ
bioethics02-25741	94	2	inflated	inflate	VERB
bioethics02-25741	94	3	costs	cost	NOUN
bioethics02-25741	94	4	for	for	ADP
bioethics02-25741	94	5	patients	patient	NOUN
bioethics02-25741	94	6	and	and	CCONJ
bioethics02-25741	94	7	healthcare	healthcare	NOUN
bioethics02-25741	94	8	providers	provider	NOUN
bioethics02-25741	94	9	[	[	X
bioethics02-25741	94	10	58	58	NUM
bioethics02-25741	94	11	]	]	PUNCT
bioethics02-25741	94	12	,	,	PUNCT
bioethics02-25741	94	13	dtca	dtca	ADJ
bioethics02-25741	94	14	is	be	AUX
bioethics02-25741	94	15	linked	link	VERB
bioethics02-25741	94	16	to	to	ADP
bioethics02-25741	94	17	concerns	concern	NOUN
bioethics02-25741	94	18	over	over	ADP
bioethics02-25741	94	19	the	the	DET
bioethics02-25741	94	20	aptitude	aptitude	NOUN
bioethics02-25741	94	21	of	of	ADP
bioethics02-25741	94	22	the	the	DET
bioethics02-25741	94	23	lay	lay	NOUN
bioethics02-25741	94	24	public	public	ADJ
bioethics02-25741	94	25	to	to	PART
bioethics02-25741	94	26	understand	understand	VERB
bioethics02-25741	94	27	risks	risk	NOUN
bioethics02-25741	94	28	and	and	CCONJ
bioethics02-25741	94	29	benefits	benefit	NOUN
bioethics02-25741	94	30	through	through	ADP
bioethics02-25741	94	31	a	a	DET
bioethics02-25741	94	32	30	30	NUM
bioethics02-25741	94	33	-	-	PUNCT
bioethics02-25741	94	34	s	s	NOUN
bioethics02-25741	94	35	tv	tv	NOUN
bioethics02-25741	94	36	or	or	CCONJ
bioethics02-25741	94	37	a	a	DET
bioethics02-25741	94	38	one	one	NUM
bioethics02-25741	94	39	page	page	NOUN
bioethics02-25741	94	40	magazine	magazine	NOUN
bioethics02-25741	94	41	advertisement	advertisement	NOUN
bioethics02-25741	94	42	.	.	PUNCT
bioethics02-25741	95	1	dtca	dtca	ADJ
bioethics02-25741	95	2	typically	typically	ADV
bioethics02-25741	95	3	commences	commence	VERB
bioethics02-25741	95	4	one	one	NUM
bioethics02-25741	95	5	year	year	NOUN
bioethics02-25741	95	6	after	after	ADP
bioethics02-25741	95	7	release	release	NOUN
bioethics02-25741	95	8	of	of	ADP
bioethics02-25741	95	9	a	a	DET
bioethics02-25741	95	10	new	new	ADJ
bioethics02-25741	95	11	drug	drug	NOUN
bioethics02-25741	95	12	59	59	NUM
bioethics02-25741	95	13	,	,	PUNCT
bioethics02-25741	95	14	which	which	PRON
bioethics02-25741	95	15	is	be	AUX
bioethics02-25741	95	16	a	a	DET
bioethics02-25741	95	17	very	very	ADV
bioethics02-25741	95	18	short	short	ADJ
bioethics02-25741	95	19	time	time	NOUN
bioethics02-25741	95	20	frame	frame	NOUN
bioethics02-25741	95	21	for	for	SCONJ
bioethics02-25741	95	22	many	many	ADJ
bioethics02-25741	95	23	unwanted	unwanted	ADJ
bioethics02-25741	95	24	side	side	NOUN
bioethics02-25741	95	25	effects	effect	NOUN
bioethics02-25741	95	26	to	to	PART
bioethics02-25741	95	27	become	become	VERB
bioethics02-25741	95	28	apparent	apparent	ADJ
bioethics02-25741	95	29	.	.	PUNCT
bioethics02-25741	96	1	the	the	DET
bioethics02-25741	96	2	us	us	PROPN
bioethics02-25741	96	3	senate	senate	PROPN
bioethics02-25741	96	4	has	have	AUX
bioethics02-25741	96	5	previously	previously	ADV
bioethics02-25741	96	6	considered	consider	VERB
bioethics02-25741	96	7	legislation	legislation	NOUN
bioethics02-25741	96	8	prohibiting	prohibit	VERB
bioethics02-25741	96	9	such	such	ADJ
bioethics02-25741	96	10	advertising	advertising	NOUN
bioethics02-25741	96	11	for	for	ADP
bioethics02-25741	96	12	at	at	ADV
bioethics02-25741	96	13	least	least	ADV
bioethics02-25741	96	14	two	two	NUM
bioethics02-25741	96	15	years	year	NOUN
bioethics02-25741	96	16	61	61	NUM
bioethics02-25741	96	17	.	.	PUNCT
bioethics02-25741	97	1	conclusions	conclusion	NOUN
bioethics02-25741	97	2	:	:	PUNCT
bioethics02-25741	97	3	given	give	VERB
bioethics02-25741	97	4	that	that	SCONJ
bioethics02-25741	97	5	many	many	ADJ
bioethics02-25741	97	6	of	of	ADP
bioethics02-25741	97	7	the	the	DET
bioethics02-25741	97	8	problems	problem	NOUN
bioethics02-25741	97	9	discussed	discuss	VERB
bioethics02-25741	97	10	above	above	ADV
bioethics02-25741	97	11	are	be	AUX
bioethics02-25741	97	12	closely	closely	ADV
bioethics02-25741	97	13	linked	link	VERB
bioethics02-25741	97	14	to	to	ADP
bioethics02-25741	97	15	financial	financial	ADJ
bioethics02-25741	97	16	interests	interest	NOUN
bioethics02-25741	97	17	,	,	PUNCT
bioethics02-25741	97	18	we	we	PRON
bioethics02-25741	97	19	would	would	AUX
bioethics02-25741	97	20	argue	argue	VERB
bioethics02-25741	97	21	that	that	SCONJ
bioethics02-25741	97	22	there	there	PRON
bioethics02-25741	97	23	is	be	VERB
bioethics02-25741	97	24	an	an	DET
bioethics02-25741	97	25	urgent	urgent	ADJ
bioethics02-25741	97	26	need	need	NOUN
bioethics02-25741	97	27	to	to	PART
bioethics02-25741	97	28	better	well	ADV
bioethics02-25741	97	29	deal	deal	VERB
bioethics02-25741	97	30	with	with	ADP
bioethics02-25741	97	31	conflict	conflict	NOUN
bioethics02-25741	97	32	of	of	ADP
bioethics02-25741	97	33	interests	interest	NOUN
bioethics02-25741	97	34	in	in	ADP
bioethics02-25741	97	35	medicine	medicine	NOUN
bioethics02-25741	97	36	and	and	CCONJ
bioethics02-25741	97	37	healthcare	healthcare	PROPN
bioethics02-25741	97	38	.	.	PUNCT
bioethics02-25741	98	1	the	the	DET
bioethics02-25741	98	2	institute	institute	PROPN
bioethics02-25741	98	3	of	of	ADP
bioethics02-25741	98	4	medicine	medicine	NOUN
bioethics02-25741	98	5	has	have	AUX
bioethics02-25741	98	6	published	publish	VERB
bioethics02-25741	98	7	a	a	DET
bioethics02-25741	98	8	comprehensive	comprehensive	ADJ
bioethics02-25741	98	9	set	set	NOUN
bioethics02-25741	98	10	of	of	ADP
bioethics02-25741	98	11	recommendations	recommendation	NOUN
bioethics02-25741	98	12	on	on	ADP
bioethics02-25741	98	13	how	how	SCONJ
bioethics02-25741	98	14	to	to	PART
bioethics02-25741	98	15	deal	deal	VERB
bioethics02-25741	98	16	with	with	ADP
bioethics02-25741	98	17	conflict	conflict	NOUN
bioethics02-25741	98	18	of	of	ADP
bioethics02-25741	98	19	interests	interest	NOUN
bioethics02-25741	98	20	in	in	ADP
bioethics02-25741	98	21	medicine	medicine	NOUN
bioethics02-25741	98	22	so	so	SCONJ
bioethics02-25741	98	23	that	that	SCONJ
bioethics02-25741	98	24	the	the	DET
bioethics02-25741	98	25	undue	undue	ADJ
bioethics02-25741	98	26	industry	industry	NOUN
bioethics02-25741	98	27	influences	influence	NOUN
bioethics02-25741	98	28	we	we	PRON
bioethics02-25741	98	29	describe	describe	VERB
bioethics02-25741	98	30	above	above	ADV
bioethics02-25741	98	31	are	be	AUX
bioethics02-25741	98	32	eliminated	eliminate	VERB
bioethics02-25741	98	33	62	62	NUM
bioethics02-25741	98	34	.	.	PUNCT
bioethics02-25741	99	1	these	these	DET
bioethics02-25741	99	2	recommendations	recommendation	NOUN
bioethics02-25741	99	3	cover	cover	VERB
bioethics02-25741	99	4	general	general	ADJ
bioethics02-25741	99	5	policy	policy	NOUN
bioethics02-25741	99	6	measures	measure	NOUN
bioethics02-25741	99	7	,	,	PUNCT
bioethics02-25741	99	8	medical	medical	ADJ
bioethics02-25741	99	9	research	research	NOUN
bioethics02-25741	99	10	,	,	PUNCT
bioethics02-25741	99	11	undergraduate	undergraduate	NOUN
bioethics02-25741	99	12	and	and	CCONJ
bioethics02-25741	99	13	continuous	continuous	ADJ
bioethics02-25741	99	14	medical	medical	ADJ
bioethics02-25741	99	15	education	education	NOUN
bioethics02-25741	99	16	,	,	PUNCT
bioethics02-25741	99	17	medical	medical	ADJ
bioethics02-25741	99	18	practice	practice	NOUN
bioethics02-25741	99	19	,	,	PUNCT
bioethics02-25741	99	20	as	as	ADV
bioethics02-25741	99	21	well	well	ADV
bioethics02-25741	99	22	as	as	ADP
bioethics02-25741	99	23	clinical	clinical	ADJ
bioethics02-25741	99	24	guideline	guideline	NOUN
bioethics02-25741	99	25	formation	formation	NOUN
bioethics02-25741	99	26	.	.	PUNCT
bioethics02-25741	100	1	the	the	DET
bioethics02-25741	100	2	evidence	evidence	NOUN
bioethics02-25741	100	3	we	we	PRON
bioethics02-25741	100	4	presented	present	VERB
bioethics02-25741	100	5	highlights	highlight	NOUN
bioethics02-25741	100	6	the	the	DET
bioethics02-25741	100	7	case	case	NOUN
bioethics02-25741	100	8	for	for	ADP
bioethics02-25741	100	9	tighter	tight	ADJ
bioethics02-25741	100	10	regulation	regulation	NOUN
bioethics02-25741	100	11	on	on	ADP
bioethics02-25741	100	12	how	how	SCONJ
bioethics02-25741	100	13	the	the	DET
bioethics02-25741	100	14	healthcare	healthcare	NOUN
bioethics02-25741	100	15	industry	industry	NOUN
bioethics02-25741	100	16	designs	design	NOUN
bioethics02-25741	100	17	,	,	PUNCT
bioethics02-25741	100	18	conducts	conduct	NOUN
bioethics02-25741	100	19	,	,	PUNCT
bioethics02-25741	100	20	disseminates	disseminate	NOUN
bioethics02-25741	100	21	and	and	CCONJ
bioethics02-25741	100	22	publicizes	publicize	VERB
bioethics02-25741	100	23	their	their	PRON
bioethics02-25741	100	24	research	research	NOUN
bioethics02-25741	100	25	,	,	PUNCT
bioethics02-25741	100	26	markets	market	VERB
bioethics02-25741	100	27	their	their	PRON
bioethics02-25741	100	28	products	product	NOUN
bioethics02-25741	100	29	and	and	CCONJ
bioethics02-25741	100	30	interacts	interact	VERB
bioethics02-25741	100	31	with	with	ADP
bioethics02-25741	100	32	medical	medical	ADJ
bioethics02-25741	100	33	students	student	NOUN
bioethics02-25741	100	34	,	,	PUNCT
bioethics02-25741	100	35	health	health	NOUN
bioethics02-25741	100	36	professionals	professional	NOUN
bioethics02-25741	100	37	and	and	CCONJ
bioethics02-25741	100	38	researchers	researcher	NOUN
bioethics02-25741	100	39	.	.	PUNCT
bioethics02-25741	101	1	currently	currently	ADV
bioethics02-25741	101	2	,	,	PUNCT
bioethics02-25741	101	3	industry	industry	NOUN
bioethics02-25741	101	4	expenditure	expenditure	NOUN
bioethics02-25741	101	5	influences	influence	NOUN
bioethics02-25741	101	6	and	and	CCONJ
bioethics02-25741	101	7	determines	determine	VERB
bioethics02-25741	101	8	medical	medical	ADJ
bioethics02-25741	101	9	practice	practice	NOUN
bioethics02-25741	101	10	and	and	CCONJ
bioethics02-25741	101	11	attitudes	attitude	NOUN
bioethics02-25741	101	12	at	at	ADP
bioethics02-25741	101	13	various	various	ADJ
bioethics02-25741	101	14	levels	level	NOUN
bioethics02-25741	101	15	at	at	ADP
bioethics02-25741	101	16	the	the	DET
bioethics02-25741	101	17	expense	expense	NOUN
bioethics02-25741	101	18	of	of	ADP
bioethics02-25741	101	19	patients	patient	NOUN
bioethics02-25741	101	20	‘	'	PUNCT
bioethics02-25741	101	21	health	health	NOUN
bioethics02-25741	101	22	,	,	PUNCT
bioethics02-25741	101	23	healthcare	healthcare	NOUN
bioethics02-25741	101	24	budgets	budget	NOUN
bioethics02-25741	101	25	and	and	CCONJ
bioethics02-25741	101	26	medicine‘s	medicine‘s	PROPN
bioethics02-25741	101	27	integrity	integrity	NOUN
bioethics02-25741	101	28	.	.	PUNCT
bioethics02-25741	102	1	there	there	PRON
bioethics02-25741	102	2	are	be	VERB
bioethics02-25741	102	3	positive	positive	ADJ
bioethics02-25741	102	4	signs	sign	NOUN
bioethics02-25741	102	5	of	of	ADP
bioethics02-25741	102	6	action	action	NOUN
bioethics02-25741	102	7	taken	take	VERB
bioethics02-25741	102	8	in	in	ADP
bioethics02-25741	102	9	both	both	DET
bioethics02-25741	102	10	united	united	PROPN
bioethics02-25741	102	11	states	states	PROPN
bioethics02-25741	102	12	and	and	CCONJ
bioethics02-25741	102	13	europe	europe	PROPN
bioethics02-25741	102	14	,	,	PUNCT
bioethics02-25741	102	15	for	for	ADP
bioethics02-25741	102	16	example	example	NOUN
bioethics02-25741	102	17	,	,	PUNCT
bioethics02-25741	102	18	the	the	DET
bioethics02-25741	102	19	sunshine	sunshine	PROPN
bioethics02-25741	102	20	act	act	NOUN
bioethics02-25741	102	21	in	in	ADP
bioethics02-25741	102	22	the	the	DET
bioethics02-25741	102	23	united	united	PROPN
bioethics02-25741	102	24	states	states	PROPN
bioethics02-25741	102	25	that	that	PRON
bioethics02-25741	102	26	requires	require	VERB
bioethics02-25741	102	27	drug	drug	NOUN
bioethics02-25741	102	28	companies	company	NOUN
bioethics02-25741	102	29	to	to	PART
bioethics02-25741	102	30	declare	declare	VERB
bioethics02-25741	102	31	all	all	DET
bioethics02-25741	102	32	payments	payment	NOUN
bioethics02-25741	102	33	and	and	CCONJ
bioethics02-25741	102	34	hospitality	hospitality	NOUN
bioethics02-25741	102	35	or	or	CCONJ
bioethics02-25741	102	36	gifts	gift	NOUN
bioethics02-25741	102	37	they	they	PRON
bioethics02-25741	102	38	give	give	VERB
bioethics02-25741	102	39	to	to	ADP
bioethics02-25741	102	40	doctors	doctor	NOUN
bioethics02-25741	102	41	.	.	PUNCT
bioethics02-25741	103	1	in	in	ADP
bioethics02-25741	103	2	denmark	denmark	PROPN
bioethics02-25741	103	3	,	,	PUNCT
bioethics02-25741	103	4	companies	company	NOUN
bioethics02-25741	103	5	have	have	AUX
bioethics02-25741	103	6	been	be	AUX
bioethics02-25741	103	7	required	require	VERB
bioethics02-25741	103	8	to	to	PART
bioethics02-25741	103	9	declare	declare	VERB
bioethics02-25741	103	10	their	their	PRON
bioethics02-25741	103	11	payments	payment	NOUN
bioethics02-25741	103	12	to	to	ADP
bioethics02-25741	103	13	doctors	doctor	NOUN
bioethics02-25741	103	14	since	since	SCONJ
bioethics02-25741	103	15	2008	2008	NUM
bioethics02-25741	103	16	,	,	PUNCT
bioethics02-25741	103	17	in	in	ADP
bioethics02-25741	103	18	scotland	scotland	PROPN
bioethics02-25741	103	19	,	,	PUNCT
bioethics02-25741	103	20	doctors	doctor	NOUN
bioethics02-25741	103	21	have	have	VERB
bioethics02-25741	103	22	to	to	PART
bioethics02-25741	103	23	declare	declare	VERB
bioethics02-25741	103	24	such	such	ADJ
bioethics02-25741	103	25	transactions	transaction	NOUN
bioethics02-25741	103	26	themselves	themselves	PRON
bioethics02-25741	103	27	,	,	PUNCT
bioethics02-25741	103	28	and	and	CCONJ
bioethics02-25741	103	29	france	france	PROPN
bioethics02-25741	103	30	is	be	AUX
bioethics02-25741	103	31	currently	currently	ADV
bioethics02-25741	103	32	preparing	prepare	VERB
bioethics02-25741	103	33	such	such	ADJ
bioethics02-25741	103	34	legislation	legislation	NOUN
bioethics02-25741	103	35	.	.	PUNCT
bioethics02-25741	104	1	the	the	DET
bioethics02-25741	104	2	new	new	PROPN
bioethics02-25741	104	3	england	england	PROPN
bioethics02-25741	104	4	journal	journal	PROPN
bioethics02-25741	104	5	of	of	ADP
bioethics02-25741	104	6	medicine	medicine	NOUN
bioethics02-25741	104	7	banned	ban	VERB
bioethics02-25741	104	8	cost	cost	NOUN
bioethics02-25741	104	9	-	-	PUNCT
bioethics02-25741	104	10	effectiveness	effectiveness	NOUN
bioethics02-25741	104	11	evaluations	evaluation	NOUN
bioethics02-25741	104	12	sponsored	sponsor	VERB
bioethics02-25741	104	13	by	by	ADP
bioethics02-25741	104	14	product	product	NOUN
bioethics02-25741	104	15	manufacturers	manufacturer	NOUN
bioethics02-25741	104	16	almost	almost	ADV
bioethics02-25741	104	17	two	two	NUM
bioethics02-25741	104	18	decades	decade	NOUN
bioethics02-25741	104	19	ago	ago	ADV
bioethics02-25741	104	20	.	.	PUNCT
bioethics02-25741	105	1	these	these	PRON
bioethics02-25741	105	2	are	be	AUX
bioethics02-25741	105	3	some	some	DET
bioethics02-25741	105	4	indicative	indicative	ADJ
bioethics02-25741	105	5	steps	step	NOUN
bioethics02-25741	105	6	towards	towards	ADP
bioethics02-25741	105	7	redefining	redefine	VERB
bioethics02-25741	105	8	the	the	DET
bioethics02-25741	105	9	mission	mission	NOUN
bioethics02-25741	105	10	of	of	ADP
bioethics02-25741	105	11	medicine	medicine	NOUN
bioethics02-25741	105	12	towards	towards	ADP
bioethics02-25741	105	13	a	a	DET
bioethics02-25741	105	14	more	more	ADV
bioethics02-25741	105	15	objective	objective	ADJ
bioethics02-25741	105	16	and	and	CCONJ
bioethics02-25741	105	17	patient-	patient-	NOUN
bioethics02-25741	105	18	,	,	PUNCT
bioethics02-25741	105	19	populationand	populationand	VERB
bioethics02-25741	105	20	society	society	NOUN
bioethics02-25741	105	21	-	-	PUNCT
bioethics02-25741	105	22	benefit	benefit	NOUN
bioethics02-25741	105	23	direction	direction	NOUN
bioethics02-25741	105	24	that	that	PRON
bioethics02-25741	105	25	is	be	AUX
bioethics02-25741	105	26	free	free	ADJ
bioethics02-25741	105	27	from	from	ADP
bioethics02-25741	105	28	conflict	conflict	NOUN
bioethics02-25741	105	29	of	of	ADP
bioethics02-25741	105	30	interests	interest	NOUN
bioethics02-25741	105	31	.	.	PUNCT
bioethics02-25741	106	1	conflict	conflict	NOUN
bioethics02-25741	106	2	of	of	ADP
bioethics02-25741	106	3	interests	interest	NOUN
bioethics02-25741	106	4	:	:	PUNCT
bioethics02-25741	106	5	none	none	NOUN
bioethics02-25741	106	6	of	of	ADP
bioethics02-25741	106	7	the	the	DET
bioethics02-25741	106	8	authors	author	NOUN
bioethics02-25741	106	9	have	have	VERB
bioethics02-25741	106	10	any	any	DET
bioethics02-25741	106	11	conflict	conflict	NOUN
bioethics02-25741	106	12	of	of	ADP
bioethics02-25741	106	13	interest	interest	NOUN
bioethics02-25741	106	14	to	to	PART
bioethics02-25741	106	15	declare	declare	VERB
bioethics02-25741	106	16	.	.	PUNCT
bioethics02-25741	107	1	bangladesh	bangladesh	PROPN
bioethics02-25741	107	2	journal	journal	PROPN
bioethics02-25741	107	3	of	of	ADP
bioethics02-25741	107	4	bioethics	bioethic	NOUN
bioethics02-25741	107	5	2015	2015	NUM
bioethics02-25741	107	6	;	;	PUNCT
bioethics02-25741	107	7	6(2):15	6(2):15	X
bioethics02-25741	107	8	-	-	SYM
bioethics02-25741	107	9	22	22	NUM
bioethics02-25741	107	10	19	19	NUM
bioethics02-25741	107	11	references	reference	NOUN
bioethics02-25741	107	12	1	1	NUM
bioethics02-25741	107	13	the	the	DET
bioethics02-25741	107	14	lancet	lancet	NOUN
bioethics02-25741	107	15	(	(	PUNCT
bioethics02-25741	107	16	in	in	ADP
bioethics02-25741	107	17	-	-	PUNCT
bioethics02-25741	107	18	house	house	NOUN
bioethics02-25741	107	19	editorial	editorial	NOUN
bioethics02-25741	107	20	)	)	PUNCT
bioethics02-25741	107	21	.	.	PUNCT
bioethics02-25741	108	1	lessons	lesson	NOUN
bioethics02-25741	108	2	from	from	ADP
bioethics02-25741	108	3	lipitor	lipitor	NOUN
bioethics02-25741	108	4	and	and	CCONJ
bioethics02-25741	108	5	the	the	DET
bioethics02-25741	108	6	broken	broken	ADJ
bioethics02-25741	108	7	blockbuster	blockbuster	ADJ
bioethics02-25741	108	8	drug	drug	NOUN
bioethics02-25741	108	9	model	model	NOUN
bioethics02-25741	108	10	.	.	PUNCT
bioethics02-25741	109	1	lancet	lancet	PROPN
bioethics02-25741	109	2	2011;378:1976	2011;378:1976	NUM
bioethics02-25741	109	3	.	.	PUNCT
bioethics02-25741	110	1	2	2	NUM
bioethics02-25741	110	2	international	international	ADJ
bioethics02-25741	110	3	monetary	monetary	ADJ
bioethics02-25741	110	4	fund	fund	NOUN
bioethics02-25741	110	5	.	.	PUNCT
bioethics02-25741	111	1	world	world	PROPN
bioethics02-25741	111	2	economic	economic	ADJ
bioethics02-25741	111	3	outlook	outlook	NOUN
bioethics02-25741	111	4	database	database	NOUN
bioethics02-25741	112	1	[	[	X
bioethics02-25741	112	2	internet	internet	NOUN
bioethics02-25741	112	3	]	]	PUNCT
bioethics02-25741	112	4	.	.	PUNCT
bioethics02-25741	113	1	nominal	nominal	PROPN
bioethics02-25741	113	2	gdp	gdp	NOUN
bioethics02-25741	113	3	list	list	NOUN
bioethics02-25741	113	4	of	of	ADP
bioethics02-25741	113	5	countries	country	NOUN
bioethics02-25741	113	6	for	for	ADP
bioethics02-25741	113	7	the	the	DET
bioethics02-25741	113	8	year	year	NOUN
bioethics02-25741	113	9	2010	2010	NUM
bioethics02-25741	113	10	.	.	PUNCT
bioethics02-25741	114	1	2011	2011	NUM
bioethics02-25741	114	2	.	.	PUNCT
bioethics02-25741	115	1	available	available	ADJ
bioethics02-25741	115	2	at	at	ADP
bioethics02-25741	115	3	:	:	PUNCT
bioethics02-25741	115	4	www.imf.org/external/pubs/ft/weo/2011/02/	www.imf.org/external/pubs/ft/weo/2011/02/	NUM
bioethics02-25741	115	5	weodata	weodata	PROPN
bioethics02-25741	115	6	/	/	SYM
bioethics02-25741	115	7	index.aspx	index.aspx	PROPN
bioethics02-25741	115	8	.	.	PUNCT
bioethics02-25741	115	9	access	access	NOUN
bioethics02-25741	115	10	on	on	ADP
bioethics02-25741	115	11	24	24	NUM
bioethics02-25741	115	12	january	january	PROPN
bioethics02-25741	115	13	2012	2012	NUM
bioethics02-25741	115	14	.	.	PUNCT
bioethics02-25741	116	1	3	3	NUM
bioethics02-25741	116	2	ioannidis	ioannidis	PROPN
bioethics02-25741	116	3	jpa	jpa	PROPN
bioethics02-25741	116	4	,	,	PUNCT
bioethics02-25741	116	5	karassa	karassa	ADJ
bioethics02-25741	116	6	fb	fb	INTJ
bioethics02-25741	116	7	.	.	PUNCT
bioethics02-25741	117	1	the	the	DET
bioethics02-25741	117	2	need	need	NOUN
bioethics02-25741	117	3	to	to	PART
bioethics02-25741	117	4	consider	consider	VERB
bioethics02-25741	117	5	the	the	DET
bioethics02-25741	117	6	wider	wide	ADJ
bioethics02-25741	117	7	agenda	agenda	NOUN
bioethics02-25741	117	8	in	in	ADP
bioethics02-25741	117	9	systematic	systematic	ADJ
bioethics02-25741	117	10	reviews	review	NOUN
bioethics02-25741	117	11	and	and	CCONJ
bioethics02-25741	117	12	meta	meta	NOUN
bioethics02-25741	117	13	-	-	PUNCT
bioethics02-25741	117	14	analyses	analysis	NOUN
bioethics02-25741	117	15	:	:	PUNCT
bioethics02-25741	117	16	breadth	breadth	NOUN
bioethics02-25741	117	17	,	,	PUNCT
bioethics02-25741	117	18	timing	timing	NOUN
bioethics02-25741	117	19	and	and	CCONJ
bioethics02-25741	117	20	depth	depth	NOUN
bioethics02-25741	117	21	of	of	ADP
bioethics02-25741	117	22	evidence	evidence	NOUN
bioethics02-25741	117	23	.	.	PUNCT
bioethics02-25741	118	1	bmj	bmj	PROPN
bioethics02-25741	118	2	2010;341	2010;341	NUM
bioethics02-25741	118	3	:	:	PUNCT
bioethics02-25741	118	4	c4875	c4875	PROPN
bioethics02-25741	118	5	.	.	PUNCT
bioethics02-25741	118	6	doi:10.1136	doi:10.1136	PROPN
bioethics02-25741	118	7	/	/	SYM
bioethics02-25741	118	8	bmj.c4875	bmj.c4875	PROPN
bioethics02-25741	118	9	.	.	PUNCT
bioethics02-25741	119	1	4	4	NUM
bioethics02-25741	119	2	abbott	abbott	PROPN
bioethics02-25741	119	3	.	.	PUNCT
bioethics02-25741	119	4	2009	2009	NUM
bioethics02-25741	119	5	annual	annual	ADJ
bioethics02-25741	119	6	report	report	NOUN
bioethics02-25741	119	7	[	[	X
bioethics02-25741	119	8	internet	internet	NOUN
bioethics02-25741	119	9	]	]	PUNCT
bioethics02-25741	119	10	2009	2009	NUM
bioethics02-25741	119	11	.	.	PUNCT
bioethics02-25741	119	12	available	available	ADJ
bioethics02-25741	119	13	at	at	ADP
bioethics02-25741	119	14	:	:	PUNCT
bioethics02-25741	119	15	http://	http://	PROPN
bioethics02-25741	119	16	www.abbott.com/annual-reports/2009/downloads/	www.abbott.com/annual-reports/2009/downloads/	PROPN
bioethics02-25741	119	17	editorial_section_only.pdf	editorial_section_only.pdf	PROPN
bioethics02-25741	119	18	.	.	PROPN
bioethics02-25741	119	19	access	access	NOUN
bioethics02-25741	119	20	on	on	ADP
bioethics02-25741	119	21	12	12	NUM
bioethics02-25741	119	22	february	february	NOUN
bioethics02-25741	119	23	2013	2013	NUM
bioethics02-25741	119	24	.	.	PUNCT
bioethics02-25741	120	1	5	5	NUM
bioethics02-25741	120	2	massdevice	massdevice	NOUN
bioethics02-25741	120	3	staff	staff	NOUN
bioethics02-25741	120	4	.	.	PUNCT
bioethics02-25741	121	1	massdevice	massdevice	PROPN
bioethics02-25741	121	2	blog	blog	PROPN
bioethics02-25741	121	3	:	:	PUNCT
bioethics02-25741	121	4	abbott	abbott	PROPN
bioethics02-25741	121	5	labs	labs	PROPN
bioethics02-25741	121	6	and	and	CCONJ
bioethics02-25741	121	7	boston	boston	PROPN
bioethics02-25741	121	8	scientific	scientific	ADJ
bioethics02-25741	121	9	together	together	ADV
bioethics02-25741	121	10	make	make	VERB
bioethics02-25741	121	11	up	up	ADP
bioethics02-25741	121	12	about	about	ADV
bioethics02-25741	121	13	64	64	NUM
bioethics02-25741	121	14	percent	percent	NOUN
bioethics02-25741	121	15	of	of	ADP
bioethics02-25741	121	16	u.s	u.s	PROPN
bioethics02-25741	121	17	.	.	PROPN
bioethics02-25741	121	18	drug	drug	NOUN
bioethics02-25741	121	19	eluting	eluting	NOUN
bioethics02-25741	121	20	stent	stent	NOUN
bioethics02-25741	121	21	market	market	NOUN
bioethics02-25741	122	1	[	[	X
bioethics02-25741	122	2	internet	internet	NOUN
bioethics02-25741	122	3	]	]	PUNCT
bioethics02-25741	122	4	.	.	PUNCT
bioethics02-25741	123	1	c2011	c2011	PROPN
bioethics02-25741	123	2	.	.	PUNCT
bioethics02-25741	123	3	available	available	ADJ
bioethics02-25741	123	4	at	at	ADP
bioethics02-25741	123	5	:	:	PUNCT
bioethics02-25741	123	6	http://www	http://www	PROPN
bioethics02-25741	123	7	.	.	PROPN
bioethics02-25741	123	8	massdevice.com/news/abbott-and-bostonscientific-dominate-46-billion-drug-eluting-stent-market	massdevice.com/news/abbott-and-bostonscientific-dominate-46-billion-drug-eluting-stent-market	PROPN
bioethics02-25741	123	9	.	.	PUNCT
bioethics02-25741	124	1	access	access	NOUN
bioethics02-25741	124	2	on	on	ADP
bioethics02-25741	124	3	12	12	NUM
bioethics02-25741	124	4	february	february	NOUN
bioethics02-25741	124	5	2013	2013	NUM
bioethics02-25741	124	6	.	.	PUNCT
bioethics02-25741	125	1	6	6	NUM
bioethics02-25741	125	2	prasad	prasad	PROPN
bioethics02-25741	125	3	v	v	NOUN
bioethics02-25741	125	4	,	,	PUNCT
bioethics02-25741	125	5	cifu	cifu	NOUN
bioethics02-25741	125	6	a	a	PRON
bioethics02-25741	125	7	,	,	PUNCT
bioethics02-25741	125	8	ioannidis	ioannidis	PROPN
bioethics02-25741	125	9	jpa	jpa	PROPN
bioethics02-25741	125	10	.	.	PUNCT
bioethics02-25741	126	1	reversals	reversal	NOUN
bioethics02-25741	126	2	of	of	ADP
bioethics02-25741	126	3	established	establish	VERB
bioethics02-25741	126	4	medical	medical	ADJ
bioethics02-25741	126	5	practices	practice	NOUN
bioethics02-25741	126	6	:	:	PUNCT
bioethics02-25741	126	7	evidence	evidence	NOUN
bioethics02-25741	126	8	to	to	PART
bioethics02-25741	126	9	abandon	abandon	VERB
bioethics02-25741	126	10	ship	ship	NOUN
bioethics02-25741	126	11	.	.	PUNCT
bioethics02-25741	127	1	jama	jama	PROPN
bioethics02-25741	127	2	2012	2012	NUM
bioethics02-25741	127	3	;	;	PUNCT
bioethics02-25741	127	4	307:37–8	307:37–8	NUM
bioethics02-25741	127	5	.	.	NOUN
bioethics02-25741	127	6	7	7	NUM
bioethics02-25741	127	7	katritsis	katritsis	NOUN
bioethics02-25741	127	8	dg	dg	NOUN
bioethics02-25741	127	9	,	,	PUNCT
bioethics02-25741	127	10	ioannidis	ioannidis	PROPN
bioethics02-25741	127	11	jpa	jpa	PROPN
bioethics02-25741	127	12	.	.	PUNCT
bioethics02-25741	128	1	percutaneous	percutaneous	ADJ
bioethics02-25741	128	2	coronary	coronary	ADJ
bioethics02-25741	128	3	intervention	intervention	NOUN
bioethics02-25741	128	4	versus	versus	ADP
bioethics02-25741	128	5	conservative	conservative	ADJ
bioethics02-25741	128	6	therapy	therapy	NOUN
bioethics02-25741	128	7	in	in	ADP
bioethics02-25741	128	8	nonacute	nonacute	ADJ
bioethics02-25741	128	9	coronary	coronary	ADJ
bioethics02-25741	128	10	artery	artery	NOUN
bioethics02-25741	128	11	disease	disease	NOUN
bioethics02-25741	128	12	.	.	PUNCT
bioethics02-25741	129	1	circulation	circulation	NOUN
bioethics02-25741	129	2	2005	2005	NUM
bioethics02-25741	129	3	;	;	PUNCT
bioethics02-25741	130	1	111:2906–12	111:2906–12	NUM
bioethics02-25741	130	2	.	.	NOUN
bioethics02-25741	130	3	8	8	NUM
bioethics02-25741	130	4	boden	boden	ADJ
bioethics02-25741	130	5	we	we	PRON
bioethics02-25741	130	6	,	,	PUNCT
bioethics02-25741	130	7	o‘rourke	o‘rourke	PROPN
bioethics02-25741	130	8	ra	ra	PROPN
bioethics02-25741	130	9	,	,	PUNCT
bioethics02-25741	130	10	teo	teo	PROPN
bioethics02-25741	130	11	kk	kk	PROPN
bioethics02-25741	130	12	,	,	PUNCT
bioethics02-25741	130	13	hartigan	hartigan	PROPN
bioethics02-25741	130	14	pm	pm	PROPN
bioethics02-25741	130	15	,	,	PUNCT
bioethics02-25741	130	16	maron	maron	PROPN
bioethics02-25741	130	17	dj	dj	PROPN
bioethics02-25741	130	18	,	,	PUNCT
bioethics02-25741	130	19	kostuk	kostuk	X
bioethics02-25741	130	20	wj	wj	PROPN
bioethics02-25741	130	21	et	et	PROPN
bioethics02-25741	130	22	al	al	PROPN
bioethics02-25741	130	23	.	.	PROPN
bioethics02-25741	131	1	optimal	optimal	ADJ
bioethics02-25741	131	2	medical	medical	ADJ
bioethics02-25741	131	3	therapy	therapy	NOUN
bioethics02-25741	131	4	with	with	ADP
bioethics02-25741	131	5	or	or	CCONJ
bioethics02-25741	131	6	without	without	ADP
bioethics02-25741	131	7	pci	pci	ADJ
bioethics02-25741	131	8	for	for	ADP
bioethics02-25741	131	9	stable	stable	ADJ
bioethics02-25741	131	10	coronary	coronary	ADJ
bioethics02-25741	131	11	disease	disease	NOUN
bioethics02-25741	131	12	.	.	PUNCT
bioethics02-25741	132	1	n	n	PROPN
bioethics02-25741	132	2	engl	engl	PROPN
bioethics02-25741	132	3	j	j	PROPN
bioethics02-25741	132	4	med	med	PROPN
bioethics02-25741	132	5	2007	2007	NUM
bioethics02-25741	132	6	;	;	PUNCT
bioethics02-25741	132	7	356:1503–16	356:1503–16	NUM
bioethics02-25741	132	8	.	.	NOUN
bioethics02-25741	132	9	9	9	NUM
bioethics02-25741	132	10	stergiopoulos	stergiopoulos	PROPN
bioethics02-25741	132	11	k	k	PROPN
bioethics02-25741	132	12	,	,	PUNCT
bioethics02-25741	132	13	brown	brown	PROPN
bioethics02-25741	132	14	dl	dl	PROPN
bioethics02-25741	132	15	.	.	PROPN
bioethics02-25741	132	16	initial	initial	ADJ
bioethics02-25741	132	17	coronary	coronary	ADJ
bioethics02-25741	132	18	stent	stent	NOUN
bioethics02-25741	132	19	implantation	implantation	NOUN
bioethics02-25741	132	20	with	with	ADP
bioethics02-25741	132	21	medical	medical	ADJ
bioethics02-25741	132	22	therapy	therapy	NOUN
bioethics02-25741	132	23	vs	vs	ADP
bioethics02-25741	132	24	medical	medical	ADJ
bioethics02-25741	132	25	therapy	therapy	NOUN
bioethics02-25741	132	26	alone	alone	ADV
bioethics02-25741	132	27	for	for	ADP
bioethics02-25741	132	28	stable	stable	ADJ
bioethics02-25741	132	29	coronary	coronary	ADJ
bioethics02-25741	132	30	artery	artery	NOUN
bioethics02-25741	132	31	disease	disease	NOUN
bioethics02-25741	132	32	:	:	PUNCT
bioethics02-25741	132	33	meta	meta	ADJ
bioethics02-25741	132	34	-	-	PUNCT
bioethics02-25741	132	35	analysis	analysis	NOUN
bioethics02-25741	132	36	of	of	ADP
bioethics02-25741	132	37	randomized	randomized	ADJ
bioethics02-25741	132	38	controlled	control	VERB
bioethics02-25741	132	39	trials	trial	NOUN
bioethics02-25741	132	40	.	.	PUNCT
bioethics02-25741	133	1	arch	arch	ADJ
bioethics02-25741	133	2	intern	intern	NOUN
bioethics02-25741	133	3	med	med	PROPN
bioethics02-25741	133	4	2012	2012	NUM
bioethics02-25741	133	5	;	;	PUNCT
bioethics02-25741	133	6	172:312–9	172:312–9	NUM
bioethics02-25741	133	7	.	.	NOUN
bioethics02-25741	133	8	10	10	NUM
bioethics02-25741	133	9	lexchin	lexchin	PROPN
bioethics02-25741	133	10	j	j	PROPN
bioethics02-25741	133	11	,	,	PUNCT
bioethics02-25741	133	12	bero	bero	PROPN
bioethics02-25741	133	13	la	la	PROPN
bioethics02-25741	133	14	,	,	PUNCT
bioethics02-25741	133	15	djulbegovic	djulbegovic	PROPN
bioethics02-25741	133	16	b	b	PROPN
bioethics02-25741	133	17	,	,	PUNCT
bioethics02-25741	133	18	clark	clark	PROPN
bioethics02-25741	133	19	o.	o.	PROPN
bioethics02-25741	133	20	pharmaceutical	pharmaceutical	PROPN
bioethics02-25741	133	21	industry	industry	NOUN
bioethics02-25741	133	22	sponsorship	sponsorship	NOUN
bioethics02-25741	133	23	and	and	CCONJ
bioethics02-25741	133	24	research	research	NOUN
bioethics02-25741	133	25	outcome	outcome	NOUN
bioethics02-25741	133	26	and	and	CCONJ
bioethics02-25741	133	27	quality	quality	NOUN
bioethics02-25741	133	28	:	:	PUNCT
bioethics02-25741	133	29	systematic	systematic	ADJ
bioethics02-25741	133	30	review	review	NOUN
bioethics02-25741	133	31	.	.	PUNCT
bioethics02-25741	134	1	bmj	bmj	PROPN
bioethics02-25741	134	2	2003	2003	NUM
bioethics02-25741	134	3	;	;	PUNCT
bioethics02-25741	134	4	326:1167–70	326:1167–70	NUM
bioethics02-25741	134	5	.	.	PUNCT
bioethics02-25741	135	1	11	11	NUM
bioethics02-25741	135	2	als	al	NOUN
bioethics02-25741	135	3	-	-	PUNCT
bioethics02-25741	135	4	nielsen	nielsen	PROPN
bioethics02-25741	135	5	b	b	PROPN
bioethics02-25741	135	6	,	,	PUNCT
bioethics02-25741	135	7	chen	chen	PROPN
bioethics02-25741	135	8	w	w	PROPN
bioethics02-25741	135	9	,	,	PUNCT
bioethics02-25741	135	10	gluud	gluud	PROPN
bioethics02-25741	135	11	c	c	PROPN
bioethics02-25741	135	12	,	,	PUNCT
bioethics02-25741	135	13	kjaergard	kjaergard	PROPN
bioethics02-25741	135	14	ll	ll	PROPN
bioethics02-25741	135	15	.	.	PUNCT
bioethics02-25741	136	1	association	association	NOUN
bioethics02-25741	136	2	of	of	ADP
bioethics02-25741	136	3	funding	funding	NOUN
bioethics02-25741	136	4	and	and	CCONJ
bioethics02-25741	136	5	conclusions	conclusion	NOUN
bioethics02-25741	136	6	in	in	ADP
bioethics02-25741	136	7	randomized	randomized	ADJ
bioethics02-25741	136	8	drug	drug	NOUN
bioethics02-25741	136	9	trials	trial	NOUN
bioethics02-25741	136	10	:	:	PUNCT
bioethics02-25741	136	11	a	a	DET
bioethics02-25741	136	12	reflection	reflection	NOUN
bioethics02-25741	136	13	of	of	ADP
bioethics02-25741	136	14	treatment	treatment	NOUN
bioethics02-25741	136	15	effect	effect	NOUN
bioethics02-25741	136	16	or	or	CCONJ
bioethics02-25741	136	17	adverse	adverse	ADJ
bioethics02-25741	136	18	events	event	NOUN
bioethics02-25741	136	19	?	?	PUNCT
bioethics02-25741	137	1	jama	jama	PROPN
bioethics02-25741	137	2	2003	2003	NUM
bioethics02-25741	137	3	;	;	PUNCT
bioethics02-25741	137	4	290:921–8	290:921–8	NUM
bioethics02-25741	137	5	.	.	PUNCT
bioethics02-25741	137	6	12	12	NUM
bioethics02-25741	137	7	lathyris	lathyris	NOUN
bioethics02-25741	137	8	dn	dn	PROPN
bioethics02-25741	137	9	,	,	PUNCT
bioethics02-25741	137	10	patsopoulos	patsopoulo	NOUN
bioethics02-25741	137	11	na	na	NOUN
bioethics02-25741	137	12	,	,	PUNCT
bioethics02-25741	137	13	salanti	salanti	NOUN
bioethics02-25741	137	14	g	g	NOUN
bioethics02-25741	137	15	,	,	PUNCT
bioethics02-25741	137	16	ioannidis	ioannidis	PROPN
bioethics02-25741	137	17	jpa	jpa	PROPN
bioethics02-25741	137	18	.	.	PUNCT
bioethics02-25741	138	1	industry	industry	NOUN
bioethics02-25741	138	2	sponsorship	sponsorship	NOUN
bioethics02-25741	138	3	and	and	CCONJ
bioethics02-25741	138	4	selection	selection	NOUN
bioethics02-25741	138	5	of	of	ADP
bioethics02-25741	138	6	comparators	comparator	NOUN
bioethics02-25741	138	7	in	in	ADP
bioethics02-25741	138	8	randomized	randomized	ADJ
bioethics02-25741	138	9	clinical	clinical	ADJ
bioethics02-25741	138	10	trials	trial	NOUN
bioethics02-25741	138	11	.	.	PUNCT
bioethics02-25741	139	1	eur	eur	PROPN
bioethics02-25741	139	2	j	j	PROPN
bioethics02-25741	139	3	clin	clin	PROPN
bioethics02-25741	139	4	invest	invest	VERB
bioethics02-25741	139	5	2010	2010	NUM
bioethics02-25741	139	6	;	;	PUNCT
bioethics02-25741	139	7	40:172–82	40:172–82	PROPN
bioethics02-25741	139	8	.	.	PUNCT
bioethics02-25741	140	1	13	13	NUM
bioethics02-25741	140	2	vedula	vedula	PROPN
bioethics02-25741	140	3	ss	ss	PROPN
bioethics02-25741	140	4	,	,	PUNCT
bioethics02-25741	140	5	bero	bero	PROPN
bioethics02-25741	140	6	l	l	PROPN
bioethics02-25741	140	7	,	,	PUNCT
bioethics02-25741	140	8	scherer	scherer	PROPN
bioethics02-25741	140	9	rw	rw	PROPN
bioethics02-25741	140	10	,	,	PUNCT
bioethics02-25741	140	11	dickersin	dickersin	PROPN
bioethics02-25741	140	12	k.	k.	PROPN
bioethics02-25741	140	13	outcome	outcome	PROPN
bioethics02-25741	140	14	reporting	report	VERB
bioethics02-25741	140	15	in	in	ADP
bioethics02-25741	140	16	industry	industry	NOUN
bioethics02-25741	140	17	-	-	PUNCT
bioethics02-25741	140	18	sponsored	sponsor	VERB
bioethics02-25741	140	19	trials	trial	NOUN
bioethics02-25741	140	20	of	of	ADP
bioethics02-25741	140	21	gabapentin	gabapentin	NOUN
bioethics02-25741	140	22	for	for	ADP
bioethics02-25741	140	23	offlabel	offlabel	NOUN
bioethics02-25741	140	24	use	use	NOUN
bioethics02-25741	140	25	.	.	PUNCT
bioethics02-25741	141	1	n	n	PROPN
bioethics02-25741	141	2	engl	engl	PROPN
bioethics02-25741	141	3	j	j	PROPN
bioethics02-25741	141	4	med	med	PROPN
bioethics02-25741	141	5	2009;361:1963–71	2009;361:1963–71	PROPN
bioethics02-25741	141	6	.	.	PUNCT
bioethics02-25741	142	1	14	14	NUM
bioethics02-25741	142	2	ross	ross	PROPN
bioethics02-25741	142	3	js	js	PROPN
bioethics02-25741	142	4	,	,	PUNCT
bioethics02-25741	142	5	hill	hill	PROPN
bioethics02-25741	142	6	kp	kp	PROPN
bioethics02-25741	142	7	,	,	PUNCT
bioethics02-25741	142	8	egilman	egilman	NOUN
bioethics02-25741	142	9	ds	ds	PROPN
bioethics02-25741	142	10	,	,	PUNCT
bioethics02-25741	142	11	krumholz	krumholz	PROPN
bioethics02-25741	142	12	h.	h.	PROPN
bioethics02-25741	142	13	guest	guest	PROPN
bioethics02-25741	142	14	authorship	authorship	NOUN
bioethics02-25741	142	15	and	and	CCONJ
bioethics02-25741	142	16	ghostwriting	ghostwriting	NOUN
bioethics02-25741	142	17	in	in	ADP
bioethics02-25741	142	18	publications	publication	NOUN
bioethics02-25741	142	19	related	relate	VERB
bioethics02-25741	142	20	to	to	PART
bioethics02-25741	142	21	rofecoxib	rofecoxib	VERB
bioethics02-25741	142	22	:	:	PUNCT
bioethics02-25741	142	23	a	a	DET
bioethics02-25741	142	24	case	case	NOUN
bioethics02-25741	142	25	study	study	NOUN
bioethics02-25741	142	26	of	of	ADP
bioethics02-25741	142	27	industry	industry	NOUN
bioethics02-25741	142	28	documents	document	NOUN
bioethics02-25741	142	29	from	from	ADP
bioethics02-25741	142	30	rofecoxib	rofecoxib	ADJ
bioethics02-25741	142	31	litigation	litigation	NOUN
bioethics02-25741	142	32	.	.	PUNCT
bioethics02-25741	143	1	jama	jama	PROPN
bioethics02-25741	143	2	2008	2008	NUM
bioethics02-25741	143	3	;	;	PUNCT
bioethics02-25741	143	4	299:1800	299:1800	NUM
bioethics02-25741	143	5	–	–	PUNCT
bioethics02-25741	143	6	12	12	NUM
bioethics02-25741	143	7	.	.	SYM
bioethics02-25741	143	8	15	15	NUM
bioethics02-25741	143	9	sismondo	sismondo	NOUN
bioethics02-25741	143	10	s.	s.	PROPN
bioethics02-25741	143	11	ghosts	ghost	NOUN
bioethics02-25741	143	12	in	in	ADP
bioethics02-25741	143	13	the	the	DET
bioethics02-25741	143	14	machine	machine	NOUN
bioethics02-25741	143	15	.	.	PUNCT
bioethics02-25741	144	1	soc	soc	NOUN
bioethics02-25741	144	2	stud	stud	VERB
bioethics02-25741	144	3	sci	sci	PROPN
bioethics02-25741	144	4	2009	2009	NUM
bioethics02-25741	144	5	;	;	PUNCT
bioethics02-25741	144	6	39:171–98	39:171–98	NUM
bioethics02-25741	144	7	.	.	PUNCT
bioethics02-25741	145	1	16	16	NUM
bioethics02-25741	145	2	lundh	lundh	NOUN
bioethics02-25741	145	3	a	a	DET
bioethics02-25741	145	4	,	,	PUNCT
bioethics02-25741	145	5	barbateskovic	barbateskovic	PROPN
bioethics02-25741	145	6	m	m	PROPN
bioethics02-25741	145	7	,	,	PUNCT
bioethics02-25741	145	8	hr_objartsson	hr_objartsson	PROPN
bioethics02-25741	145	9	a	a	PRON
bioethics02-25741	145	10	,	,	PUNCT
bioethics02-25741	145	11	gøtzsche	gøtzsche	PROPN
bioethics02-25741	145	12	pc	pc	NOUN
bioethics02-25741	145	13	.	.	PUNCT
bioethics02-25741	146	1	conflicts	conflict	NOUN
bioethics02-25741	146	2	of	of	ADP
bioethics02-25741	146	3	interest	interest	NOUN
bioethics02-25741	146	4	at	at	ADP
bioethics02-25741	146	5	medical	medical	ADJ
bioethics02-25741	146	6	journals	journal	NOUN
bioethics02-25741	146	7	:	:	PUNCT
bioethics02-25741	146	8	the	the	DET
bioethics02-25741	146	9	influence	influence	NOUN
bioethics02-25741	146	10	of	of	ADP
bioethics02-25741	146	11	industry	industry	NOUN
bioethics02-25741	146	12	-	-	PUNCT
bioethics02-25741	146	13	supported	support	VERB
bioethics02-25741	146	14	randomised	randomised	ADJ
bioethics02-25741	146	15	trials	trial	NOUN
bioethics02-25741	146	16	on	on	ADP
bioethics02-25741	146	17	journal	journal	ADJ
bioethics02-25741	146	18	impact	impact	NOUN
bioethics02-25741	146	19	factors	factor	NOUN
bioethics02-25741	146	20	and	and	CCONJ
bioethics02-25741	146	21	revenue	revenue	NOUN
bioethics02-25741	146	22	–	–	PUNCT
bioethics02-25741	146	23	cohort	cohort	NOUN
bioethics02-25741	146	24	study	study	NOUN
bioethics02-25741	146	25	.	.	PUNCT
bioethics02-25741	147	1	plos	plos	PROPN
bioethics02-25741	147	2	med	med	PROPN
bioethics02-25741	147	3	2010;7	2010;7	NUM
bioethics02-25741	147	4	:	:	PUNCT
bioethics02-25741	147	5	e1000354	e1000354	PROPN
bioethics02-25741	147	6	.	.	NOUN
bioethics02-25741	147	7	17	17	NUM
bioethics02-25741	147	8	ioannidis	ioannidis	PROPN
bioethics02-25741	147	9	jpa	jpa	PROPN
bioethics02-25741	147	10	.	.	PUNCT
bioethics02-25741	148	1	meta	meta	PROPN
bioethics02-25741	148	2	-	-	PUNCT
bioethics02-25741	148	3	research	research	NOUN
bioethics02-25741	148	4	:	:	PUNCT
bioethics02-25741	148	5	the	the	DET
bioethics02-25741	148	6	art	art	NOUN
bioethics02-25741	148	7	of	of	ADP
bioethics02-25741	148	8	getting	get	VERB
bioethics02-25741	148	9	it	it	PRON
bioethics02-25741	148	10	wrong	wrong	ADJ
bioethics02-25741	148	11	.	.	PUNCT
bioethics02-25741	149	1	res	re	NOUN
bioethics02-25741	149	2	synth	synth	ADJ
bioethics02-25741	149	3	methods	method	NOUN
bioethics02-25741	149	4	2010	2010	NUM
bioethics02-25741	149	5	;	;	PUNCT
bioethics02-25741	149	6	1:169–84	1:169–84	NUM
bioethics02-25741	149	7	.	.	PUNCT
bioethics02-25741	150	1	18	18	NUM
bioethics02-25741	150	2	doshi	doshi	PROPN
bioethics02-25741	150	3	p	p	PROPN
bioethics02-25741	150	4	,	,	PUNCT
bioethics02-25741	150	5	jones	jones	PROPN
bioethics02-25741	150	6	m	m	PROPN
bioethics02-25741	150	7	,	,	PUNCT
bioethics02-25741	150	8	jefferson	jefferson	PROPN
bioethics02-25741	150	9	t.	t.	PROPN
bioethics02-25741	150	10	rethinking	rethink	VERB
bioethics02-25741	150	11	credible	credible	ADJ
bioethics02-25741	150	12	evidence	evidence	NOUN
bioethics02-25741	150	13	synthesis	synthesis	NOUN
bioethics02-25741	150	14	.	.	PUNCT
bioethics02-25741	151	1	bmj	bmj	PROPN
bioethics02-25741	151	2	2012	2012	NUM
bioethics02-25741	151	3	;	;	PUNCT
bioethics02-25741	151	4	344	344	NUM
bioethics02-25741	151	5	:	:	PUNCT
bioethics02-25741	151	6	d7898	d7898	PROPN
bioethics02-25741	151	7	.	.	PROPN
bioethics02-25741	152	1	19	19	NUM
bioethics02-25741	152	2	jørgensen	jørgensen	ADJ
bioethics02-25741	152	3	aw	aw	INTJ
bioethics02-25741	152	4	,	,	PUNCT
bioethics02-25741	152	5	hilden	hilden	PROPN
bioethics02-25741	152	6	j	j	PROPN
bioethics02-25741	152	7	,	,	PUNCT
bioethics02-25741	152	8	gøtzsche	gøtzsche	PROPN
bioethics02-25741	152	9	pc	pc	PROPN
bioethics02-25741	152	10	.	.	PUNCT
bioethics02-25741	153	1	cochrane	cochrane	NOUN
bioethics02-25741	153	2	reviews	review	NOUN
bioethics02-25741	153	3	compared	compare	VERB
bioethics02-25741	153	4	with	with	ADP
bioethics02-25741	153	5	industry	industry	NOUN
bioethics02-25741	153	6	supported	support	VERB
bioethics02-25741	153	7	meta	meta	ADJ
bioethics02-25741	153	8	-	-	PUNCT
bioethics02-25741	153	9	analyses	analysis	NOUN
bioethics02-25741	153	10	and	and	CCONJ
bioethics02-25741	153	11	other	other	ADJ
bioethics02-25741	153	12	meta	meta	NOUN
bioethics02-25741	153	13	-	-	PUNCT
bioethics02-25741	153	14	analyses	analysis	NOUN
bioethics02-25741	153	15	of	of	ADP
bioethics02-25741	153	16	the	the	DET
bioethics02-25741	153	17	same	same	ADJ
bioethics02-25741	153	18	drugs	drug	NOUN
bioethics02-25741	153	19	:	:	PUNCT
bioethics02-25741	153	20	systematic	systematic	ADJ
bioethics02-25741	153	21	review	review	NOUN
bioethics02-25741	153	22	.	.	PUNCT
bioethics02-25741	154	1	bmj	bmj	PROPN
bioethics02-25741	154	2	2006	2006	NUM
bioethics02-25741	154	3	;	;	PUNCT
bioethics02-25741	154	4	333:782	333:782	NUM
bioethics02-25741	154	5	.	.	PUNCT
bioethics02-25741	155	1	http://www.imf.org/external/pubs/ft/weo/2011/02/	http://www.imf.org/external/pubs/ft/weo/2011/02/	NOUN
bioethics02-25741	155	2	http://www.abbott.com/annual-reports/2009/downloads/	http://www.abbott.com/annual-reports/2009/downloads/	NOUN
bioethics02-25741	155	3	http://www/	http://www/	PUNCT
bioethics02-25741	155	4	bangladesh	bangladesh	PROPN
bioethics02-25741	155	5	journal	journal	NOUN
bioethics02-25741	155	6	of	of	ADP
bioethics02-25741	155	7	bioethics	bioethic	NOUN
bioethics02-25741	155	8	2015	2015	NUM
bioethics02-25741	155	9	;	;	PUNCT
bioethics02-25741	156	1	6(2):15	6(2):15	X
bioethics02-25741	156	2	-	-	SYM
bioethics02-25741	156	3	22	22	NUM
bioethics02-25741	156	4	20	20	NUM
bioethics02-25741	156	5	20	20	NUM
bioethics02-25741	156	6	yank	yank	NOUN
bioethics02-25741	156	7	v	v	NOUN
bioethics02-25741	156	8	,	,	PUNCT
bioethics02-25741	156	9	rennie	rennie	PROPN
bioethics02-25741	156	10	d	d	PROPN
bioethics02-25741	156	11	,	,	PUNCT
bioethics02-25741	156	12	bero	bero	PROPN
bioethics02-25741	156	13	la	la	PROPN
bioethics02-25741	156	14	.	.	PUNCT
bioethics02-25741	156	15	financial	financial	ADJ
bioethics02-25741	156	16	ties	tie	NOUN
bioethics02-25741	156	17	and	and	CCONJ
bioethics02-25741	156	18	concordance	concordance	NOUN
bioethics02-25741	156	19	between	between	ADP
bioethics02-25741	156	20	results	result	NOUN
bioethics02-25741	156	21	and	and	CCONJ
bioethics02-25741	156	22	conclusions	conclusion	NOUN
bioethics02-25741	156	23	in	in	ADP
bioethics02-25741	156	24	meta	meta	NOUN
bioethics02-25741	156	25	-	-	PUNCT
bioethics02-25741	156	26	analyses	analysis	NOUN
bioethics02-25741	156	27	:	:	PUNCT
bioethics02-25741	156	28	retrospective	retrospective	ADJ
bioethics02-25741	156	29	cohort	cohort	NOUN
bioethics02-25741	156	30	study	study	NOUN
bioethics02-25741	156	31	.	.	PUNCT
bioethics02-25741	157	1	bmj	bmj	PROPN
bioethics02-25741	157	2	2007	2007	NUM
bioethics02-25741	157	3	;	;	PUNCT
bioethics02-25741	157	4	335:1202–5	335:1202–5	NUM
bioethics02-25741	157	5	.	.	PUNCT
bioethics02-25741	158	1	21	21	NUM
bioethics02-25741	158	2	roseman	roseman	PROPN
bioethics02-25741	158	3	m	m	PROPN
bioethics02-25741	158	4	,	,	PUNCT
bioethics02-25741	158	5	milette	milette	PROPN
bioethics02-25741	158	6	k	k	PROPN
bioethics02-25741	158	7	,	,	PUNCT
bioethics02-25741	158	8	bero	bero	PROPN
bioethics02-25741	158	9	la	la	PROPN
bioethics02-25741	158	10	,	,	PUNCT
bioethics02-25741	158	11	coyne	coyne	PROPN
bioethics02-25741	158	12	jc	jc	PROPN
bioethics02-25741	158	13	,	,	PUNCT
bioethics02-25741	158	14	lexchin	lexchin	PROPN
bioethics02-25741	158	15	j	j	PROPN
bioethics02-25741	158	16	,	,	PUNCT
bioethics02-25741	158	17	turner	turner	PROPN
bioethics02-25741	158	18	eh	eh	INTJ
bioethics02-25741	158	19	et	et	PROPN
bioethics02-25741	158	20	al	al	PROPN
bioethics02-25741	158	21	.	.	PUNCT
bioethics02-25741	158	22	reporting	reporting	NOUN
bioethics02-25741	158	23	of	of	ADP
bioethics02-25741	158	24	conflicts	conflict	NOUN
bioethics02-25741	158	25	of	of	ADP
bioethics02-25741	158	26	interest	interest	NOUN
bioethics02-25741	158	27	in	in	ADP
bioethics02-25741	158	28	metaanalyses	metaanalyse	NOUN
bioethics02-25741	158	29	of	of	ADP
bioethics02-25741	158	30	trials	trial	NOUN
bioethics02-25741	158	31	of	of	ADP
bioethics02-25741	158	32	pharmacological	pharmacological	ADJ
bioethics02-25741	158	33	treatments	treatment	NOUN
bioethics02-25741	158	34	.	.	PUNCT
bioethics02-25741	159	1	jama	jama	PROPN
bioethics02-25741	159	2	2011	2011	NUM
bioethics02-25741	159	3	;	;	PUNCT
bioethics02-25741	159	4	305:1008–17	305:1008–17	NUM
bioethics02-25741	159	5	.	.	X
bioethics02-25741	159	6	22	22	NUM
bioethics02-25741	159	7	gøtzsche	gøtzsche	PROPN
bioethics02-25741	159	8	pc	pc	NOUN
bioethics02-25741	159	9	,	,	PUNCT
bioethics02-25741	159	10	ioannidis	ioannidis	NOUN
bioethics02-25741	159	11	jp	jp	NOUN
bioethics02-25741	159	12	.	.	PUNCT
bioethics02-25741	159	13	content	content	PROPN
bioethics02-25741	159	14	area	area	NOUN
bioethics02-25741	159	15	experts	expert	NOUN
bioethics02-25741	159	16	as	as	ADP
bioethics02-25741	159	17	authors	author	NOUN
bioethics02-25741	159	18	:	:	PUNCT
bioethics02-25741	159	19	helpful	helpful	ADJ
bioethics02-25741	159	20	or	or	CCONJ
bioethics02-25741	159	21	harmful	harmful	ADJ
bioethics02-25741	159	22	for	for	ADP
bioethics02-25741	159	23	systematic	systematic	ADJ
bioethics02-25741	159	24	reviews	review	NOUN
bioethics02-25741	159	25	and	and	CCONJ
bioethics02-25741	159	26	metaanalyses	metaanalyse	NOUN
bioethics02-25741	159	27	?	?	PUNCT
bioethics02-25741	160	1	bmj	bmj	NOUN
bioethics02-25741	160	2	2012;345	2012;345	NUM
bioethics02-25741	160	3	:	:	PUNCT
bioethics02-25741	160	4	e7031	e7031	NOUN
bioethics02-25741	160	5	.	.	PUNCT
bioethics02-25741	161	1	23	23	NUM
bioethics02-25741	161	2	lasser	lasser	PROPN
bioethics02-25741	161	3	ke	ke	PROPN
bioethics02-25741	161	4	,	,	PUNCT
bioethics02-25741	161	5	allen	allen	PROPN
bioethics02-25741	161	6	pd	pd	PROPN
bioethics02-25741	161	7	,	,	PUNCT
bioethics02-25741	161	8	woolhandler	woolhandler	X
bioethics02-25741	161	9	sj	sj	PROPN
bioethics02-25741	161	10	,	,	PUNCT
bioethics02-25741	161	11	himmelstein	himmelstein	PROPN
bioethics02-25741	161	12	du	du	PROPN
bioethics02-25741	161	13	,	,	PUNCT
bioethics02-25741	161	14	wolfe	wolfe	PROPN
bioethics02-25741	161	15	sm	sm	PROPN
bioethics02-25741	161	16	,	,	PUNCT
bioethics02-25741	161	17	bor	bor	PROPN
bioethics02-25741	161	18	dh	dh	PROPN
bioethics02-25741	161	19	.	.	PUNCT
bioethics02-25741	162	1	timing	timing	NOUN
bioethics02-25741	162	2	of	of	ADP
bioethics02-25741	162	3	new	new	ADJ
bioethics02-25741	162	4	black	black	ADJ
bioethics02-25741	162	5	box	box	NOUN
bioethics02-25741	162	6	warnings	warning	NOUN
bioethics02-25741	162	7	and	and	CCONJ
bioethics02-25741	162	8	withdrawals	withdrawal	NOUN
bioethics02-25741	162	9	for	for	ADP
bioethics02-25741	162	10	prescription	prescription	NOUN
bioethics02-25741	162	11	medications	medication	NOUN
bioethics02-25741	162	12	.	.	PUNCT
bioethics02-25741	163	1	jama	jama	PROPN
bioethics02-25741	163	2	2002	2002	NUM
bioethics02-25741	163	3	;	;	PUNCT
bioethics02-25741	163	4	287:2215–20	287:2215–20	NUM
bioethics02-25741	163	5	.	.	PUNCT
bioethics02-25741	163	6	24	24	NUM
bioethics02-25741	163	7	cohen	cohen	PROPN
bioethics02-25741	163	8	d.	d.	PROPN
bioethics02-25741	163	9	rosiglitazone	rosiglitazone	PROPN
bioethics02-25741	163	10	:	:	PUNCT
bioethics02-25741	163	11	what	what	PRON
bioethics02-25741	163	12	went	go	VERB
bioethics02-25741	163	13	wrong	wrong	ADJ
bioethics02-25741	163	14	?	?	PUNCT
bioethics02-25741	164	1	bmj	bmj	PROPN
bioethics02-25741	164	2	2010	2010	NUM
bioethics02-25741	164	3	;	;	PUNCT
bioethics02-25741	164	4	341	341	NUM
bioethics02-25741	164	5	:	:	PUNCT
bioethics02-25741	164	6	c4848	c4848	NOUN
bioethics02-25741	164	7	.	.	NOUN
bioethics02-25741	164	8	25	25	NUM
bioethics02-25741	164	9	wang	wang	PROPN
bioethics02-25741	164	10	at	at	ADP
bioethics02-25741	164	11	,	,	PUNCT
bioethics02-25741	164	12	mccoy	mccoy	PROPN
bioethics02-25741	164	13	cp	cp	PROPN
bioethics02-25741	164	14	,	,	PUNCT
bioethics02-25741	164	15	murad	murad	PROPN
bioethics02-25741	164	16	mh	mh	PROPN
bioethics02-25741	164	17	,	,	PUNCT
bioethics02-25741	164	18	montori	montori	PROPN
bioethics02-25741	164	19	vm	vm	PROPN
bioethics02-25741	164	20	.	.	PROPN
bioethics02-25741	164	21	association	association	PROPN
bioethics02-25741	164	22	between	between	ADP
bioethics02-25741	164	23	industry	industry	NOUN
bioethics02-25741	164	24	affiliation	affiliation	NOUN
bioethics02-25741	164	25	and	and	CCONJ
bioethics02-25741	164	26	position	position	NOUN
bioethics02-25741	164	27	on	on	ADP
bioethics02-25741	164	28	cardiovascular	cardiovascular	ADJ
bioethics02-25741	164	29	risk	risk	NOUN
bioethics02-25741	164	30	with	with	ADP
bioethics02-25741	164	31	rosiglitazone	rosiglitazone	NOUN
bioethics02-25741	164	32	:	:	PUNCT
bioethics02-25741	164	33	cross	cross	VERB
bioethics02-25741	164	34	sectional	sectional	ADJ
bioethics02-25741	164	35	systematic	systematic	ADJ
bioethics02-25741	164	36	review	review	NOUN
bioethics02-25741	164	37	.	.	PUNCT
bioethics02-25741	165	1	bmj	bmj	PROPN
bioethics02-25741	165	2	2010	2010	NUM
bioethics02-25741	165	3	;	;	PUNCT
bioethics02-25741	165	4	340	340	NUM
bioethics02-25741	165	5	:	:	PUNCT
bioethics02-25741	165	6	c1344	c1344	PROPN
bioethics02-25741	165	7	.	.	PROPN
bioethics02-25741	165	8	26	26	NUM
bioethics02-25741	165	9	bresalier	bresali	ADJ
bioethics02-25741	165	10	rs	rs	NOUN
bioethics02-25741	165	11	,	,	PUNCT
bioethics02-25741	165	12	sandler	sandler	NOUN
bioethics02-25741	165	13	rs	rs	PROPN
bioethics02-25741	165	14	,	,	PUNCT
bioethics02-25741	165	15	quan	quan	PROPN
bioethics02-25741	165	16	h	h	PROPN
bioethics02-25741	165	17	,	,	PUNCT
bioethics02-25741	165	18	bolognese	bolognese	PROPN
bioethics02-25741	165	19	ja	ja	PROPN
bioethics02-25741	165	20	,	,	PUNCT
bioethics02-25741	165	21	oxenius	oxenius	PROPN
bioethics02-25741	165	22	b	b	PROPN
bioethics02-25741	165	23	,	,	PUNCT
bioethics02-25741	165	24	horgan	horgan	PROPN
bioethics02-25741	165	25	k	k	PROPN
bioethics02-25741	165	26	et	et	PROPN
bioethics02-25741	165	27	al	al	PROPN
bioethics02-25741	165	28	.	.	PUNCT
bioethics02-25741	166	1	the	the	DET
bioethics02-25741	166	2	adenomatous	adenomatous	ADJ
bioethics02-25741	166	3	polyp	polyp	NOUN
bioethics02-25741	166	4	prevention	prevention	NOUN
bioethics02-25741	166	5	on	on	ADP
bioethics02-25741	166	6	vioxx	vioxx	NOUN
bioethics02-25741	166	7	trial	trial	NOUN
bioethics02-25741	166	8	investigators	investigator	NOUN
bioethics02-25741	166	9	.	.	PUNCT
bioethics02-25741	167	1	cardiovascular	cardiovascular	ADJ
bioethics02-25741	167	2	events	event	NOUN
bioethics02-25741	167	3	associated	associate	VERB
bioethics02-25741	167	4	with	with	ADP
bioethics02-25741	167	5	rofecoxib	rofecoxib	NOUN
bioethics02-25741	167	6	in	in	ADP
bioethics02-25741	167	7	a	a	DET
bioethics02-25741	167	8	colorectal	colorectal	ADJ
bioethics02-25741	167	9	adenoma	adenoma	ADJ
bioethics02-25741	167	10	chemoprevention	chemoprevention	NOUN
bioethics02-25741	167	11	trial	trial	NOUN
bioethics02-25741	167	12	.	.	PUNCT
bioethics02-25741	168	1	n	n	PROPN
bioethics02-25741	169	1	engl	engl	PROPN
bioethics02-25741	169	2	j	j	PROPN
bioethics02-25741	169	3	med	med	PROPN
bioethics02-25741	169	4	2005	2005	NUM
bioethics02-25741	169	5	;	;	PUNCT
bioethics02-25741	169	6	352:1092–102	352:1092–102	NUM
bioethics02-25741	169	7	.	.	NOUN
bioethics02-25741	169	8	27	27	NUM
bioethics02-25741	169	9	curfman	curfman	NOUN
bioethics02-25741	169	10	gd	gd	PROPN
bioethics02-25741	169	11	,	,	PUNCT
bioethics02-25741	169	12	morrissey	morrissey	PROPN
bioethics02-25741	169	13	s	s	PROPN
bioethics02-25741	169	14	,	,	PUNCT
bioethics02-25741	169	15	drazen	drazen	PROPN
bioethics02-25741	169	16	jm	jm	PROPN
bioethics02-25741	169	17	.	.	PROPN
bioethics02-25741	169	18	expression	expression	NOUN
bioethics02-25741	169	19	of	of	ADP
bioethics02-25741	169	20	concern	concern	NOUN
bioethics02-25741	169	21	:	:	PUNCT
bioethics02-25741	169	22	bombardier	bombardier	PROPN
bioethics02-25741	169	23	et	et	PROPN
bioethics02-25741	169	24	al	al	PROPN
bioethics02-25741	169	25	.	.	PROPN
bioethics02-25741	169	26	,	,	PUNCT
bioethics02-25741	169	27	―comparison	―comparison	PROPN
bioethics02-25741	169	28	of	of	ADP
bioethics02-25741	169	29	upper	upper	ADJ
bioethics02-25741	169	30	gastrointestinal	gastrointestinal	ADJ
bioethics02-25741	169	31	toxicity	toxicity	NOUN
bioethics02-25741	169	32	of	of	ADP
bioethics02-25741	169	33	rofecoxib	rofecoxib	NOUN
bioethics02-25741	169	34	and	and	CCONJ
bioethics02-25741	169	35	naproxen	naproxen	NOUN
bioethics02-25741	169	36	in	in	ADP
bioethics02-25741	169	37	patients	patient	NOUN
bioethics02-25741	169	38	with	with	ADP
bioethics02-25741	169	39	rheumatoid	rheumatoid	NOUN
bioethics02-25741	169	40	arthritis‖.	arthritis‖.	PROPN
bioethics02-25741	169	41	n	n	CCONJ
bioethics02-25741	169	42	engl	engl	PROPN
bioethics02-25741	169	43	j	j	PROPN
bioethics02-25741	169	44	med	med	PROPN
bioethics02-25741	169	45	2005	2005	NUM
bioethics02-25741	169	46	;	;	PUNCT
bioethics02-25741	169	47	353:2813–4	353:2813–4	NUM
bioethics02-25741	169	48	.	.	PUNCT
bioethics02-25741	170	1	28	28	NUM
bioethics02-25741	170	2	berenson	berenson	PROPN
bioethics02-25741	170	3	a.	a.	NOUN
bioethics02-25741	170	4	for	for	ADP
bioethics02-25741	170	5	merck	merck	PROPN
bioethics02-25741	170	6	,	,	PUNCT
bioethics02-25741	170	7	vioxx	vioxx	NOUN
bioethics02-25741	170	8	paper	paper	NOUN
bioethics02-25741	170	9	trail	trail	NOUN
bioethics02-25741	170	10	won‘t	won‘t	NOUN
bioethics02-25741	170	11	go	go	VERB
bioethics02-25741	170	12	away	away	ADV
bioethics02-25741	170	13	.	.	PUNCT
bioethics02-25741	171	1	new	new	PROPN
bioethics02-25741	171	2	york	york	PROPN
bioethics02-25741	171	3	times	times	PROPN
bioethics02-25741	171	4	.	.	PUNCT
bioethics02-25741	172	1	2005	2005	NUM
bioethics02-25741	172	2	aug	aug	PROPN
bioethics02-25741	172	3	21	21	NUM
bioethics02-25741	172	4	;	;	PUNCT
bioethics02-25741	172	5	sect	sect	VERB
bioethics02-25741	172	6	a	a	DET
bioethics02-25741	172	7	:	:	SYM
bioethics02-25741	172	8	1	1	NUM
bioethics02-25741	172	9	.	.	NUM
bioethics02-25741	172	10	29	29	NUM
bioethics02-25741	172	11	bell	bell	PROPN
bioethics02-25741	172	12	cm	cm	PROPN
bioethics02-25741	172	13	,	,	PUNCT
bioethics02-25741	172	14	urbach	urbach	PROPN
bioethics02-25741	172	15	dr	dr	PROPN
bioethics02-25741	172	16	,	,	PUNCT
bioethics02-25741	172	17	ray	ray	PROPN
bioethics02-25741	172	18	jg	jg	PROPN
bioethics02-25741	172	19	,	,	PUNCT
bioethics02-25741	172	20	bayoumi	bayoumi	VERB
bioethics02-25741	172	21	a	a	PRON
bioethics02-25741	172	22	,	,	PUNCT
bioethics02-25741	172	23	rosen	rosen	PROPN
bioethics02-25741	172	24	ab	ab	PROPN
bioethics02-25741	172	25	,	,	PUNCT
bioethics02-25741	172	26	greenberg	greenberg	PROPN
bioethics02-25741	172	27	d	d	PROPN
bioethics02-25741	172	28	et	et	PROPN
bioethics02-25741	172	29	al	al	PROPN
bioethics02-25741	172	30	.	.	PROPN
bioethics02-25741	172	31	bias	bias	PROPN
bioethics02-25741	172	32	in	in	ADP
bioethics02-25741	172	33	published	publish	VERB
bioethics02-25741	172	34	cost	cost	NOUN
bioethics02-25741	172	35	effectiveness	effectiveness	NOUN
bioethics02-25741	172	36	studies	study	NOUN
bioethics02-25741	172	37	:	:	PUNCT
bioethics02-25741	172	38	systematic	systematic	ADJ
bioethics02-25741	172	39	review	review	NOUN
bioethics02-25741	172	40	.	.	PUNCT
bioethics02-25741	173	1	bmj	bmj	PROPN
bioethics02-25741	173	2	2006	2006	NUM
bioethics02-25741	173	3	;	;	PUNCT
bioethics02-25741	173	4	332:699–703	332:699–703	NUM
bioethics02-25741	173	5	.	.	NOUN
bioethics02-25741	174	1	30	30	NUM
bioethics02-25741	174	2	miners	miner	NOUN
bioethics02-25741	174	3	ah	ah	INTJ
bioethics02-25741	174	4	,	,	PUNCT
bioethics02-25741	174	5	garau	garau	PROPN
bioethics02-25741	174	6	m	m	NOUN
bioethics02-25741	174	7	,	,	PUNCT
bioethics02-25741	174	8	fidan	fidan	PROPN
bioethics02-25741	174	9	d	d	PROPN
bioethics02-25741	174	10	,	,	PUNCT
bioethics02-25741	174	11	fischer	fischer	PROPN
bioethics02-25741	174	12	aj	aj	PROPN
bioethics02-25741	174	13	.	.	PROPN
bioethics02-25741	174	14	comparing	compare	VERB
bioethics02-25741	174	15	estimates	estimate	NOUN
bioethics02-25741	174	16	of	of	ADP
bioethics02-25741	174	17	cost	cost	NOUN
bioethics02-25741	174	18	effectiveness	effectiveness	NOUN
bioethics02-25741	174	19	submitted	submit	VERB
bioethics02-25741	174	20	to	to	ADP
bioethics02-25741	174	21	the	the	DET
bioethics02-25741	174	22	national	national	PROPN
bioethics02-25741	174	23	institute	institute	PROPN
bioethics02-25741	174	24	for	for	ADP
bioethics02-25741	174	25	clinical	clinical	ADJ
bioethics02-25741	174	26	excellence	excellence	NOUN
bioethics02-25741	174	27	(	(	PUNCT
bioethics02-25741	174	28	nice	nice	ADJ
bioethics02-25741	174	29	)	)	PUNCT
bioethics02-25741	174	30	by	by	ADP
bioethics02-25741	174	31	different	different	ADJ
bioethics02-25741	174	32	organisations	organisation	NOUN
bioethics02-25741	174	33	:	:	PUNCT
bioethics02-25741	174	34	retrospective	retrospective	ADJ
bioethics02-25741	174	35	study	study	NOUN
bioethics02-25741	174	36	.	.	PUNCT
bioethics02-25741	175	1	bmj	bmj	PROPN
bioethics02-25741	175	2	2005	2005	NUM
bioethics02-25741	175	3	;	;	PUNCT
bioethics02-25741	175	4	330:65	330:65	NUM
bioethics02-25741	175	5	.	.	NOUN
bioethics02-25741	175	6	31	31	NUM
bioethics02-25741	175	7	polyzos	polyzos	PROPN
bioethics02-25741	175	8	np	np	INTJ
bioethics02-25741	175	9	,	,	PUNCT
bioethics02-25741	175	10	valachis	valachis	PRON
bioethics02-25741	175	11	a	a	DET
bioethics02-25741	175	12	,	,	PUNCT
bioethics02-25741	175	13	mauri	mauri	PROPN
bioethics02-25741	175	14	d	d	PROPN
bioethics02-25741	175	15	,	,	PUNCT
bioethics02-25741	175	16	ioannidis	ioannidis	NOUN
bioethics02-25741	175	17	jp	jp	NOUN
bioethics02-25741	175	18	.	.	PUNCT
bioethics02-25741	176	1	industry	industry	NOUN
bioethics02-25741	176	2	involvement	involvement	NOUN
bioethics02-25741	176	3	and	and	CCONJ
bioethics02-25741	176	4	baseline	baseline	NOUN
bioethics02-25741	176	5	assumptions	assumption	NOUN
bioethics02-25741	176	6	of	of	ADP
bioethics02-25741	176	7	costeffectiveness	costeffectiveness	NOUN
bioethics02-25741	176	8	analyses	analysis	NOUN
bioethics02-25741	176	9	:	:	PUNCT
bioethics02-25741	176	10	diagnostic	diagnostic	ADJ
bioethics02-25741	176	11	accuracy	accuracy	NOUN
bioethics02-25741	176	12	of	of	ADP
bioethics02-25741	176	13	the	the	DET
bioethics02-25741	176	14	papanicolaou	papanicolaou	NOUN
bioethics02-25741	176	15	test	test	NOUN
bioethics02-25741	176	16	.	.	PUNCT
bioethics02-25741	177	1	cmaj	cmaj	PROPN
bioethics02-25741	177	2	2011	2011	NUM
bioethics02-25741	177	3	;	;	PUNCT
bioethics02-25741	177	4	183	183	NUM
bioethics02-25741	177	5	:	:	PUNCT
bioethics02-25741	177	6	e337–43	e337–43	NOUN
bioethics02-25741	177	7	.	.	NOUN
bioethics02-25741	177	8	32	32	NUM
bioethics02-25741	177	9	rozenbaum	rozenbaum	PROPN
bioethics02-25741	177	10	mh	mh	PROPN
bioethics02-25741	177	11	,	,	PUNCT
bioethics02-25741	177	12	hoek	hoek	PROPN
bioethics02-25741	177	13	aj	aj	PROPN
bioethics02-25741	177	14	,	,	PUNCT
bioethics02-25741	177	15	hak	hak	PROPN
bioethics02-25741	177	16	e	e	PROPN
bioethics02-25741	177	17	,	,	PUNCT
bioethics02-25741	177	18	postma	postma	PROPN
bioethics02-25741	177	19	mj	mj	PROPN
bioethics02-25741	177	20	.	.	PUNCT
bioethics02-25741	177	21	huge	huge	ADJ
bioethics02-25741	177	22	impact	impact	NOUN
bioethics02-25741	177	23	of	of	ADP
bioethics02-25741	177	24	assumptions	assumption	NOUN
bioethics02-25741	177	25	on	on	ADP
bioethics02-25741	177	26	indirect	indirect	ADJ
bioethics02-25741	177	27	effects	effect	NOUN
bioethics02-25741	177	28	on	on	ADP
bioethics02-25741	177	29	the	the	DET
bioethics02-25741	177	30	costeffectiveness	costeffectiveness	NOUN
bioethics02-25741	177	31	of	of	ADP
bioethics02-25741	177	32	routine	routine	ADJ
bioethics02-25741	177	33	infant	infant	NOUN
bioethics02-25741	177	34	vaccination	vaccination	NOUN
bioethics02-25741	177	35	with	with	ADP
bioethics02-25741	177	36	7	7	NUM
bioethics02-25741	177	37	-	-	PUNCT
bioethics02-25741	177	38	valent	valent	NOUN
bioethics02-25741	177	39	conjugate	conjugate	ADJ
bioethics02-25741	177	40	vaccine	vaccine	NOUN
bioethics02-25741	177	41	(	(	PUNCT
bioethics02-25741	177	42	prevnar	prevnar	PROPN
bioethics02-25741	177	43	)	)	PUNCT
bioethics02-25741	177	44	.	.	PUNCT
bioethics02-25741	178	1	vaccine	vaccine	NOUN
bioethics02-25741	178	2	2010	2010	NUM
bioethics02-25741	178	3	;	;	PUNCT
bioethics02-25741	178	4	28:2367–9	28:2367–9	NUM
bioethics02-25741	178	5	.	.	PUNCT
bioethics02-25741	179	1	33	33	NUM
bioethics02-25741	179	2	mendelson	mendelson	PROPN
bioethics02-25741	179	3	tb	tb	PROPN
bioethics02-25741	179	4	,	,	PUNCT
bioethics02-25741	179	5	meltzer	meltzer	PROPN
bioethics02-25741	179	6	m	m	PROPN
bioethics02-25741	179	7	,	,	PUNCT
bioethics02-25741	179	8	campbell	campbell	PROPN
bioethics02-25741	179	9	eg	eg	PROPN
bioethics02-25741	179	10	,	,	PUNCT
bioethics02-25741	179	11	caplan	caplan	PROPN
bioethics02-25741	179	12	al	al	PROPN
bioethics02-25741	179	13	,	,	PUNCT
bioethics02-25741	179	14	kirkpatrick	kirkpatrick	PROPN
bioethics02-25741	179	15	jn	jn	PROPN
bioethics02-25741	179	16	.	.	PROPN
bioethics02-25741	179	17	conflicts	conflict	NOUN
bioethics02-25741	179	18	of	of	ADP
bioethics02-25741	179	19	interest	interest	NOUN
bioethics02-25741	179	20	in	in	ADP
bioethics02-25741	179	21	cardiovascular	cardiovascular	ADJ
bioethics02-25741	179	22	clinical	clinical	ADJ
bioethics02-25741	179	23	practice	practice	NOUN
bioethics02-25741	179	24	guidelines	guideline	NOUN
bioethics02-25741	179	25	.	.	PUNCT
bioethics02-25741	180	1	arch	arch	ADJ
bioethics02-25741	180	2	intern	intern	NOUN
bioethics02-25741	180	3	med	med	PROPN
bioethics02-25741	180	4	2011	2011	NUM
bioethics02-25741	180	5	;	;	PUNCT
bioethics02-25741	180	6	171:577–84	171:577–84	PROPN
bioethics02-25741	180	7	.	.	PUNCT
bioethics02-25741	181	1	34	34	NUM
bioethics02-25741	181	2	neuman	neuman	PROPN
bioethics02-25741	181	3	j	j	PROPN
bioethics02-25741	181	4	,	,	PUNCT
bioethics02-25741	181	5	korenstein	korenstein	PROPN
bioethics02-25741	181	6	d	d	PROPN
bioethics02-25741	181	7	,	,	PUNCT
bioethics02-25741	181	8	ross	ross	PROPN
bioethics02-25741	181	9	js	js	PROPN
bioethics02-25741	181	10	,	,	PUNCT
bioethics02-25741	181	11	keyhani	keyhani	PROPN
bioethics02-25741	181	12	s.	s.	PROPN
bioethics02-25741	181	13	prevalence	prevalence	PROPN
bioethics02-25741	181	14	of	of	ADP
bioethics02-25741	181	15	financial	financial	ADJ
bioethics02-25741	181	16	conflicts	conflict	NOUN
bioethics02-25741	181	17	of	of	ADP
bioethics02-25741	181	18	interest	interest	NOUN
bioethics02-25741	181	19	among	among	ADP
bioethics02-25741	181	20	panel	panel	NOUN
bioethics02-25741	181	21	members	member	NOUN
bioethics02-25741	181	22	producing	produce	VERB
bioethics02-25741	181	23	clinical	clinical	ADJ
bioethics02-25741	181	24	practice	practice	NOUN
bioethics02-25741	181	25	guidelines	guideline	NOUN
bioethics02-25741	181	26	in	in	ADP
bioethics02-25741	181	27	canada	canada	PROPN
bioethics02-25741	181	28	and	and	CCONJ
bioethics02-25741	181	29	united	united	PROPN
bioethics02-25741	181	30	states	states	PROPN
bioethics02-25741	181	31	:	:	PUNCT
bioethics02-25741	181	32	cross	cross	VERB
bioethics02-25741	181	33	sectional	sectional	ADJ
bioethics02-25741	181	34	study	study	NOUN
bioethics02-25741	181	35	.	.	PUNCT
bioethics02-25741	182	1	bmj	bmj	PROPN
bioethics02-25741	182	2	2011	2011	NUM
bioethics02-25741	182	3	;	;	PUNCT
bioethics02-25741	182	4	343	343	NUM
bioethics02-25741	182	5	:	:	PUNCT
bioethics02-25741	182	6	d5621	d5621	PROPN
bioethics02-25741	182	7	.	.	PROPN
bioethics02-25741	182	8	35	35	NUM
bioethics02-25741	182	9	norris	norris	PROPN
bioethics02-25741	182	10	sl	sl	PROPN
bioethics02-25741	182	11	,	,	PUNCT
bioethics02-25741	182	12	holmer	holmer	PROPN
bioethics02-25741	182	13	hk	hk	PROPN
bioethics02-25741	182	14	,	,	PUNCT
bioethics02-25741	182	15	ogden	ogden	PROPN
bioethics02-25741	182	16	la	la	PROPN
bioethics02-25741	182	17	,	,	PUNCT
bioethics02-25741	182	18	burda	burda	PROPN
bioethics02-25741	182	19	bu	bu	PROPN
bioethics02-25741	182	20	.	.	PUNCT
bioethics02-25741	183	1	conflict	conflict	NOUN
bioethics02-25741	183	2	of	of	ADP
bioethics02-25741	183	3	interest	interest	NOUN
bioethics02-25741	183	4	in	in	ADP
bioethics02-25741	183	5	clinical	clinical	ADJ
bioethics02-25741	183	6	practice	practice	NOUN
bioethics02-25741	183	7	guideline	guideline	NOUN
bioethics02-25741	183	8	development	development	NOUN
bioethics02-25741	183	9	:	:	PUNCT
bioethics02-25741	183	10	a	a	DET
bioethics02-25741	183	11	systematic	systematic	ADJ
bioethics02-25741	183	12	review	review	NOUN
bioethics02-25741	183	13	.	.	PUNCT
bioethics02-25741	184	1	plos	plos	PROPN
bioethics02-25741	184	2	one	one	NUM
bioethics02-25741	184	3	2011	2011	NUM
bioethics02-25741	184	4	;	;	PUNCT
bioethics02-25741	184	5	6	6	NUM
bioethics02-25741	184	6	:	:	SYM
bioethics02-25741	184	7	e25153	e25153	PROPN
bioethics02-25741	184	8	.	.	PROPN
bioethics02-25741	184	9	36	36	NUM
bioethics02-25741	184	10	tricoci	tricoci	ADJ
bioethics02-25741	184	11	p	p	X
bioethics02-25741	184	12	,	,	PUNCT
bioethics02-25741	184	13	allen	allen	PROPN
bioethics02-25741	184	14	jm	jm	PROPN
bioethics02-25741	184	15	,	,	PUNCT
bioethics02-25741	184	16	kramer	kramer	PROPN
bioethics02-25741	184	17	jm	jm	PROPN
bioethics02-25741	184	18	,	,	PUNCT
bioethics02-25741	184	19	califf	califf	PROPN
bioethics02-25741	184	20	rm	rm	PROPN
bioethics02-25741	184	21	,	,	PUNCT
bioethics02-25741	184	22	smith	smith	PROPN
bioethics02-25741	184	23	sc	sc	PROPN
bioethics02-25741	184	24	.	.	PUNCT
bioethics02-25741	185	1	scientific	scientific	ADJ
bioethics02-25741	185	2	evidence	evidence	NOUN
bioethics02-25741	185	3	underlying	underlie	VERB
bioethics02-25741	185	4	the	the	DET
bioethics02-25741	185	5	acc	acc	PROPN
bioethics02-25741	185	6	/	/	SYM
bioethics02-25741	185	7	aha	aha	INTJ
bioethics02-25741	185	8	clinical	clinical	ADJ
bioethics02-25741	185	9	practice	practice	NOUN
bioethics02-25741	185	10	guidelines	guideline	NOUN
bioethics02-25741	185	11	.	.	PUNCT
bioethics02-25741	186	1	jama	jama	PROPN
bioethics02-25741	186	2	2009	2009	NUM
bioethics02-25741	186	3	;	;	PUNCT
bioethics02-25741	186	4	301:831–41	301:831–41	NUM
bioethics02-25741	186	5	.	.	PUNCT
bioethics02-25741	186	6	37	37	NUM
bioethics02-25741	186	7	choudhry	choudhry	PROPN
bioethics02-25741	186	8	nk	nk	PROPN
bioethics02-25741	186	9	,	,	PUNCT
bioethics02-25741	186	10	stelfox	stelfox	ADJ
bioethics02-25741	186	11	ht	ht	PROPN
bioethics02-25741	186	12	,	,	PUNCT
bioethics02-25741	186	13	detsky	detsky	NOUN
bioethics02-25741	186	14	as	as	ADP
bioethics02-25741	186	15	.	.	PUNCT
bioethics02-25741	186	16	relationships	relationship	NOUN
bioethics02-25741	186	17	between	between	ADP
bioethics02-25741	186	18	authors	author	NOUN
bioethics02-25741	186	19	of	of	ADP
bioethics02-25741	186	20	clinical	clinical	ADJ
bioethics02-25741	186	21	practice	practice	NOUN
bioethics02-25741	186	22	guidelines	guideline	NOUN
bioethics02-25741	186	23	and	and	CCONJ
bioethics02-25741	186	24	the	the	DET
bioethics02-25741	186	25	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	186	26	industry	industry	NOUN
bioethics02-25741	186	27	.	.	PUNCT
bioethics02-25741	187	1	jama	jama	PROPN
bioethics02-25741	187	2	2002	2002	NUM
bioethics02-25741	187	3	;	;	PUNCT
bioethics02-25741	187	4	287:612–7	287:612–7	NUM
bioethics02-25741	187	5	.	.	PUNCT
bioethics02-25741	188	1	38	38	NUM
bioethics02-25741	188	2	montori	montori	PROPN
bioethics02-25741	188	3	vm	vm	PROPN
bioethics02-25741	188	4	,	,	PUNCT
bioethics02-25741	188	5	fernandez	fernandez	PROPN
bioethics02-25741	188	6	-	-	PUNCT
bioethics02-25741	188	7	balsells	balsells	PROPN
bioethics02-25741	188	8	m.	m.	NOUN
bioethics02-25741	188	9	glycemic	glycemic	ADJ
bioethics02-25741	188	10	control	control	NOUN
bioethics02-25741	188	11	in	in	ADP
bioethics02-25741	188	12	type	type	NOUN
bioethics02-25741	188	13	2	2	NUM
bioethics02-25741	188	14	diabetes	diabetes	NOUN
bioethics02-25741	188	15	:	:	PUNCT
bioethics02-25741	188	16	time	time	NOUN
bioethics02-25741	188	17	for	for	ADP
bioethics02-25741	188	18	an	an	DET
bioethics02-25741	188	19	evidence	evidence	NOUN
bioethics02-25741	188	20	-	-	PUNCT
bioethics02-25741	188	21	based	base	VERB
bioethics02-25741	188	22	about	about	ADP
bioethics02-25741	188	23	-	-	PUNCT
bioethics02-25741	188	24	face	face	NOUN
bioethics02-25741	188	25	?	?	PUNCT
bioethics02-25741	189	1	ann	ann	PROPN
bioethics02-25741	189	2	intern	intern	PROPN
bioethics02-25741	189	3	med	med	PROPN
bioethics02-25741	189	4	2009	2009	NUM
bioethics02-25741	189	5	;	;	PUNCT
bioethics02-25741	189	6	150:803–8	150:803–8	NUM
bioethics02-25741	189	7	.	.	PUNCT
bioethics02-25741	190	1	39	39	NUM
bioethics02-25741	190	2	yudkin	yudkin	NOUN
bioethics02-25741	190	3	js	js	PROPN
bioethics02-25741	190	4	,	,	PUNCT
bioethics02-25741	190	5	richter	richter	PROPN
bioethics02-25741	190	6	b	b	PROPN
bioethics02-25741	190	7	,	,	PUNCT
bioethics02-25741	190	8	gale	gale	NOUN
bioethics02-25741	190	9	ea	ea	NOUN
bioethics02-25741	190	10	.	.	PUNCT
bioethics02-25741	190	11	intensified	intensify	VERB
bioethics02-25741	190	12	glucose	glucose	NOUN
bioethics02-25741	190	13	lowering	lower	VERB
bioethics02-25741	190	14	in	in	ADP
bioethics02-25741	190	15	type	type	NOUN
bioethics02-25741	190	16	2	2	NUM
bioethics02-25741	190	17	diabetes	diabetes	NOUN
bioethics02-25741	190	18	:	:	PUNCT
bioethics02-25741	190	19	time	time	NOUN
bioethics02-25741	190	20	for	for	ADP
bioethics02-25741	190	21	a	a	DET
bioethics02-25741	190	22	reappraisal	reappraisal	NOUN
bioethics02-25741	190	23	.	.	PUNCT
bioethics02-25741	191	1	diabetologia	diabetologia	NOUN
bioethics02-25741	191	2	2010	2010	NUM
bioethics02-25741	191	3	;	;	PUNCT
bioethics02-25741	191	4	53:2079–85	53:2079–85	NUM
bioethics02-25741	191	5	.	.	PUNCT
bioethics02-25741	192	1	40	40	NUM
bioethics02-25741	192	2	silverman	silverman	PROPN
bioethics02-25741	192	3	gk	gk	PROPN
bioethics02-25741	192	4	,	,	PUNCT
bioethics02-25741	192	5	loewenstein	loewenstein	ADJ
bioethics02-25741	192	6	gf	gf	PROPN
bioethics02-25741	192	7	,	,	PUNCT
bioethics02-25741	192	8	anderson	anderson	PROPN
bioethics02-25741	192	9	bl	bl	PROPN
bioethics02-25741	192	10	,	,	PUNCT
bioethics02-25741	192	11	ubel	ubel	PROPN
bioethics02-25741	192	12	pa	pa	PROPN
bioethics02-25741	192	13	,	,	PUNCT
bioethics02-25741	192	14	zinberg	zinberg	PROPN
bioethics02-25741	192	15	s	s	PROPN
bioethics02-25741	192	16	,	,	PUNCT
bioethics02-25741	192	17	schulkin	schulkin	PROPN
bioethics02-25741	192	18	j.	j.	PROPN
bioethics02-25741	192	19	failure	failure	NOUN
bioethics02-25741	192	20	to	to	PART
bioethics02-25741	192	21	discount	discount	VERB
bioethics02-25741	192	22	for	for	ADP
bioethics02-25741	192	23	conflict	conflict	NOUN
bioethics02-25741	192	24	of	of	ADP
bioethics02-25741	192	25	interest	interest	NOUN
bioethics02-25741	192	26	when	when	SCONJ
bioethics02-25741	192	27	evaluating	evaluate	VERB
bioethics02-25741	192	28	medical	medical	ADJ
bioethics02-25741	192	29	literature	literature	NOUN
bioethics02-25741	192	30	:	:	PUNCT
bioethics02-25741	192	31	a	a	DET
bioethics02-25741	192	32	randomised	randomised	ADJ
bioethics02-25741	192	33	trial	trial	NOUN
bioethics02-25741	192	34	of	of	ADP
bioethics02-25741	192	35	physicians	physician	NOUN
bioethics02-25741	192	36	.	.	PUNCT
bioethics02-25741	193	1	j	j	PROPN
bioethics02-25741	193	2	med	med	PROPN
bioethics02-25741	193	3	ethics	ethic	NOUN
bioethics02-25741	193	4	2010	2010	NUM
bioethics02-25741	193	5	;	;	PUNCT
bioethics02-25741	193	6	36:265–70	36:265–70	PROPN
bioethics02-25741	193	7	.	.	PUNCT
bioethics02-25741	194	1	bangladesh	bangladesh	PROPN
bioethics02-25741	194	2	journal	journal	PROPN
bioethics02-25741	194	3	of	of	ADP
bioethics02-25741	194	4	bioethics	bioethic	NOUN
bioethics02-25741	194	5	2015	2015	NUM
bioethics02-25741	194	6	;	;	PUNCT
bioethics02-25741	194	7	6(2):15	6(2):15	X
bioethics02-25741	194	8	-	-	SYM
bioethics02-25741	194	9	22	22	NUM
bioethics02-25741	194	10	21	21	NUM
bioethics02-25741	194	11	41	41	NUM
bioethics02-25741	194	12	moynihan	moynihan	PROPN
bioethics02-25741	194	13	r.	r.	PROPN
bioethics02-25741	194	14	key	key	PROPN
bioethics02-25741	194	15	opinion	opinion	NOUN
bioethics02-25741	194	16	leaders	leader	NOUN
bioethics02-25741	194	17	:	:	PUNCT
bioethics02-25741	194	18	independent	independent	ADJ
bioethics02-25741	194	19	experts	expert	NOUN
bioethics02-25741	194	20	or	or	CCONJ
bioethics02-25741	194	21	drug	drug	NOUN
bioethics02-25741	194	22	representatives	representative	NOUN
bioethics02-25741	194	23	in	in	ADP
bioethics02-25741	194	24	disguise	disguise	NOUN
bioethics02-25741	194	25	?	?	PUNCT
bioethics02-25741	195	1	bmj	bmj	PROPN
bioethics02-25741	195	2	2008	2008	NUM
bioethics02-25741	195	3	;	;	PUNCT
bioethics02-25741	195	4	336:1402	336:1402	X
bioethics02-25741	195	5	–	–	PUNCT
bioethics02-25741	195	6	3	3	NUM
bioethics02-25741	195	7	.	.	NOUN
bioethics02-25741	195	8	42	42	NUM
bioethics02-25741	196	1	meffert	meffert	ADJ
bioethics02-25741	196	2	jj	jj	PROPN
bioethics02-25741	196	3	.	.	PROPN
bioethics02-25741	196	4	key	key	ADJ
bioethics02-25741	196	5	opinion	opinion	NOUN
bioethics02-25741	196	6	leaders	leader	NOUN
bioethics02-25741	196	7	:	:	PUNCT
bioethics02-25741	196	8	where	where	SCONJ
bioethics02-25741	196	9	they	they	PRON
bioethics02-25741	196	10	come	come	VERB
bioethics02-25741	196	11	from	from	ADP
bioethics02-25741	196	12	and	and	CCONJ
bioethics02-25741	196	13	how	how	SCONJ
bioethics02-25741	196	14	that	that	PRON
bioethics02-25741	196	15	affects	affect	VERB
bioethics02-25741	196	16	the	the	DET
bioethics02-25741	196	17	drugs	drug	NOUN
bioethics02-25741	196	18	you	you	PRON
bioethics02-25741	196	19	prescribe	prescribe	VERB
bioethics02-25741	196	20	.	.	PUNCT
bioethics02-25741	197	1	dermatol	dermatol	NOUN
bioethics02-25741	197	2	ther	ther	ADV
bioethics02-25741	197	3	2009	2009	NUM
bioethics02-25741	197	4	;	;	PUNCT
bioethics02-25741	197	5	22:262–8	22:262–8	NUM
bioethics02-25741	197	6	.	.	X
bioethics02-25741	198	1	43	43	NUM
bioethics02-25741	198	2	kesselheim	kesselheim	NOUN
bioethics02-25741	198	3	as	as	ADP
bioethics02-25741	198	4	,	,	PUNCT
bioethics02-25741	198	5	misono	misono	PROPN
bioethics02-25741	198	6	as	as	ADP
bioethics02-25741	198	7	,	,	PUNCT
bioethics02-25741	198	8	lee	lee	PROPN
bioethics02-25741	198	9	jl	jl	PROPN
bioethics02-25741	198	10	,	,	PUNCT
bioethics02-25741	198	11	stedman	stedman	PROPN
bioethics02-25741	198	12	mr	mr	PROPN
bioethics02-25741	198	13	,	,	PUNCT
bioethics02-25741	198	14	brookhart	brookhart	PROPN
bioethics02-25741	198	15	ma	ma	PROPN
bioethics02-25741	198	16	,	,	PUNCT
bioethics02-25741	198	17	choudhry	choudhry	PROPN
bioethics02-25741	198	18	nk	nk	PROPN
bioethics02-25741	198	19	et	et	PROPN
bioethics02-25741	198	20	al	al	PROPN
bioethics02-25741	198	21	.	.	PROPN
bioethics02-25741	198	22	clinical	clinical	ADJ
bioethics02-25741	198	23	equivalence	equivalence	NOUN
bioethics02-25741	198	24	of	of	ADP
bioethics02-25741	198	25	generic	generic	ADJ
bioethics02-25741	198	26	and	and	CCONJ
bioethics02-25741	198	27	brand	brand	NOUN
bioethics02-25741	198	28	-	-	PUNCT
bioethics02-25741	198	29	name	name	NOUN
bioethics02-25741	198	30	drugs	drug	NOUN
bioethics02-25741	198	31	used	use	VERB
bioethics02-25741	198	32	in	in	ADP
bioethics02-25741	198	33	cardiovascular	cardiovascular	ADJ
bioethics02-25741	198	34	disease	disease	NOUN
bioethics02-25741	198	35	:	:	PUNCT
bioethics02-25741	198	36	a	a	DET
bioethics02-25741	198	37	systematic	systematic	ADJ
bioethics02-25741	198	38	review	review	NOUN
bioethics02-25741	198	39	and	and	CCONJ
bioethics02-25741	198	40	meta	meta	ADJ
bioethics02-25741	198	41	-	-	PUNCT
bioethics02-25741	198	42	analysis	analysis	NOUN
bioethics02-25741	198	43	.	.	PUNCT
bioethics02-25741	199	1	jama	jama	PROPN
bioethics02-25741	199	2	2008;300:2514–26	2008;300:2514–26	NUM
bioethics02-25741	199	3	.	.	PROPN
bioethics02-25741	200	1	44	44	NUM
bioethics02-25741	200	2	sierles	sierle	NOUN
bioethics02-25741	200	3	fs	fs	ADP
bioethics02-25741	200	4	,	,	PUNCT
bioethics02-25741	200	5	brodkey	brodkey	PROPN
bioethics02-25741	200	6	ac	ac	PROPN
bioethics02-25741	200	7	,	,	PUNCT
bioethics02-25741	200	8	cleary	cleary	PROPN
bioethics02-25741	200	9	lm	lm	PROPN
bioethics02-25741	200	10	,	,	PUNCT
bioethics02-25741	200	11	mccurdy	mccurdy	PROPN
bioethics02-25741	200	12	fa	fa	PROPN
bioethics02-25741	200	13	,	,	PUNCT
bioethics02-25741	200	14	mintz	mintz	PROPN
bioethics02-25741	200	15	m	m	PROPN
bioethics02-25741	200	16	,	,	PUNCT
bioethics02-25741	200	17	frank	frank	PROPN
bioethics02-25741	200	18	j	j	PROPN
bioethics02-25741	200	19	et	et	PROPN
bioethics02-25741	200	20	al	al	PROPN
bioethics02-25741	200	21	.	.	PROPN
bioethics02-25741	201	1	medical	medical	ADJ
bioethics02-25741	201	2	students	student	NOUN
bioethics02-25741	201	3	‘	‘	PART
bioethics02-25741	201	4	exposure	exposure	NOUN
bioethics02-25741	201	5	to	to	ADP
bioethics02-25741	201	6	and	and	CCONJ
bioethics02-25741	201	7	attitudes	attitude	NOUN
bioethics02-25741	201	8	about	about	ADP
bioethics02-25741	201	9	drug	drug	NOUN
bioethics02-25741	201	10	company	company	NOUN
bioethics02-25741	201	11	interactions	interaction	NOUN
bioethics02-25741	201	12	.	.	PUNCT
bioethics02-25741	202	1	jama	jama	PROPN
bioethics02-25741	202	2	2005	2005	NUM
bioethics02-25741	202	3	;	;	PUNCT
bioethics02-25741	202	4	294:1034–42	294:1034–42	PROPN
bioethics02-25741	202	5	.	.	PROPN
bioethics02-25741	202	6	45	45	NUM
bioethics02-25741	202	7	austad	austad	PROPN
bioethics02-25741	202	8	ke	ke	PROPN
bioethics02-25741	202	9	,	,	PUNCT
bioethics02-25741	202	10	avorn	avorn	PROPN
bioethics02-25741	202	11	j	j	PROPN
bioethics02-25741	202	12	,	,	PUNCT
bioethics02-25741	202	13	kesselheim	kesselheim	PROPN
bioethics02-25741	202	14	as	as	ADP
bioethics02-25741	202	15	.	.	PUNCT
bioethics02-25741	202	16	medical	medical	ADJ
bioethics02-25741	202	17	students	student	NOUN
bioethics02-25741	202	18	‘	‘	PART
bioethics02-25741	202	19	exposure	exposure	NOUN
bioethics02-25741	202	20	to	to	ADP
bioethics02-25741	202	21	and	and	CCONJ
bioethics02-25741	202	22	attitudes	attitude	NOUN
bioethics02-25741	202	23	about	about	ADP
bioethics02-25741	202	24	the	the	DET
bioethics02-25741	202	25	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	202	26	industry	industry	NOUN
bioethics02-25741	202	27	:	:	PUNCT
bioethics02-25741	202	28	a	a	DET
bioethics02-25741	202	29	systematic	systematic	ADJ
bioethics02-25741	202	30	review	review	NOUN
bioethics02-25741	202	31	.	.	PUNCT
bioethics02-25741	203	1	plos	plos	PROPN
bioethics02-25741	203	2	med	med	PROPN
bioethics02-25741	203	3	2011	2011	NUM
bioethics02-25741	203	4	;	;	PUNCT
bioethics02-25741	203	5	8	8	NUM
bioethics02-25741	203	6	:	:	PUNCT
bioethics02-25741	203	7	e1001037	e1001037	NOUN
bioethics02-25741	203	8	.	.	PUNCT
bioethics02-25741	203	9	46	46	NUM
bioethics02-25741	203	10	grande	grande	PROPN
bioethics02-25741	203	11	d	d	PROPN
bioethics02-25741	203	12	,	,	PUNCT
bioethics02-25741	203	13	frosch	frosch	PROPN
bioethics02-25741	203	14	dl	dl	PROPN
bioethics02-25741	203	15	,	,	PUNCT
bioethics02-25741	203	16	perkins	perkins	PROPN
bioethics02-25741	203	17	aw	aw	INTJ
bioethics02-25741	203	18	,	,	PUNCT
bioethics02-25741	203	19	kahn	kahn	PROPN
bioethics02-25741	203	20	be	be	PROPN
bioethics02-25741	203	21	.	.	PUNCT
bioethics02-25741	204	1	effect	effect	NOUN
bioethics02-25741	204	2	of	of	ADP
bioethics02-25741	204	3	exposure	exposure	NOUN
bioethics02-25741	204	4	to	to	ADP
bioethics02-25741	204	5	small	small	ADJ
bioethics02-25741	204	6	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	204	7	promotional	promotional	ADJ
bioethics02-25741	204	8	items	item	NOUN
bioethics02-25741	204	9	on	on	ADP
bioethics02-25741	204	10	treatment	treatment	NOUN
bioethics02-25741	204	11	preferences	preference	NOUN
bioethics02-25741	204	12	.	.	PUNCT
bioethics02-25741	205	1	arch	arch	ADJ
bioethics02-25741	205	2	intern	intern	NOUN
bioethics02-25741	205	3	med	med	PROPN
bioethics02-25741	205	4	2009	2009	NUM
bioethics02-25741	205	5	;	;	PUNCT
bioethics02-25741	205	6	169:887–93	169:887–93	NUM
bioethics02-25741	205	7	.	.	PUNCT
bioethics02-25741	206	1	47	47	NUM
bioethics02-25741	206	2	campbell	campbell	PROPN
bioethics02-25741	206	3	eg	eg	PROPN
bioethics02-25741	206	4	,	,	PUNCT
bioethics02-25741	206	5	weissman	weissman	PROPN
bioethics02-25741	206	6	js	js	PROPN
bioethics02-25741	206	7	,	,	PUNCT
bioethics02-25741	206	8	ehringhaus	ehringhaus	PROPN
bioethics02-25741	206	9	s	s	PROPN
bioethics02-25741	206	10	,	,	PUNCT
bioethics02-25741	206	11	rao	rao	PROPN
bioethics02-25741	206	12	sr	sr	PROPN
bioethics02-25741	206	13	,	,	PUNCT
bioethics02-25741	206	14	moy	moy	PROPN
bioethics02-25741	206	15	b	b	PROPN
bioethics02-25741	206	16	,	,	PUNCT
bioethics02-25741	206	17	feibelmann	feibelmann	PROPN
bioethics02-25741	206	18	s	s	PART
bioethics02-25741	206	19	et	et	NOUN
bioethics02-25741	206	20	al	al	PROPN
bioethics02-25741	206	21	.	.	PUNCT
bioethics02-25741	207	1	institutional	institutional	ADJ
bioethics02-25741	207	2	academic	academic	ADJ
bioethics02-25741	207	3	industry	industry	NOUN
bioethics02-25741	207	4	relationships	relationship	NOUN
bioethics02-25741	207	5	.	.	PUNCT
bioethics02-25741	208	1	jama	jama	PROPN
bioethics02-25741	208	2	2007	2007	NUM
bioethics02-25741	208	3	;	;	PUNCT
bioethics02-25741	208	4	298:1779–86	298:1779–86	NUM
bioethics02-25741	208	5	.	.	PUNCT
bioethics02-25741	209	1	48	48	NUM
bioethics02-25741	209	2	steinman	steinman	PROPN
bioethics02-25741	209	3	ma	ma	PROPN
bioethics02-25741	209	4	,	,	PUNCT
bioethics02-25741	209	5	landefeld	landefeld	VERB
bioethics02-25741	209	6	cs	cs	PROPN
bioethics02-25741	209	7	,	,	PUNCT
bioethics02-25741	209	8	baron	baron	NOUN
bioethics02-25741	209	9	rb	rb	NOUN
bioethics02-25741	209	10	.	.	PUNCT
bioethics02-25741	210	1	industry	industry	NOUN
bioethics02-25741	210	2	support	support	NOUN
bioethics02-25741	210	3	of	of	ADP
bioethics02-25741	210	4	cme	cme	PROPN
bioethics02-25741	210	5	—	—	PUNCT
bioethics02-25741	210	6	are	be	AUX
bioethics02-25741	210	7	we	we	PRON
bioethics02-25741	210	8	at	at	ADP
bioethics02-25741	210	9	the	the	DET
bioethics02-25741	210	10	tipping	tipping	NOUN
bioethics02-25741	210	11	point	point	NOUN
bioethics02-25741	210	12	?	?	PUNCT
bioethics02-25741	211	1	n	n	CCONJ
bioethics02-25741	211	2	engl	engl	PROPN
bioethics02-25741	211	3	j	j	PROPN
bioethics02-25741	211	4	med	med	PROPN
bioethics02-25741	211	5	2012	2012	NUM
bioethics02-25741	211	6	;	;	PUNCT
bioethics02-25741	212	1	366:1069–71	366:1069–71	PROPN
bioethics02-25741	212	2	.	.	PUNCT
bioethics02-25741	213	1	49	49	NUM
bioethics02-25741	213	2	avorn	avorn	PROPN
bioethics02-25741	213	3	j	j	PROPN
bioethics02-25741	213	4	,	,	PUNCT
bioethics02-25741	213	5	choudhry	choudhry	PROPN
bioethics02-25741	213	6	nk	nk	PROPN
bioethics02-25741	213	7	.	.	PROPN
bioethics02-25741	213	8	funding	funding	PROPN
bioethics02-25741	213	9	for	for	ADP
bioethics02-25741	213	10	medical	medical	ADJ
bioethics02-25741	213	11	education	education	NOUN
bioethics02-25741	213	12	:	:	PUNCT
bioethics02-25741	213	13	maintaining	maintain	VERB
bioethics02-25741	213	14	a	a	DET
bioethics02-25741	213	15	healthy	healthy	ADJ
bioethics02-25741	213	16	separation	separation	NOUN
bioethics02-25741	213	17	from	from	ADP
bioethics02-25741	213	18	industry	industry	NOUN
bioethics02-25741	213	19	.	.	PUNCT
bioethics02-25741	214	1	circulation	circulation	NOUN
bioethics02-25741	214	2	2010	2010	NUM
bioethics02-25741	214	3	;	;	PUNCT
bioethics02-25741	214	4	121:2228–34	121:2228–34	NUM
bioethics02-25741	214	5	.	.	PUNCT
bioethics02-25741	215	1	50	50	NUM
bioethics02-25741	215	2	wazana	wazana	PROPN
bioethics02-25741	215	3	a.	a.	NOUN
bioethics02-25741	215	4	physicians	physician	NOUN
bioethics02-25741	215	5	and	and	CCONJ
bioethics02-25741	215	6	the	the	DET
bioethics02-25741	215	7	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	215	8	industry	industry	NOUN
bioethics02-25741	215	9	:	:	PUNCT
bioethics02-25741	215	10	is	be	AUX
bioethics02-25741	215	11	a	a	DET
bioethics02-25741	215	12	gift	gift	NOUN
bioethics02-25741	215	13	ever	ever	ADV
bioethics02-25741	215	14	just	just	ADV
bioethics02-25741	215	15	a	a	DET
bioethics02-25741	215	16	gift	gift	NOUN
bioethics02-25741	215	17	?	?	PUNCT
bioethics02-25741	216	1	jama	jama	PROPN
bioethics02-25741	216	2	2000	2000	NUM
bioethics02-25741	216	3	;	;	PUNCT
bioethics02-25741	216	4	283:373–80	283:373–80	NUM
bioethics02-25741	216	5	.	.	PUNCT
bioethics02-25741	217	1	51	51	NUM
bioethics02-25741	217	2	brody	brody	PROPN
bioethics02-25741	217	3	h.	h.	PROPN
bioethics02-25741	217	4	pharmaceutical	pharmaceutical	PROPN
bioethics02-25741	217	5	industry	industry	NOUN
bioethics02-25741	217	6	financial	financial	ADJ
bioethics02-25741	217	7	support	support	NOUN
bioethics02-25741	217	8	for	for	ADP
bioethics02-25741	217	9	medical	medical	ADJ
bioethics02-25741	217	10	education	education	NOUN
bioethics02-25741	217	11	;	;	PUNCT
bioethics02-25741	217	12	benefit	benefit	NOUN
bioethics02-25741	217	13	,	,	PUNCT
bioethics02-25741	217	14	or	or	CCONJ
bioethics02-25741	217	15	undue	undue	ADJ
bioethics02-25741	217	16	harm	harm	NOUN
bioethics02-25741	217	17	?	?	PUNCT
bioethics02-25741	218	1	j	j	PROPN
bioethics02-25741	218	2	law	law	NOUN
bioethics02-25741	218	3	med	me	VERB
bioethics02-25741	218	4	ethics	ethic	NOUN
bioethics02-25741	218	5	2009	2009	NUM
bioethics02-25741	218	6	;	;	PUNCT
bioethics02-25741	218	7	37:451–60	37:451–60	NOUN
bioethics02-25741	218	8	.	.	PUNCT
bioethics02-25741	219	1	52	52	NUM
bioethics02-25741	219	2	campbell	campbell	PROPN
bioethics02-25741	219	3	eg	eg	PROPN
bioethics02-25741	219	4	,	,	PUNCT
bioethics02-25741	219	5	gruen	gruen	PROPN
bioethics02-25741	219	6	rl	rl	PROPN
bioethics02-25741	219	7	,	,	PUNCT
bioethics02-25741	219	8	mountford	mountford	PROPN
bioethics02-25741	219	9	j	j	PROPN
bioethics02-25741	219	10	,	,	PUNCT
bioethics02-25741	219	11	miller	miller	PROPN
bioethics02-25741	219	12	lg	lg	PROPN
bioethics02-25741	219	13	,	,	PUNCT
bioethics02-25741	219	14	cleary	cleary	PROPN
bioethics02-25741	219	15	pd	pd	PROPN
bioethics02-25741	219	16	,	,	PUNCT
bioethics02-25741	219	17	blumenthal	blumenthal	PROPN
bioethics02-25741	219	18	d.	d.	PROPN
bioethics02-25741	219	19	a	a	DET
bioethics02-25741	219	20	national	national	ADJ
bioethics02-25741	219	21	survey	survey	NOUN
bioethics02-25741	219	22	of	of	ADP
bioethics02-25741	219	23	physician	physician	ADJ
bioethics02-25741	219	24	-	-	PUNCT
bioethics02-25741	219	25	industry	industry	NOUN
bioethics02-25741	219	26	relationships	relationship	NOUN
bioethics02-25741	219	27	.	.	PUNCT
bioethics02-25741	220	1	n	n	PROPN
bioethics02-25741	220	2	engl	engl	PROPN
bioethics02-25741	220	3	j	j	PROPN
bioethics02-25741	220	4	med	med	PROPN
bioethics02-25741	220	5	2007	2007	NUM
bioethics02-25741	220	6	;	;	PUNCT
bioethics02-25741	220	7	356:1742–50	356:1742–50	NUM
bioethics02-25741	220	8	.	.	PUNCT
bioethics02-25741	220	9	53	53	NUM
bioethics02-25741	220	10	gagnon	gagnon	PROPN
bioethics02-25741	220	11	m	m	PROPN
bioethics02-25741	220	12	-	-	PUNCT
bioethics02-25741	220	13	a	a	PROPN
bioethics02-25741	220	14	,	,	PUNCT
bioethics02-25741	220	15	lexchin	lexchin	NOUN
bioethics02-25741	220	16	j.	j.	PROPN
bioethics02-25741	220	17	the	the	DET
bioethics02-25741	220	18	cost	cost	NOUN
bioethics02-25741	220	19	of	of	ADP
bioethics02-25741	220	20	pushing	push	VERB
bioethics02-25741	220	21	pills	pill	NOUN
bioethics02-25741	220	22	:	:	PUNCT
bioethics02-25741	220	23	a	a	DET
bioethics02-25741	220	24	new	new	ADJ
bioethics02-25741	220	25	estimate	estimate	NOUN
bioethics02-25741	220	26	of	of	ADP
bioethics02-25741	220	27	pharmaceutical	pharmaceutical	NOUN
bioethics02-25741	220	28	promotion	promotion	NOUN
bioethics02-25741	220	29	expenditures	expenditure	NOUN
bioethics02-25741	220	30	in	in	ADP
bioethics02-25741	220	31	the	the	DET
bioethics02-25741	220	32	united	united	PROPN
bioethics02-25741	220	33	states	states	PROPN
bioethics02-25741	220	34	.	.	PUNCT
bioethics02-25741	221	1	plos	plos	PROPN
bioethics02-25741	221	2	med	med	PROPN
bioethics02-25741	221	3	2008	2008	NUM
bioethics02-25741	221	4	;	;	PUNCT
bioethics02-25741	221	5	5	5	NUM
bioethics02-25741	221	6	:	:	PUNCT
bioethics02-25741	221	7	e1	e1	NOUN
bioethics02-25741	221	8	.	.	PUNCT
bioethics02-25741	222	1	54	54	NUM
bioethics02-25741	222	2	chren	chren	PROPN
bioethics02-25741	222	3	mm	mm	PROPN
bioethics02-25741	222	4	,	,	PUNCT
bioethics02-25741	222	5	landefeld	landefeld	VERB
bioethics02-25741	222	6	cs	cs	PROPN
bioethics02-25741	222	7	.	.	PROPN
bioethics02-25741	222	8	physicians	physician	NOUN
bioethics02-25741	222	9	‘	‘	PART
bioethics02-25741	222	10	behavior	behavior	NOUN
bioethics02-25741	222	11	and	and	CCONJ
bioethics02-25741	222	12	their	their	PRON
bioethics02-25741	222	13	interactions	interaction	NOUN
bioethics02-25741	222	14	with	with	ADP
bioethics02-25741	222	15	drug	drug	NOUN
bioethics02-25741	222	16	companies	company	NOUN
bioethics02-25741	222	17	:	:	PUNCT
bioethics02-25741	222	18	a	a	DET
bioethics02-25741	222	19	controlled	control	VERB
bioethics02-25741	222	20	study	study	NOUN
bioethics02-25741	222	21	of	of	ADP
bioethics02-25741	222	22	physicians	physician	NOUN
bioethics02-25741	222	23	who	who	PRON
bioethics02-25741	222	24	requested	request	VERB
bioethics02-25741	222	25	additions	addition	NOUN
bioethics02-25741	222	26	to	to	ADP
bioethics02-25741	222	27	a	a	DET
bioethics02-25741	222	28	hospital	hospital	NOUN
bioethics02-25741	222	29	drug	drug	NOUN
bioethics02-25741	222	30	formulary	formulary	NOUN
bioethics02-25741	222	31	.	.	PUNCT
bioethics02-25741	223	1	jama	jama	PROPN
bioethics02-25741	223	2	1994	1994	NUM
bioethics02-25741	223	3	;	;	PUNCT
bioethics02-25741	223	4	271:684–9	271:684–9	NUM
bioethics02-25741	223	5	.	.	PUNCT
bioethics02-25741	224	1	55	55	NUM
bioethics02-25741	224	2	giannakakis	giannakakis	PROPN
bioethics02-25741	224	3	ia	ia	PROPN
bioethics02-25741	224	4	,	,	PUNCT
bioethics02-25741	224	5	ioannidis	ioannidis	PROPN
bioethics02-25741	224	6	jpa	jpa	PROPN
bioethics02-25741	224	7	.	.	PUNCT
bioethics02-25741	225	1	arabian	arabian	ADJ
bioethics02-25741	225	2	nights—1001	nights—1001	ADJ
bioethics02-25741	225	3	tales	tale	NOUN
bioethics02-25741	225	4	of	of	ADP
bioethics02-25741	225	5	how	how	SCONJ
bioethics02-25741	225	6	pharmaceutical	pharmaceutical	ADJ
bioethics02-25741	225	7	companies	company	NOUN
bioethics02-25741	225	8	cater	cater	VERB
bioethics02-25741	225	9	to	to	ADP
bioethics02-25741	225	10	the	the	DET
bioethics02-25741	225	11	material	material	NOUN
bioethics02-25741	225	12	needs	need	NOUN
bioethics02-25741	225	13	of	of	ADP
bioethics02-25741	225	14	doctors	doctor	NOUN
bioethics02-25741	225	15	:	:	PUNCT
bioethics02-25741	225	16	case	case	NOUN
bioethics02-25741	225	17	report	report	NOUN
bioethics02-25741	225	18	.	.	PUNCT
bioethics02-25741	226	1	bmj	bmj	PROPN
bioethics02-25741	226	2	2000;321:1563–4	2000;321:1563–4	NUM
bioethics02-25741	226	3	.	.	PUNCT
bioethics02-25741	227	1	56	56	NUM
bioethics02-25741	227	2	norgine	norgine	PROPN
bioethics02-25741	227	3	mp	mp	PROPN
bioethics02-25741	227	4	,	,	PUNCT
bioethics02-25741	227	5	martin	martin	PROPN
bioethics02-25741	227	6	p.	p.	PROPN
bioethics02-25741	227	7	norgine‘s	norgine‘s	PROPN
bioethics02-25741	227	8	reply	reply	NOUN
bioethics02-25741	227	9	to	to	PART
bioethics02-25741	227	10	abpi	abpi	VERB
bioethics02-25741	227	11	.	.	PUNCT
bioethics02-25741	228	1	bmj	bmj	PROPN
bioethics02-25741	228	2	2010	2010	NUM
bioethics02-25741	228	3	;	;	PUNCT
bioethics02-25741	228	4	340	340	NUM
bioethics02-25741	228	5	:	:	PUNCT
bioethics02-25741	228	6	c1869	c1869	PROPN
bioethics02-25741	228	7	.	.	PUNCT
bioethics02-25741	229	1	57	57	NUM
bioethics02-25741	229	2	licurse	licurse	NOUN
bioethics02-25741	229	3	a	a	NOUN
bioethics02-25741	229	4	,	,	PUNCT
bioethics02-25741	229	5	barber	barber	PROPN
bioethics02-25741	229	6	e	e	PROPN
bioethics02-25741	229	7	,	,	PUNCT
bioethics02-25741	229	8	joffe	joffe	PROPN
bioethics02-25741	229	9	s	s	PROPN
bioethics02-25741	229	10	,	,	PUNCT
bioethics02-25741	229	11	gross	gross	ADJ
bioethics02-25741	229	12	c.	c.	NOUN
bioethics02-25741	229	13	the	the	DET
bioethics02-25741	229	14	impact	impact	NOUN
bioethics02-25741	229	15	of	of	ADP
bioethics02-25741	229	16	disclosing	disclose	VERB
bioethics02-25741	229	17	financial	financial	ADJ
bioethics02-25741	229	18	ties	tie	NOUN
bioethics02-25741	229	19	in	in	ADP
bioethics02-25741	229	20	research	research	NOUN
bioethics02-25741	229	21	and	and	CCONJ
bioethics02-25741	229	22	clinical	clinical	ADJ
bioethics02-25741	229	23	care	care	NOUN
bioethics02-25741	229	24	:	:	PUNCT
bioethics02-25741	229	25	a	a	DET
bioethics02-25741	229	26	systematic	systematic	ADJ
bioethics02-25741	229	27	review	review	NOUN
bioethics02-25741	229	28	.	.	PUNCT
bioethics02-25741	230	1	arch	arch	ADJ
bioethics02-25741	230	2	intern	intern	NOUN
bioethics02-25741	230	3	med	med	PROPN
bioethics02-25741	230	4	2010	2010	NUM
bioethics02-25741	230	5	;	;	PUNCT
bioethics02-25741	230	6	170:675–82	170:675–82	NUM
bioethics02-25741	230	7	.	.	NOUN
bioethics02-25741	230	8	58	58	NUM
bioethics02-25741	230	9	law	law	NOUN
bioethics02-25741	230	10	mr	mr	PROPN
bioethics02-25741	230	11	,	,	PUNCT
bioethics02-25741	230	12	soumerai	soumerai	PROPN
bioethics02-25741	230	13	sb	sb	PROPN
bioethics02-25741	230	14	,	,	PUNCT
bioethics02-25741	230	15	adams	adams	PROPN
bioethics02-25741	230	16	as	as	ADP
bioethics02-25741	230	17	,	,	PUNCT
bioethics02-25741	230	18	majumdar	majumdar	PROPN
bioethics02-25741	230	19	sr	sr	PROPN
bioethics02-25741	230	20	.	.	PUNCT
bioethics02-25741	231	1	costs	cost	NOUN
bioethics02-25741	231	2	and	and	CCONJ
bioethics02-25741	231	3	consequences	consequence	NOUN
bioethics02-25741	231	4	of	of	ADP
bioethics02-25741	231	5	direct	direct	ADJ
bioethics02-25741	231	6	-	-	PUNCT
bioethics02-25741	231	7	to	to	ADP
bioethics02-25741	231	8	-	-	PUNCT
bioethics02-25741	231	9	consumer	consumer	NOUN
bioethics02-25741	231	10	advertising	advertising	NOUN
bioethics02-25741	231	11	for	for	ADP
bioethics02-25741	231	12	clopidogrel	clopidogrel	NOUN
bioethics02-25741	231	13	in	in	ADP
bioethics02-25741	231	14	medicaid	medicaid	PROPN
bioethics02-25741	231	15	.	.	PUNCT
bioethics02-25741	232	1	arch	arch	PROPN
bioethics02-25741	232	2	intern	intern	NOUN
bioethics02-25741	232	3	med	med	PROPN
bioethics02-25741	232	4	2009	2009	NUM
bioethics02-25741	232	5	;	;	PUNCT
bioethics02-25741	233	1	169:1969–74	169:1969–74	NUM
bioethics02-25741	233	2	.	.	PUNCT
bioethics02-25741	234	1	59	59	NUM
bioethics02-25741	234	2	donohue	donohue	PROPN
bioethics02-25741	234	3	jm	jm	PROPN
bioethics02-25741	234	4	,	,	PUNCT
bioethics02-25741	234	5	cevasco	cevasco	PROPN
bioethics02-25741	234	6	m	m	PROPN
bioethics02-25741	234	7	,	,	PUNCT
bioethics02-25741	234	8	rosenthal	rosenthal	PROPN
bioethics02-25741	234	9	mb	mb	PROPN
bioethics02-25741	234	10	.	.	PROPN
bioethics02-25741	234	11	a	a	DET
bioethics02-25741	234	12	decade	decade	NOUN
bioethics02-25741	234	13	of	of	ADP
bioethics02-25741	234	14	direct	direct	ADJ
bioethics02-25741	234	15	-	-	PUNCT
bioethics02-25741	234	16	toconsumer	toconsumer	NOUN
bioethics02-25741	234	17	advertising	advertising	NOUN
bioethics02-25741	234	18	of	of	ADP
bioethics02-25741	234	19	prescription	prescription	NOUN
bioethics02-25741	234	20	drugs	drug	NOUN
bioethics02-25741	234	21	.	.	PUNCT
bioethics02-25741	235	1	n	n	PRON
bioethics02-25741	235	2	engl	engl	PROPN
bioethics02-25741	235	3	j	j	PROPN
bioethics02-25741	235	4	med	med	PROPN
bioethics02-25741	235	5	2007	2007	NUM
bioethics02-25741	235	6	;	;	PUNCT
bioethics02-25741	235	7	357:673–81	357:673–81	NUM
bioethics02-25741	235	8	.	.	PUNCT
bioethics02-25741	235	9	60	60	NUM
bioethics02-25741	235	10	kaiser	kaiser	PROPN
bioethics02-25741	235	11	family	family	PROPN
bioethics02-25741	235	12	foundation	foundation	PROPN
bioethics02-25741	236	1	[	[	X
bioethics02-25741	236	2	internet	internet	NOUN
bioethics02-25741	236	3	]	]	PUNCT
bioethics02-25741	236	4	.	.	PUNCT
bioethics02-25741	237	1	prescription	prescription	NOUN
bioethics02-25741	237	2	drug	drug	NOUN
bioethics02-25741	237	3	trends	trend	NOUN
bioethics02-25741	237	4	.	.	PUNCT
bioethics02-25741	238	1	menlo	menlo	PROPN
bioethics02-25741	238	2	park	park	PROPN
bioethics02-25741	238	3	,	,	PUNCT
bioethics02-25741	238	4	california	california	PROPN
bioethics02-25741	238	5	;	;	PUNCT
bioethics02-25741	238	6	c2010	c2010	PROPN
bioethics02-25741	238	7	.	.	PROPN
bioethics02-25741	238	8	available	available	ADJ
bioethics02-25741	238	9	at	at	ADP
bioethics02-25741	238	10	:	:	PUNCT
bioethics02-25741	238	11	http://www.kff.org/	http://www.kff.org/	ADJ
bioethics02-25741	238	12	rxdrugs	rxdrug	NOUN
bioethics02-25741	238	13	/	/	SYM
bioethics02-25741	238	14	upload/3057	upload/3057	NOUN
bioethics02-25741	238	15	-	-	PUNCT
bioethics02-25741	238	16	08.pdf	08.pdf	PROPN
bioethics02-25741	238	17	.	.	PUNCT
bioethics02-25741	238	18	access	access	NOUN
bioethics02-25741	238	19	on	on	ADP
bioethics02-25741	238	20	12	12	NUM
bioethics02-25741	238	21	february	february	NOUN
bioethics02-25741	238	22	2013	2013	NUM
bioethics02-25741	238	23	.	.	PUNCT
bioethics02-25741	239	1	61	61	NUM
bioethics02-25741	239	2	shuchman	shuchman	NOUN
bioethics02-25741	239	3	m.	m.	NOUN
bioethics02-25741	239	4	drug	drug	NOUN
bioethics02-25741	239	5	risks	risk	NOUN
bioethics02-25741	239	6	and	and	CCONJ
bioethics02-25741	239	7	free	free	ADJ
bioethics02-25741	239	8	speech	speech	NOUN
bioethics02-25741	239	9	:	:	PUNCT
bioethics02-25741	239	10	can	can	AUX
bioethics02-25741	239	11	congress	congress	PROPN
bioethics02-25741	239	12	ban	ban	VERB
bioethics02-25741	239	13	consumer	consumer	NOUN
bioethics02-25741	239	14	drug	drug	NOUN
bioethics02-25741	239	15	ads	ad	NOUN
bioethics02-25741	239	16	?	?	PUNCT
bioethics02-25741	240	1	n	n	CCONJ
bioethics02-25741	240	2	engl	engl	PROPN
bioethics02-25741	240	3	j	j	PROPN
bioethics02-25741	240	4	med	med	PROPN
bioethics02-25741	240	5	2007	2007	NUM
bioethics02-25741	240	6	;	;	PUNCT
bioethics02-25741	240	7	356:2236	356:2236	NUM
bioethics02-25741	240	8	–	–	PUNCT
bioethics02-25741	240	9	9	9	NUM
bioethics02-25741	240	10	.	.	X
bioethics02-25741	240	11	http://www.kff.org/	http://www.kff.org/	PROPN
bioethics02-25741	240	12	bangladesh	bangladesh	PROPN
bioethics02-25741	240	13	journal	journal	NOUN
bioethics02-25741	240	14	of	of	ADP
bioethics02-25741	240	15	bioethics	bioethic	NOUN
bioethics02-25741	240	16	2015	2015	NUM
bioethics02-25741	240	17	;	;	PUNCT
bioethics02-25741	240	18	6(2):15	6(2):15	X
bioethics02-25741	240	19	-	-	SYM
bioethics02-25741	240	20	22	22	NUM
bioethics02-25741	240	21	22	22	NUM
bioethics02-25741	240	22	62	62	NUM
bioethics02-25741	240	23	institute	institute	NOUN
bioethics02-25741	240	24	of	of	ADP
bioethics02-25741	240	25	medicine	medicine	NOUN
bioethics02-25741	240	26	.	.	PUNCT
bioethics02-25741	241	1	chapters	chapter	NOUN
bioethics02-25741	241	2	3–8	3–8	NUM
bioethics02-25741	241	3	.	.	PUNCT
bioethics02-25741	242	1	in	in	ADP
bioethics02-25741	242	2	:	:	PUNCT
bioethics02-25741	242	3	lo	lo	PROPN
bioethics02-25741	242	4	b	b	PROPN
bioethics02-25741	242	5	,	,	PUNCT
bioethics02-25741	242	6	fields	fields	PROPN
bioethics02-25741	242	7	mj	mj	PROPN
bioethics02-25741	242	8	,	,	PUNCT
bioethics02-25741	242	9	editors	editor	NOUN
bioethics02-25741	242	10	.	.	PUNCT
bioethics02-25741	243	1	conflict	conflict	NOUN
bioethics02-25741	243	2	of	of	ADP
bioethics02-25741	243	3	interest	interest	NOUN
bioethics02-25741	243	4	in	in	ADP
bioethics02-25741	243	5	medical	medical	ADJ
bioethics02-25741	243	6	research	research	NOUN
bioethics02-25741	243	7	,	,	PUNCT
bioethics02-25741	243	8	education	education	NOUN
bioethics02-25741	243	9	,	,	PUNCT
bioethics02-25741	243	10	and	and	CCONJ
bioethics02-25741	243	11	practice	practice	NOUN
bioethics02-25741	243	12	.	.	PUNCT
bioethics02-25741	244	1	washington	washington	PROPN
bioethics02-25741	244	2	,	,	PUNCT
bioethics02-25741	244	3	dc	dc	PROPN
bioethics02-25741	244	4	:	:	PUNCT
bioethics02-25741	244	5	national	national	PROPN
bioethics02-25741	244	6	academy	academy	PROPN
bioethics02-25741	244	7	of	of	ADP
bioethics02-25741	244	8	sciences	sciences	PROPN
bioethics02-25741	244	9	;	;	PUNCT
bioethics02-25741	244	10	2009	2009	NUM
bioethics02-25741	244	11	:	:	PUNCT
bioethics02-25741	244	12	pp	pp	ADP
bioethics02-25741	244	13	.	.	PUNCT
bioethics02-25741	245	1	62–229	62–229	NUM
bioethics02-25741	245	2	.	.	PUNCT